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1
iNTroducTioN
Cardiovascular disease (CVD) is a global health issue. In 2012, an estimated 17.5 mil-
lion people died of CVD worldwide, accounting for approximately 31% of all deaths [1]. 
About 80% of these deaths were due to coronary artery disease (7.6 million) and stroke 
(5.7 million) [1]. CVD is not only an important cause of mortality, but also of morbidity, 
with many individuals living with the consequences and limitations of coronary artery 
disease, cerebrovascular artery disease and peripheral artery disease. CVD is the single 
most important cause of lost health globally [1].
The underlying pathology of these conditions is atherosclerosis. Atherosclerosis may 
result from a combination of several risk factors, including smoking, diabetes mellitus, 
hyperlipidemia, hypertension, abdominal obesity, physical inactivity, a diet low in fruit 
and vegetables, regular alcohol consumption and psychosocial factors [2]. Collectively, 
these nine risk factors are estimated to account for 90% of the population attributable 
risk of myocardial infarction in men, and 94% in women [2].
APoLiPoProTEiN B ANd AThEroscLErosis
One of the main lipid risk factors for atherosclerosis, is an increased apolipoprotein (apo) 
B / apo A-I ratio [2]. Apo B is the structural protein present on the surface of all athero-
genic lipoproteins, including very low-density lipoproteins (VLDL), intermediate-density 
lipoproteins (IDL), low-density lipoproteins (LDL), chylomicrons and their respective 
remnants [3]. In contrast, apo A-I is the main apolipoprotein of high-density lipoproteins 
(HDL) [4].
The gene encoding for apo B is located on chromosome 2 [5]. In humans, two forms 
of apo B exist. Apo B100 is present on hepatically derived LDL, IDL, VLDL and their rem-
nants. This protein of 4536 amino acids is synthesized in the liver, and plays a crucial 
role in the assembly of VLDL particles [3]. In addition, apo B serves as the ligand for the 
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uptake of atherogenic lipoproteins by the LDL-receptor [3]. Apo B48 is synthesized in 
the intestine. In the intestine, the single nucleotide for amino acid 2153 in the mRNA of 
the apo B gene is changed into a stop codon, resulting in an apo B protein of 2152 amino 
acids, which is 48% of the length of the apo B100 protein [3]. Apo B48 is crucial in the 
formation of chylomicrons [3].
Plasma apo B measurement includes both apo B100 and apo B48, with apo B100 
making up the vast majority of all circulating apo B-containing lipoproteins [6]. Plasma 
apo B is a strong predictor of future CVD, with an estimated relative risk ratio (RRR) of 
1.43 (95% confidence interval 1.35 to 1.51) [7]. In fact, apo B is considered to be an even 
better cardiovascular risk marker than LDL-cholesterol [7], which is currently one of the 
cornerstones of cardiovascular risk management guidelines [8].
chyLoMicroN ANd VLdL syNThEsis
Lipids and fat-soluble vitamins ingested with the diet are transported from the intestine 
to the circulation by chylomicrons. In the intestine, dietary triglycerides are hydrolyzed 
into free fatty acids (FFAs) and 2-monoacylglycerols (MAG) [9]. These FFAs and MAG are 
then transported from the intestinal lumen to the smooth endoplasmatic reticulum 
(SER) of the enterocyte, where they are resynthesized into triglycerides [9,10]. The forma-
tion of chylomicrons starts in the rough endoplasmatic reticulum (RER), where nascent 
apo B48 is translocated into the lumen of the endoplasmatic reticulum (ER) [11]. The 
microsomal transfer protein (MTP) shuttles triglycerides from within the ER to an accep-
tor apo B48 molecule, giving rise to a primordial apo B-containing lipoprotein [11]. This 
particle is then enriched and expanded with lipids present within the ER, resulting in a 
prechylomicron, with a core containing triglycerides, cholesteryl esters and fat-soluble 
vitamins, and an outer layer with phospholipids, free cholesterol, apo B48 and apo A-IV 
[9,11]. The prechylomicron leaves the ER and is transported to the Golgi apparatus in 
prechylomicron transport vesicles. Several proteins, including apo B48 and CD36, are 
involved in this transport [12]. Within the Golgi, apo A-I is attached, resulting in the 
formation of a mature chylomicron, which is secreted into the lymphatic system [13,14].
In the circulation, the triglycerides present in chylomicrons are hydrolyzed into MAG 
and FFAs by the endothelium-bound enzyme lipoprotein lipase (LPL), giving rise to 
chylomicron remnant particles [15]. The dietary FFAs and chylomicron remnants can be 
taken up by the liver, to be used for the synthesis of VLDL [16]. The assembly of VLDL be-
gins in the ER of hepatocytes. In humans, the liver lacks an editing enzyme complex such 
as in the intestine and therefore, hepatic triglyceride-rich lipoproteins (TRLs) contain 
solely apo B100 as structural apolipoprotein [17]. Apo B100 is synthesized in the RER and 
under the influence of MTP, the nascent lipoprotein becomes enriched with triglycerides 
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1which are synthesized in the SER [17]. This gives rise to pre-VLDL, which can be further 
processed to form triglyceride-poor VLDL2. The VLDL synthesis in the liver is a continuous 
process, and VLDL secretion is controlled mainly by intracellular degradation, depending 
largely on lipidation of the nascent VLDL particles [18]. Therefore, pre-VLDL that is not 
transformed to VLDL2 is subject to posttranslational degradation [18]. Otherwise, VLDL2 
is transported to the Golgi, where it is either secreted into the circulation, or converted 
to triglyceride-rich VLDL1, which is then released into the circulation.
The large VLDL particles in the circulation are hydrolyzed by LPL, resulting in the 
formation of intermediate-density lipoproteins (IDL) and eventually low-density 
lipoproteins (LDL) [19]. However, since chylomicrons and VLDL largely share the same 
lipolytic pathway, competition at the level of several steps involved in the lipolysis and 
removal of TRLs from the circulation may occur. These include not only LPL [15], but also 
hepatic lipase, the low-density lipoprotein receptor (LDL-R), the LDL receptor-related 
protein 1 (LRP-1) and heparan sulfate proteoglycans [19,20]. This competition may lead 
to accumulation of TRLs in the circulation.
iNfLAMMATioN ANd LEukocyTE AcTiVATioN iN AThEroscLErosis
In the past decades, it has become evident that inflammation plays a key role in the 
development of atherosclerosis. Several inflammatory markers, including C-reactive 
protein (CRP), total leukocyte count and the third component of complement (C3) have 
been associated with CVD [21-24].
Postprandial inflammation starts with the increase of remnant lipoproteins and glu-
cose in the circulation. This leads to activation of circulating leukocytes, which interact 
with the endothelium [25-29]. Endothelial dysfunction, due to for instance hypercho-
lesterolemia, smoking, hypertension or diabetes mellitus, may induce the expression 
of endothelial adhesion molecules, such as vascular cell adhesion molecule 1 (VCAM-1) 
[25,29]. An important step in the development of atherosclerosis is the activation of 
leukocytes in the circulation. Unstimulated neutrophils have some adherence to endo-
thelial cells, but enhanced adherence is almost entirely dependent on the expression 
of integrins on the leukocyte surface [30]. These integrins are stored in intracellular 
granules and are brought to the surface upon stimulation [31,32]. CD11b, also known as 
complement receptor 3 or Mac-1, is expressed on activated neutrophils and monocytes 
[30]. The most important ligand for CD11b on endothelial cells is intercellular adhesion 
molecule-1 (ICAM-1) [33,34]. CD66b, also known as CEACAM8, is a marker of neutrophil 
degranulation [32,35]. Once leukocytes have adhered to the endothelium, they are 
stimulated by chemoattractant signals, in particular monocyte chemotactic protein-1 
(MCP-1), to migrate into the arterial wall [29]. Subendothelial migrated monocytes dif-
16 Chapter 1
ferentiate into macrophages, which can take up modified lipoproteins, leading to foam 
cell formation [25]. This process results in the recruitment of even more leukocytes to the 
lesion site, and in the production of cytokines, chemokines and growth factors, further 
damaging the endothelial wall, and eventually leading to necrosis [25].
PosTPrANdiAL LiPids iNducE iNfLAMMATioN
Lipids induce a state of inflammation, with increased levels of adhesion molecules, cyto-
kines, oxidative stress and leukocyte activation. An in vitro study demonstrated that TRLs 
with a high triglyceride and cholesterol content stimulate human aortic endothelial cells 
to express VCAM-1 [36], and during hypertriglyceridemia, the adhesion of monocytes to 
VCAM-1 is increased [37]. Not only TRLs itself, but also the FFAs released by hydrolysis of 
these particles stimulate endothelial cells to express adhesion molecules and to produce 
inflammatory cytokines [38]. In an in vivo study, ingestion of a high-fat meal resulted 
in an increase in neutrophil count, interleukin-6 (IL-6) and hydroperoxides, with a si-
multaneous decrease in endothelial function, reflected by flow-mediated endothelium-
dependent dilatation [39]. Others showed that ingestion of a high-fat meal by healthy 
volunteers increased serum bacterial endotoxin, or lipopolysaccharide (LPS), which may 
also lead to leukocyte activation and inflammation [40]. The ingestion of fat therefore 
results in increased leukocyte activation, which is reflected by an increase of surface 
expression of CD11b, CD11c and CD14 on monocytes, and CD11b, CD66b and CD62L 
on neutrophils, as has been shown in vitro [41,42] and in vivo [27,37,43,44]. These data 
point at a pro-inflammatory effect of dietary lipids on circulating inflammatory cells with 
detrimental effects on the vessel wall.
Apo B-containing lipoproteins have been shown to adhere to postprandial leukocytes 
in the circulation [26]. By adding labeled palmitic acid to an oral fat load, it was demon-
strated that leukocytes become enriched with dietary FFAs [26]. The uptake of TRLs by 
leukocytes is most likely mediated by different receptors, such as the LDL-R, LRP-1 and 
the apo B48 receptor [37,45,46]. Opsonization of remnants in the circulation may be 
directly related to leukocyte activation.
The molecular mechanism behind lipid-induced inflammation probably involves 
activation of the transcription factor nuclear factor kappa B (NF-κB). The remnants 
of TRLs migrate into the subendothelial space, where they induce the production 
of reactive oxygen species (ROS). This may lead to the oxidative modification of LDL, 
and these oxidized lipoproteins (oxLDL) are easily taken up by macrophages, smooth 
muscle cells and endothelial cells via scavenger receptors, such as CD36, SR-AI/II, SR-BI 
and the lectin-like oxidized LDL receptor 1 (LOX-1) [47,48]. Internalized lipoproteins can 
induce activation of the protein kinase C (PKC) pathway, resulting in activation of the IκB 
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1kinase complex and subsequently NF-κB. Activated NF-κB will induce the transcription 
of genes encoding for several cytokines, including tumor necrosis factor-alpha (TNF-α), 
interferon-gamma (IFN-γ), interleukin-1 beta (IL-1β), IL-6 and IL-8, chemokines, such as 
MCP-1 and macrophage inflammatory protein-1 alpha (MIP-1α) and cellular adhesion 
molecules, such as VCAM-1 (Figure 1.1).
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figure 1.1. The cellular processes involved in lipid- and glucose-induced inflammation
The remnants of triglyceride-rich lipoproteins and oxidized low-density lipoprotein (oxLDL) are taken up by 
circulating leukocytes, macrophages, endothelial cells and smooth muscle cells via several scavenger receptors, 
including CD36, SR-AI/II, SR-BI and lectin-like oxidized LDL receptor 1 (LOX-1). Intracellular, remnants and oxLDL 
activate the protein kinase C (PKC) pathway, resulting in activation of nuclear factor kappaB (NF-κB). NF-κB 
induces the transcription of several inflammatory genes, including genes encoding for cytokines, chemokines 
and adhesion molecules. During hyperglycemia, the intracellular synthesis of diacylglycerol (DAG) in endothelial 
cells, smooth muscle cells, monocytes and macrophages is increased, leading to further activation of the PKC 
pathway. Activation of the PKC pathway in monocytes also results in the release of the integrins CD11b, CD11c 
and CD14 stored in intracellular vesicles. In addition, during hyperglycemia, advanced glycation end products 
(AGEs) are formed. These AGEs are taken up by endothelial cells, monocytes and macrophages via the recep-
tor for AGE (RAGE) and lactoferrin-like polypeptide (LF-L) complex, resulting in activation of mitogen-activated 
protein kinase (MAPK) and subsequently NF-κB activation. AGEs also enhance the formation of oxLDL, and dur-
ing hyperglycemia the expression of LOX-1 on monocytes and macrophages increases. These processes further 
facilitate the uptake of oxLDL by macrophages and thus enhance the inflammatory process.
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GLucosE ANd PosTPrANdiAL iNfLAMMATioN
Not only lipids, but also glucose may be involved in postprandial inflammation. In fact, 
the generation of oxidative stress due to hyperglycemia has been proposed to be a key 
event in the development of diabetic complications [49]. In vivo studies have demon-
strated that ingestion of glucose results in increased production of TNF-α and IL-1β 
by peripheral blood mononucleated cells [50], reduced flow-mediated endothelium-
dependent dilatation [39,51], increased formation of ROS and oxidative stress [51] and 
increased leukocyte activation [28].
Hyperglycemia may induce inflammation via several mechanisms. One is the increased 
activation of the PKC pathway in endothelial cells, macrophages and smooth muscle 
cells. Activation of PKC results in increased cytokine production via activation of NF-κB 
[52]. This increased PKC activity is probably stimulated by an increased de novo synthesis 
of diacylglycerol in endothelial cells during hyperglycemia, which is an important acti-
vator of PKC [53].
Glucose can modify proteins to form advanced glycation end products (AGEs), which 
exert a pro-inflammatory effect in several ways [54]. AGEs can interact with cellular 
binding sites, such as the receptor for AGE (RAGE) and lactoferrin-like polypeptide (LF-L) 
on endothelial cells and macrophages. This AGEs-RAGE interaction results in uptake of 
AGEs by these cells and subsequently generation of ROS and activation of NF-κB via 
activation of mitogen-activated protein kinase (MAPK) [55-58]. The interaction between 
AGEs and RAGE on circulating monocytes also induces chemotaxis, leading to increased 
migration of these cells into the subendothelial space [57]. The presence of AGEs induces 
increased expression of RAGE on endothelial cells [59], which functions as a receptor for 
the integrin CD11b on monocytes and neutrophils, promoting leukocyte adhesion to 
the vessel wall [60].
Furthermore, AGEs induce the glycosylation of apo B and phospholipids on LDL parti-
cles, making these lipoproteins more susceptible to oxidative modifications, resulting in 
enhanced uptake by macrophages via scavenger receptors [56]. During hyperglycemia, 
the surface expression of LOX-1 on macrophages is increased, thereby enhancing the 
uptake of oxLDL by these cells [52].
Moreover, glycation of the regulatory membrane protein CD59 on endothelial cells, 
which inhibits the deposition of the membrane attack complex (MAC) of complement, 
leads to reduced activity of this protein and thus a higher susceptibility of the endothe-
lium for the MAC-induced release of pro-inflammatory cytokines [61].
Finally, hyperglycemia results in a reduced antioxidant capacity. Hyperglycemia leads 
to increased reduction of glucose to sorbitol by aldose reductase, and during this pro-
cess NADPH is consumed [54]. Since the cellular antioxidant capacity depends on the 
energy provided by NADPH to the antioxidants glutathione and thioredoxin, reduction 
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1of NADPH will result in increased oxidative stress [54,62]. The cellular processes involved 
in inflammation induced by lipids and glucose are summarized in Figure 1.1.
LifEsTyLE ANd PhArMAcEuTicAL iNTErVENTioNs ModuLATiNG 
PosTPrANdiAL iNfLAMMATioN
Evidence from clinical trials is starting to emerge, demonstrating that postprandial in-
flammation can be reduced by lifestyle modifications. Several studies have established 
a positive effect of dietary antioxidants on postprandial inflammation. Foods rich in 
polyphenols, such as strawberries and black raspberries, reduce postprandial inflamma-
tion [63,64]. The daily consumption of strawberry beverages during six weeks reduced 
the postprandial oxidative modification of LDL in hyperlipidemic patients [63]. The 
consumption of black raspberries for four days attenuated the high-fat meal-induced 
production of IL-6 [64]. Flavonoids seem to reduce postprandial inflammation as well. 
An in vitro study demonstrated that the flavonoid epigallocatechin-3-gallate suppressed 
the hyperglycemia-induced expression of VCAM-1 on human umbilical vein endothelial 
cells and reduced the adhesion of monocytes to these cells, via inhibition of PKC and 
NF-κB activation [65]. This beneficial effect of flavonoids on postprandial inflammation 
has been confirmed in vivo. In a randomized trial with 30 healthy volunteers, the con-
sumption of orange juice, which contains flavonoids, with a high-fat meal reduced the 
postprandial production of ROS and prevented the postprandial increase in LPS [66]. 
Food containing carotenoids may also decrease postprandial inflammation. The con-
sumption of tomatoes containing this antioxidant reduced postprandial IL-6 production 
and prevented LDL oxidation, even though the tomatoes exaggerated postprandial 
lipemia [67]. This anti-inflammatory effect, despite an increase in serum lipids, has also 
been observed with the consumption of red wine. Although the addition of red wine to 
a meal resulted in a higher increase in serum lipids, red wine prevented the production 
of NF-κB by peripheral blood mononucleated cells [68]. In contrast, addition of vodka 
to the meal did not attenuate the NF-κB activation, indicating that this effect was not 
due to the alcohol content of the wine [68]. The anti-inflammatory effect of red wine is 
more likely the result of the antioxidants quercetin and α-tocopherol succinate, since 
treatment of human mononuclear cells with VLDL in the presence of these antioxidants 
inhibited the activation of NF-κB [68]. Collectively, these data suggest a beneficial effect 
of dietary antioxidants, such as polyphenols, flavonoids, carotenoids, quercetin and 
α-tocopherol succinate, on postprandial inflammation.
In addition to antioxidants, a diet rich in monounsaturated fatty acids (MUFA), as op-
posed to saturated fatty acids (SFA), reduces postprandial inflammation. In a small study, 
the consumption of a meal based on extra virgin olive oil, which is rich in MUFA, did not 
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elicit NF-κB activation in peripheral blood mononucleated cells, in contrast to ingestion 
of a meal based on butter, rich in SFA, or walnuts, which contained an equal amount of 
MUFA, SFA and polyunsaturated fatty acids (PUFA) [69]. This beneficial effect of MUFA 
was confirmed in another trial with 20 elderly healthy subjects. In this study, a Mediter-
ranean diet with a high virgin olive oil content not only reduced total cholesterol, LDL-C 
and apo B, but also the postprandial expression of MCP-1, matrix metalloproteinase 9 
(MMP-9) and the NF-κB subunit p65 in peripheral blood mononucleated cells [70]. In 
another small study, the addition of avocado, rich in MUFA, to a hamburger meal attenu-
ated the postprandial increase of IL-6, via reduced activity of the NF-κB pathway [71].
The effect of exercise on postprandial inflammation remains controversial. In a study 
among 20 cigarette smokers, those who reported to exercise two or more hours a 
week had lower postprandial levels of malondialdehyde than untrained smokers [72]. 
However, in a small randomized trial, exercise before a high-fat meal did not reduce 
postprandial serum lipid hydroperoxides [73]. In a cross-sectional study among middle-
aged men, active men had lower fasting levels of IL-6 and CRP than sedentary men, but 
no difference in postprandial inflammation was observed [74].
Weight loss seems to have a favorable effect on postprandial inflammation. Moderate 
weight loss reduced the postprandial soluble intercellular adhesion molecule (s-ICAM), 
MCP-1 and high-sensitivity CRP (hs-CRP) increment in 11 normolipidemic moderately 
obese men [75]. In another study, weight loss reduced postprandial IL-6 levels in eight 
men with impaired glucose tolerance [76].
Several lipid-lowering drugs are effective in lowering postprandial inflammation 
as well. Simvastatin, atorvastatin and pitavastatin have all been shown to attenuate 
postprandial inflammation [77-79]. In addition, fenofibrate reduces the production of 
TNF-α, IL-1β, IL-6, MCP-1 and MIP-1α [80,81]. Glucose-lowering drugs may also reduce 
postprandial inflammation. Rosiglitazone and metformin have been shown to increase 
levels of the antioxidant enzyme paraoxonase (PON)-1 and decrease postprandial levels 
of MCP-1 [82,83]. Treatment of patients with type 2 diabetes mellitus with nateglinide, 
a glucose-lowering drug belonging to the meglitinides class of drugs, significantly 
reduced postprandial oxidative stress and increased endothelial function [51]. Infusion 
of glucagon-like peptide 1 during hyperglycemia significantly reduced oxidative stress, 
inflammation and endothelial dysfunction in patients with type 1 diabetes mellitus [84]. 
To the best of our knowledge, no studies have compared the effect of lipid-lowering 
versus glucose-lowering therapy on postprandial inflammation in patients with diabe-
tes mellitus. The effects of different dietary and pharmaceutical interventions are sum-
marized in Table 1.1.
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ViTAMiN d: EVidENcE for A roLE iN AThEroscLErosis
Vitamin D is a fat-soluble vitamin, which we can obtain from sunlight exposure, diet 
and dietary supplements [85]. Vitamin D2, or ergocalciferol, is formed by ultraviolet ir-
radiation of ergosterol from yeast [85]. Vitamin D3, or colecalciferol, is formed through 
the ultraviolet irradiation of 7-dehydrocholesterol from lanolin [85]. Once vitamin D 
enters the human body, it is bound to vitamin D binding protein and transported to the 
liver, where it is converted to its major circulating form, 25-hydroxyvitamin D [86]. In the 
kidneys, 25-hydroxyvitamin D is metabolized to its active form, 1,25-dihydroxyvitamin 
D, by the enzyme 25-hydroxyvitamin 1-alpha-hydroxylase [85,86]. This conversion is 
regulated by levels of parathyroid hormone, calcium and phosphorus [85].
The importance of vitamin D in bone homeostasis has been acknowledged for many 
years [87]. Lately, it has become evident that vitamin D also plays a role in CVD and in 
mortality. Low vitamin D is associated with increased risk of death due to cardiovascular 
disease, cancer and all-cause mortality [88,89]. Evidence even suggests that supplemen-
tation of vitamin D3 reduces all-cause mortality in adults [89].
Although it is evident that most tissues and cells in the body, including endothelial 
cells [90] and inflammatory cells [91-93], have a vitamin D receptor, much is still un-
known about the precise mechanisms involved in the modulation of atherosclerosis by 
vitamin D. Possibly, these beneficial effects may partly be due to an effect of vitamin 
D on postprandial inflammation. A pilot study by our group indicates that vitamin D3 
supplementation may reduce postprandial leukocyte activation [94], but these results 
need to be confirmed in a randomized controlled trial.
BLood cELL-BouNd APoLiPoProTEiN B ANd AThEroscLErosis
Current measurement of apo B focusses on the lipoproteins present in plasma or serum. 
However, our research group has developed a method to measure apo B present on 
the surface of circulating blood cells by flow cytometry, and demonstrated that apo B 
can be detected on the surface of erythrocytes, monocytes and neutrophil granulocytes 
[26,95,96]. A high level of apo B bound to circulating erythrocytes (ery-apoB) was associ-
ated with a decreased prevalence of clinical and subclinical atherosclerosis [95,96]. We 
speculate that this inverse association may be due to protection of the vessel wall from 
interaction with atherogenic apo B-containing lipoproteins, and that erythrocytes trans-
port these particles from the circulation to the liver, for uptake and elimination, resulting 
in erythrocyte-mediated reverse cholesterol transport [97]. There is strong evidence that 
the binding of apo B to blood cells is mediated by the complement receptor 1 (CR1), 
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1and we have demonstrated in vitro and ex vivo that both the classical and alternative 
complement pathway are involved [98].
More research into the phenomenon of cell-bound apo B is needed. For instance, it is 
still unknown why some subjects have high ery-apoB, while others have very low or un-
detectable ery-apoB, and what determinants influence the level of ery-apoB. In addition, 
while cross-sectional data point at a protective effect of ery-apoB, prospective data are 
lacking. Since leukocytes play an important role in atherogenesis, and apo B has been 
detected on the surface of circulating leukocytes [26], the relation between leukocyte-
bound apo B and atherosclerosis needs to be investigated. Finally, the expression of CR1 
on erythrocytes is tightly regulated by polymorphisms in the CR1 gene [99]. Since CR1 is 
very likely involved in the binding of apo B-containing lipoproteins to erythrocytes, and 
ery-apoB may protect against atherosclerosis, the role of CR1 polymorphisms in future 
CVD needs to be established.
GoALs of This ThEsis
In Part 1 of this thesis, we aim to further investigate postprandial inflammation. We will 
review the value of postprandial lipid measurements, as opposed to fasting samples, in 
the prediction cardiovascular risk (Chapter 2). We will investigate the role of postpran-
dial glucose and lipids in leukocyte activation (Chapters 3 and 4). We will investigate 
whether vitamin D may inhibit postprandial inflammation (Chapter 5), and assess 
whether leukocyte activation may predict future cardiovascular events (Chapter 6).
In Part 2, we aim to further investigate blood cell-bound apo B. We will investigate the 
clinical determinants of ery-apoB (Chapter 7), assess the value of ery-apoB in the predic-
tion of future cardiovascular events (Chapter 8), investigate whether leukocyte-bound 
apo B is related to cardiovascular disease (Chapter 9), and whether CR1-polymorphisms, 
the receptor likely being involved in binding of apo B to erythrocytes, are related to 
future cardiovascular events (Chapter 10).
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ABsTrAcT
Current guidelines for the management of dyslipidaemias recommend measuring lipid 
profiles in the fasting state. The primary lipid targets are traditionally plasma total cho-
lesterol and low-density lipoprotein-cholesterol (LDL-C) levels. However, triglycerides, 
apolipoprotein (apo) B and non-high-density lipoprotein-cholesterol (non-HDL-C) 
are also suitable parameters to assess cardiovascular risk and to guide lipid-lowering 
therapy. The advantage of the use of these variables is that they can be used in both the 
fasting and nonfasting state. In most cases, postprandial lipid profiles in combination 
with apo B are as useful as fasting lipid profiles for the differentiation between familial 
lipid disorders, such as heterozygous familial hypercholesterolemia, familial combined 
hyperlipidemia and familial hypertriglyceridemia. This article will address the interpreta-
tion, applications and limitations of a nonfasting lipid profile for daily clinical practice.
The use of the nonfasting lipid profile for lipid-lowering therapy in clinical practice point of view 33
2
iNTroducTioN
The current guideline for the management of dyslipidaemias, issued by the European 
Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), recom-
mends the use of total cholesterol (TC) and low density lipoprotein-cholesterol (LDL-C) 
as the primary targets of lipid-lowering therapy [1]. According to this guideline, these 
measurements should be carried out after a 12 hour fast. LDL-C is calculated with the 
use of the Friedewald formula, which contains TC, high density lipoprotein-cholesterol 
(HDL-C) and triglycerides (LDL-C = TC – HDL-C – (fasting triglycerides / 2.2), in the case of 
mmol/L). Fasting triglycerides are believed to be more appropriate for the calculation of 
LDL-C, since triglycerides rise postprandially and are influenced by many dietary factors. 
Several studies suggest that certain lipid parameters may also be used in the nonfasting 
state for cardiovascular risk management, including triglycerides [2–5], apolipoprotein 
(apo) B and non-HDL-C. In contrast to triglycerides, apo B and non-HDL-C levels are not 
influenced by the prandial situation [6–8]. In Denmark, standard lipid measurements are 
performed nonfasting nowadays [7]. A nonfasting lipid measurement allows patients to 
eat normally before blood sampling and allows physicians to determine the lipid profile 
at any random moment. This will also contribute to patient adherence when long-term 
follow-up after initiating lipid lowering therapy is necessary, and may prevent long wait-
ing times for venipunctures in the early morning.
ThE iNfLuENcE of ThE NoNfAsTiNG sTATE oN LdL-c
Since triglyceride levels rise on average 0.5 mmol/L in women and 1.0 mmol/L in 
men, the calculated LDL-C decreases during the day, with the risk of underestimation 
when measured in the nonfasting state [9]. Recently, it has been suggested that LDL-C 
levels are 0.3–0.6 mmol/L lower when measured two hours postprandially than fast-
ing measurements [7]. Furthermore, nonfasting LDL-C levels may be less sensitive to 
predict cardiovascular disease (CVD) [4], even if a direct method of measurement is used 
[10]. Finally, it has been suggested that the concentration of LDL-C is falsely low in the 
nonfasting state due to hemodilution. Recently, a cross-sectional study with 209,180 
subjects demonstrated that fasting affected LDL-C subclass levels only slightly [11]. In 
this study, the variation of LDL-C between fasting and nonfasting samples was up to 
10%. Taken together, we suggest that the use of LDL-C in the nonfasting state is debat-
able, since LDL-C is slightly lowered in the nonfasting state.
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NoNfAsTiNG TriGLycEridEs As PrEdicTors of cArdioVAscuLAr risk
Recent studies have demonstrated the direct association between triglycerides and CVD 
[5,12]. However, the relationship between triglycerides and CVD may be caused by its 
close relationship between triglycerides and atherogenic remnant cholesterol levels [5].
Large epidemiological studies have established the power to predict CVD by the use 
of nonfasting triglycerides. The Copenhagen City Heart Study has demonstrated that 
elevated nonfasting triglycerides are associated with an increased risk of myocardial 
infarction, ischemic heart disease and death in men and women [5]. However, when 
adjusted for several covariates, including diabetes mellitus, body mass index and high-
sensitivity C-reactive protein, nonfasting triglycerides lost their predictive value of future 
cardiovascular events in women, but not in men. A meta-analysis of 29 prospective stud-
ies has shown that fasting and nonfasting triglycerides were similarly predictive of fatal 
and nonfatal coronary events [13]. Results from the Women’s Health Study even suggest 
that triglycerides measured two to four hours postprandially might be a better predictor 
of CVD than fasting triglycerides [2,4]. Each 1 standard deviation increase in nonfasting 
triglycerides was associated with a hazard ratio (HR) of 1.17 (95% confidence interval 
1.04–1.31), while the HR for fasting triglycerides was not significant [4]. The HR for a 
cardiovascular event for subjects with triglycerides >1.9 mmol/L (171 mg/dL) was 1.98 
(95% confidence interval 1.21–3.25). These data suggest that nonfasting triglycerides 
can be used for cardiovascular risk prediction.
The measurement of triglycerides is complicated by its high intra-individual variability, 
on average 22.5% [9]. The absolute intra-individual variability is higher in hypertriglyceri-
demic patients than in patients with normal triglycerides. It has been suggested that the 
variability of fasting triglycerides is lower than that of nonfasting triglycerides. However, 
we have shown that the variability of triglycerides increases only slightly during the day, 
in contrast to current believes [9]. In women and in patients with hypertriglyceridemia, 
the variability does not even differ between the fasting and nonfasting state [9].
Therefore, we suggest that the risk of false positive or false negative hypertriglyc-
eridemia is equally present in the fasting and nonfasting state with regard to the intra-
individual variability. However, since triglycerides rise during the day, triglyceridemia 
may be falsely overestimated when reference values for fasting triglycerides are used 
[9,11].
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NoN-hdL-c ANd APo B As ALTErNATiVE for LdL-c iN ThE NoNfAsTiNG 
sTATE
In patients receiving lipid-lowering therapy, the risk of cardiovascular events often re-
mains increased despite lowering of LDL-C, due to inadequate lowering of cholesterol in 
triglyceride-rich lipoproteins [14]. This has been called ‘residual risk’. Non-HDL-C and apo 
B can be considered as alternative parameters for LDL-C to guide lipid lowering therapy 
and CVD risk assessment more accurately, since they take all atherogenic lipoproteins 
into account [15,16].
Non-HDL-C represents the cholesterol content of all atherogenic lipoproteins, in-
cluding remnant lipoproteins, and it is calculated by subtracting HDL-C from TC. Apo 
B reflects the number of atherogenic lipoproteins, since each atherogenic lipoprotein 
contains a single apo B molecule. The measurement of apo B has been validated and 
standardized, resulting in a low coefficient of variation between different laboratories 
in samples with low as well as high levels of apo B [17]. Prospective studies and meta-
analyses have consistently demonstrated that non-HDL-C and apo B are at least as good 
as [4,8,18,19] or superior to [6,14,15] LDL-C in the prediction of CVD during lipid-lowering 
therapy. Another advantage of non-HDL-C and apo B over LDL-C is the fact that these 
measurements are not influenced by the prandial state and can therefore be measured 
nonfasting [20]. It has to be noted that results from a large prospective study indicated 
that, despite small changes in their concentrations, the predictive value of apo B and 
non-HDL-C decreased when these markers were measured in the nonfasting state [4].
The 2011 ESC/EAS guideline recommends the use of non-HDL-C as secondary target 
of lipid-lowering therapy in patients with hypertriglyceridemia or type 2 diabetes mel-
litus (T2DM), since in contrast to LDL-C, non-HDL-C reflects the atherogenic burden of 
circulating remnant cholesterol [1,21]. The treatment target for non-HDL-C is 0.8 mmol/L 
(30 mg/dL) higher than the respective target for LDL-C [1]. The treatment target for non-
HDL-C recommended by the ESC/EAS is 3.3 mmol/L (130 mg/dL) for patients with high 
cardiovascular risk.
Besides non-HDL-C, apo B may also be an adequate parameter for initial cardiovas-
cular risk assessment [16]. The goal for apo B recommended by the ESC/EAS guideline 
is 1.0 g/L for patients with increased cardiovascular risk and 0.8 g/L for patients with 
severely increased risk [1]. Table 2.1 gives an overview of suggested cut-off risk points 
for the nonfasting lipid profile, based on the ESC/EAS guideline [1] and results from the 
Women’s Health Study [2].
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We suggest that the potential inaccuracy of LDL-C in the nonfasting state is not a limit-
ing factor when using nonfasting lipid profiles, since non-HDL-C and apo B can be used 
as alternatives for LDL-C.
NoNfAsTiNG APo B ANd TriGLycEridEs iN ThE diAGNosis of PriMAry 
hyPErLiPidEMiAs
Mild hypercholesterolemia, hypertriglyceridemia or a combination of both are frequently 
caused by a polygenic predisposition combined with inadequate lifestyle. Nevertheless, 
it is important to detect primary lipid disorders when present. The three most frequent 
primary hyperlipidemias are familial hypercholesterolemia (FH), familial combined 
hyperlipidemia (FCH) and familial hypertriglyceridemia (FHTG). All three diseases are 
characterized by a different pathogenesis and lipid profile. FH and FCH are both associ-
ated with a strongly increased cardiovascular risk, as opposed to FHTG [22,23]. Patients 
with FHTG have an increased risk of T2DM and pancreatitis [24].
FCH, FH and FHTG can be differentiated by family history, physical examination and, 
in most cases, by a nonfasting lipid profile. Apo B and triglycerides are the most im-
portant parameters of the lipid profile to distinguish FHTG from FH and FCH [25,26]. In 
FHTG, apo B is normal, in contrast to FH and FCH [25,27], and triglycerides are strongly 
elevated, whether triglycerides are measured fasting or nonfasting [28]. Determining a 
nonfasting lipid profile will often be sufficient for differentiation between FH and FCH. 
Both diseases are accompanied by elevated apo B and LDL-C, but in FH, triglycerides are 
usually normal, whereas in FCH, triglycerides are usually elevated [29]. The value of apo 
B to distinguish FCH from FHTG is also underlined by the authors of the guideline for 
evaluation and treatment of hypertriglyceridemia, provided by the Endocrine Society 
[30]. The Nijmegen group has provided a nomogram for the diagnosis of FCH. This no-
mogram uses apo B, triglycerides and TC values [31]. However, one of the risks of using 
a nonfasting lipid profile is to get “falsely” elevated triglycerides in the case of FH, which 
Table 2.1 Suggested cut-off risk points for lipid-lowering therapy according to cardiovascular risk inde-
pendent from postprandial state
Cardiovascular risk Non-HDL-C Apo B Triglycerides
mmol/L mg/dL g/L mg/dL mmol/L mg/dL
Moderate risk < 3.8 < 145
High risk < 3.3 < 130 < 1.0 < 100
Very high risk < 2.6 < 100 < 0.8 < 80 <1.93 <171
Note: these recommendations are based on the guidelines published by the EAS/EAS [1] and results of the 
Women’s Health Study [2].
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can make differentiation between FH and FCH difficult. In this case, when both apo B 
and triglycerides are elevated in the nonfasting state, we suggest to consider a second 
lipid profile in the fasting state to adequately distinguish FH from FCH. It should be 
noted that differentiation between FCH and FH can be difficult even when using fasting 
lipid profiles, because FCH can be present if triglycerides are normal or almost normal, 
and FH can be accompanied by elevated triglycerides due to the genetic heterogeneity 
of the primary lipid disorders [30]. Here we have focused on classic genetic types of 
hyperlipidemia, although most cases of hyperlipidemia are polygenic.
coNcLusioN
In most cases, a nonfasting lipid profile is adequate for cardiovascular risk assessment, 
evaluation of lipid lowering therapy and for the differentiation between primary lipid 
disorders. The measurement of nonfasting lipid profiles has several advantages: patients 
do not need to fast and clinicians can have the lipid profile determined at any random 
time of day. Non-HDL-C and apo B are good alternatives for LDL-C and are not influenced 
by the nonfasting state.
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ABsTrAcT
Background: Leukocyte activation has been associated with vascular complications 
in type 2 diabetes mellitus (T2DM). Hyperglycemia may be involved in this leukocyte 
activation. Our aim was to investigate the role of elevated glucose concentrations on 
leukocyte activation in patients with a wide range of insulin sensitivity.
Methods: Leukocyte activation was determined after ingestion of 75 gram glucose 
in subjects with T2DM, familial combined hyperlipidemia (FCH) and healthy controls. 
Leukocyte activation markers were measured by flow cytometry. Postprandial changes 
were calculated as the area under the curve (AUC), and the incremental area under the 
curve corrected for baseline values (dAUC).
results: 51 subjects (20 T2DM, 17 FCH and 14 controls) were included. Fasting neutro-
phil CD66b expression and CD66b-AUC were respectively 36% and 39% higher in T2DM 
patients than in controls (p=0.004 and p=0.003). Fasting neutrophil CD66b expression 
correlated positively with glucose-AUC (Spearman’s rho 0.481, p<0.001) and HbA1c (rho 
0.433, p=0.002). Although fasting monocyte CD11b expression was not significantly 
different between subjects, monocyte CD11b-AUC was 26% higher in T2DM than in 
controls (p=0.006). Similar trends were observed for FCH patients. Monocyte CD11b-
dAUC correlated positively with glucose-AUC (rho 0.322, p=0.022) and HbA1c (rho 
0.319, p=0.023).
conclusions: These data suggest that both acute and chronic hyperglycemia, associated 
with insulin resistance as seen in T2DM and FCH, are involved in the increased fasting 
and postprandial leukocyte activation observed in these conditions.
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iNTroducTioN
Inflammation is important in the development of diabetic complications. Increased 
leukocyte activation has been established in patients with insulin resistance and type 
2 diabetes mellitus (T2DM) [1,2]. This leukocyte activation has been linked to microvas-
cular diabetic complications and atherosclerosis [3–5]. Activated leukocytes are able to 
adhere to the intact endothelium, and can migrate to the subendothelial space, where 
the development of atherosclerosis starts [6].
Leukocyte activation can be determined by quantitation of cell surface integrins like 
CD11b and CD66b. CD11b, or Mac-1, is involved in early adhesion of monocytes and 
neutrophils to the endothelium. CD66b, or CEACAM8, is a marker of neutrophil degranu-
lation [7].
Postprandial studies have shown that leukocytes are activated by lipids [8–10]. In ad-
dition, several studies have demonstrated the effect of glucose on leukocyte activation. 
An in vivo study showed a rapid increase in monocyte CD11b expression following the 
ingestion of glucose in T2DM patients and in healthy controls [11]. In a different study, 
administration of glucose during 15 days induced leukocyte activation in non-diabetic 
volunteers [12].
However, little is known about leukocyte activation in non-diabetic insulin resistant 
conditions. The aim of this study was to investigate the role of acute and chronic glyce-
mia in leukocyte activation in patients with a wide range of insulin sensitivity, such as 
T2DM and familial combined hyperlipidemia (FCH) [13] and in healthy controls.
MATEriALs ANd METhods
Subjects visiting our Department of Vascular Medicine, who met the diagnostic criteria 
for T2DM or FCH, were asked to undergo an oral glucose tolerance test (OGTT). Healthy 
volunteers were recruited by advertisement. T2DM was defined using the diagnostic cri-
teria of the World Health Organization [14]. FCH was defined as familial hyperlipidemia 
with a dominant inheritance pattern, elevated plasma apolipoprotein B concentrations 
(>1.2 g/L) and elevated fasting triglyceride levels (>1.7 mmol/L) [13]. Exclusion criteria 
were the presence of inflammatory disorders, a plasma C-reactive protein level above 10 
mg/L and disorders of kidney, liver and thyroid function.
In order to investigate the effect of statins on leukocyte activation, a second group 
of subjects was selected. The study design of this statin withdrawal substudy has been 
published elsewhere [15].
The studies were approved by The Institutional Review Board of the Sint Franciscus 
Gasthuis in Rotterdam and the Regional Independent Medical Ethical Committee at the 
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Maasstad Hospital in Rotterdam (registered at clinicaltrials.gov under clinical trial num-
bers NCT02130505 and NCT0634906). All participants gave written informed consent.
Blood samples were obtained fasting, and 1 and 2 hours after ingestion of 75 grams 
of oral anhydrous glucose. Blood was drawn from a peripheral vein of the forearm. For 
leukocyte activation markers, blood samples were obtained in sodium EDTA (2 mg/mL).
All clinical chemistry measurements were performed as described previously, ac-
cording to standard procedures in our laboratory [10]. The cell surface expression of 
CD11b and CD66b on monocytes and neutrophils was determined by flow cytometry, 
as described previously [10]. The fluorescent intensity of each cell was expressed as the 
mean fluorescent intensity (MFI), given in arbitrary units (au).
Data are given as mean ± SEM in the text, table and figure. The total area under the 
curve (AUC) was calculated by the trapezoidal rule using Graphpad Prism version 5.0 (LA, 
USA). The incremental integrated AUC (dAUC) was calculated after correction for base-
line values. Differences were tested by analysis of variance (ANOVA), with Fisher’s least 
significant difference (LSD) test as post-hoc analysis, or Chi-Square test for dichotomous 
variables. Correlation analysis was carried out using Spearman correlation statistics. P-
values <0.05 (2-tailed) were considered statistically significant.
rEsuLTs
A total of 51 subjects (20 T2DM patients, 17 FCH patients and 14 healthy volunteers) 
underwent an OGTT. Their baseline characteristics are listed in Table 3.1.
Table 3.1 General characteristics, fasting biochemical markers, use of medication, and fasting and post-
prandial glucose and leukocyte activation markers in T2DM patients, FCH patients and healthy controls
T2dM (n=20) fch (n=17) controls (n=14) P-value
Male/female (number) 12/8 10/7 5/9 0.316
Smoking, n (% smokers) 5 (25) 3 (18) 0 (0) 0.138
Age (years) 56.35 ± 1.33* 53.88 ± 1.51 50.07 ± 1.16 0.010
Body mass index (kg/m2) 31.29 ± 1.32*† 27.84 ± 0.74 26.01 ± 1.25 0.007
Waist circumference (m) 1.14 ± 0.04**† 1.02 ± 0.02 0.93 ± 0.04 <0.001
Systolic blood pressure 
(mmHg)
128 ± 3* 127 ± 4‡ 115 ± 2 0.009
Diastolic blood pressure 
(mmHg)
73 ± 2 78 ± 2 73 ± 2 0.069
HbA1c (%) 7.93 ± 0.26**†† 5.60 ± 0.07 5.26 ± 0.08 <0.001
Triglycerides (mmol/L) 1.88 ± 0.25* 2.65 ± 0.47‡ 0.94 ± 0.09 0.003
Total cholesterol (mmol/L) 5.12 ± 0.33 5.44 ± 0.32 5.09 ± 0.16 0.661
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Table 3.1 General characteristics, fasting biochemical markers, use of medication, and fasting and post-
prandial glucose and leukocyte activation markers in T2DM patients, FCH patients and healthy controls 
(continued)
T2dM (n=20) fch (n=17) controls (n=14) P-value
LDL cholesterol (mmol/L) 2.93 ± 0.25 3.06 ± 0.31 3.28 ± 0.17 0.624
HDL cholesterol (mmol/L) 1.22 ± 0.44 1.12 ± 0.06 1.38 ± 0.10 0.160
Apolipoprotein B (g/L) 1.11 ± 0.10 1.13 ± 0.09 0.94 ± 0.05 0.306
Apolipoprotein A-I (g/L) 1.45 ± 0.07 1.36 ± 0.04 1.47 ± 0.07 0.447
C-reactive protein (mg/L) 3.1 ± 0.8 6.0 ± 3.3 1.7 ± 0.3 0.335
Leukocyte counts (109 cells/L) 7.78 ± 0.51 7.29 ± 0.50 6.23 ± 0.41 0.098
Neutrophil counts (109 cells/L) 4.25 ± 0.38 4.19 ± 0.41 3.59 ± 0.29 0.431
Monocyte counts (109 cells/L) 0.60 ± 0.04 0.56 ± 0.05 0.52 ± 0.05 0.480
Lymphocyte counts (109 
cells/L)
2.62 ± 0.21* 2.32 ± 0.16 1.89 ± 0.14 0.029
Use of statins, n (%) 14 (70) 12 (71) 0 (0) <0.001
Use of ezetimibe, n (%) 2 (10) 8 (47) 0 (0) 0.002
Use of fibrates, n (%) 2 (10) 3 (18) 0 (0) 0.259
Use of acetylsalicylic acid, n (%) 4 (20) 5 (29) 0 (0) 0.096
Use of beta blockers, n (%) 7 (35) 3 (18) 0 (0) 0.040
Use of diuretics, n (%) 8 (40) 2 (12) 0 (0) 0.009
Use of ACE-inhibitors, n (%) 4 (20) 0 (0) 0 (0) 0.035
Use of angiotensin II receptor 
antagonists, n (%)
8 (40) 6 (35) 0 (0) 0.025
Use of calcium channel 
antagonists, n (%)
4 (20) 2 (12) 0 (0) 0.205
Glucose (mmol/L) Fasting 9.80 ± 0.72 **†† 5.61 ± 0.11 4.93 ± 0.12 <0.001
AUC 34.01 ± 1.33**†† 14.72 ± 0.95‡ 9.68 ± 0.38 <0.001
dAUC 14.19 ± 0.77**†† 3.58 ± 0.81‡ -0.19 ± 0.27 <0.001
Neutrophil CD66b (au) Fasting 9.07 ± 0.61*† 7.12 ± 0.38 6.67 ± 0.59 0.006
AUC 17.94 ± 1.22*† 14.50 ± 0.84 12.88 ± 1.27 0.008
dAUC -0.19 ± 0.36 0.26 ± 0.28 -0.47 ± 0.29 0.324
Monocyte CD11b (au) Fasting 40.31 ±1.64 38.19 ± 2.38 37.21 ± 2.07 0.540
AUC 77.61 ± 4.38* 71.39 ± 3.47 61.84 ± 2.73 0.022
dAUC -3.02 ± 2.31* -4.99 ± 2.46‡ -12.59 ± 2.19 0.021
Neutrophil CD11b (au) Fasting 34.69 ± 2.44 32.65 ± 2.28 29.90 ± 1.67 0.348
AUC 69.60 ± 4.46 68.09 ± 4.44 55.93 ± 3.39 0.073
dAUC 0.22 ± 2.15 2.80 ± 1.73 -3.87 ± 2.99 0.152
Data are given as mean ± SEM or as number (percentage). P-value for difference between groups (one-way 
ANOVA for continuous variables with LSD as post-hoc test and chi-square test for discrete variables).
*: P<0.05 T2DM patients vs controls; **: P<0.001 T2DM patients vs controls; †: P<0.05 T2DM patients vs FCH 
patients; ††: P<0.001 T2DM patients vs FCH patients; ‡: P<0.05 FCH patients vs controls; ‡‡: P<0.001 FCH patients 
vs controls
AUC: Area Under the Curve; dAUC: delta Area Under the Curve
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T2DM patients had a higher fasting plasma glucose level than FCH patients and healthy 
controls. Glucose levels increased postprandially in T2DM patients. In FCH patients, glu-
cose increased only slightly. In healthy controls, glucose levels were not different from 
fasting measurements at 1 and 2 hours postprandially (Figure 3.1A and Table 3.1).
Fasting neutrophil CD66b expression in T2DM was 36% higher than in controls and 27% 
higher than in FCH (p=0.006, Figure 3.1B). Fasting CD11b expression on monocytes or 
neutrophils was not different between the three groups (Figures 3.1C and 3.1D).
Postprandial leukocyte activation was highest in T2DM patients. Monocyte CD11b ex-
pression decreased postprandially in all groups, but the decrease was smallest in T2DM 
patients. In this group, monocyte CD11b-AUC was 26% higher than in controls (p=0.022, 
Table 3.1). Neutrophil CD66b-AUC in T2DM was 39% higher than in controls and 24% 
higher than in FCH (p=0.008).
For the total group, fasting neutrophil CD66b expression correlated positively with 
glucose-AUC (Spearman’s rho: 0.481, p<0.001) and HbA1c (rho: 0.433, p=0.002). Post-
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figure 3.1. Glucose and leukocyte activation after OGTT in subjects with different levels of insulin resis-
tance
Mean (error bars denote SEM) changes in glucose (A), expression of neutrophil CD66b (B), monocyte CD11b 
(C) and neutrophil CD11b (D) during OGTT in T2DM patients (closed circle), FCH patients (closed triangle) and 
healthy controls (open square).
Glucose-dependent leukocyte activation 47
3
prandial changes in monocyte CD11b, reflected by the dAUC, correlated positively with 
glucose-AUC (rho 0.322, p=0.022) and HbA1c (rho 0.319, p=0.023). No correlations were 
found between fasting monocyte CD11b expression, or neutrophil CD66b-dAUC, with 
measurements of acute or chronic glycemia.
In a separate statin withdrawal cohort, 54 subjects were included. Their baseline 
characteristics have been published elsewhere [15]. The statins used were simvastatin 
(n=21), atorvastatin (n=6), rosuvastatin (n=22) and pravastatin (n=6). Discontinuation of 
statins for 6 weeks did not result in significant changes in fasting leukocyte activation. 
Monocyte CD11b expression was 30.53 ± 1.03 au before and 28.59 ± 0.81 au after statin 
withdrawal (p=0.108). Neutrophil CD11b expression was 43.81 ± 1.64 au before and 
43.83 ± 1.69 au after statin withdrawal (p=0.910). Neutrophil CD66b expression was 6.14 
± 0.19 au before and 6.06 ± 0.21 au after statin withdrawal (p=0.977).
discussioN
To the best of our knowledge, this is the first study describing a correlation between 
acute and chronic hyperglycemia and postprandial leukocyte activation changes in 
subjects with a wide range of insulin sensitivity. The relevance of these observations lies 
in the fact that activated leukocytes contribute to the development of atherosclerosis 
[6] and microvascular diabetic complications [3,4].
Previous studies on the effect of glucose on leukocyte activation have shown con-
flicting results. In an earlier in vivo study by our group, baseline levels of CD11b and 
CD66b were higher in T2DM patients than in controls [1]. Others found higher fasting 
monocyte CD14 and CD18 expression in female T2DM patients compared to controls [2]. 
However, similar levels of leukocyte activation in T2DM patients and controls have also 
been reported [11].
We observed a surprisingly high fasting neutrophil CD66b expression in T2DM pa-
tients compared with healthy controls. This is in line with previous studies [1,16].
In contrast to our study, Sampson and co-workers showed a slight increase in mono-
cyte CD11b two hours after an OGTT in T2DM patients and in controls [11]. At this point, 
we have no clear explanation for this discrepancy.
Our results indicate that in patients with FCH, who are known to be insulin-resistant 
[13], fasting and postprandial levels of leukocyte activation are intermediate, compared 
to T2DM patients and controls. Although there was no acute postprandial increase in 
the expression of activation markers, the observed correlation between postprandial 
glucose response and fasting as well as postprandial leukocyte activation, indicates an 
acute effect of glucose. In addition, the correlation between leukocyte activation and 
HbA1c suggests that also chronic hyperglycemia may be responsible for the increased 
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activation of leukocytes in patients with reduced insulin sensitivity. Therefore, acute and 
chronic hyperglycemia may be involved in increased fasting and postprandial leukocyte 
activation.
A limitation of this study is that only associations between glycemia and inflammation 
were studied. In order to establish a causal relationship, the effect of glucose-lowering 
interventions on leukocyte activation needs to be evaluated in future studies. One of the 
possible confounding factors may have been the use of drugs by T2DM and FCH patients. 
Especially statins have been proposed to have anti-inflammatory effects [17,18]. Results 
of our statin withdrawal cohort demonstrated that the expression of CD11b and CD66b 
is not affected by the use of statins. The role of ezetimibe and diuretics on leukocyte 
activation in humans is unknown [19]. Beta-blockers and angiotensin II AT1 receptor 
blockers have favorable effects on the adhesiveness of leukocytes to the endothelium 
[20].
In conclusion, acute and chronic hyperglycemia due to insulin resistance as seen in 
T2DM and FCH are associated with increased leukocyte activation.
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ABsTrAcT
Background: The postprandial situation is a pro-inflammatory condition most likely 
linked to the development of atherosclerosis. We evaluated the relationship between 
apolipoprotein (apo) B48 and fasting and postprandial leukocyte activation markers.
Methods: Leukocyte activation markers and apo B48 were determined in 80 subjects 
with and without coronary artery disease (CAD). Twelve healthy subjects underwent an 
oral fat loading test (up to 8 hours).
results: Fasting apo B48 was significantly higher in patients with CAD (n=47, 8.1 ± 5.2 
mg/L) than in subjects without CAD (n=33, 5.9 ± 3.9 mg/L, p=0.022). Fasting apo B48 
and triglycerides correlated positively with fasting monocyte CD11b and neutrophil 
CD66b expression. Plasma apo B48 and leukocyte activation markers increased after an 
oral fat load. Postprandial apo B48 correlated positively with postprandial monocyte 
CD11b (Spearman’s rho: 0.615, p=0.033). No correlations were found between fasting or 
postprandial triglycerides and postprandial leukocyte activation markers. We observed 
no correlations between postprandial apo B48 and postprandial neutrophil CD11b or 
CD66b expression.
conclusion: This study suggests that chylomicron remnants may be responsible for 
postprandial leukocyte activation in the circulation. The postprandial chylomicron 
response may be a stronger mediator of postprandial inflammation than postprandial 
triglyceridemia.
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iNTroducTioN
The postprandial situation is a pro-inflammatory condition most likely linked to the de-
velopment of atherosclerosis. Postprandial lipemia activates circulating leukocytes, as 
has been demonstrated in vitro and in vivo [1–3]. Activated leukocytes can adhere to the 
intact endothelium and migrate to the subendothelial space, where the development of 
atherosclerosis is initiated [4].
Both, increased leukocyte activation and postprandial triglycerides have been linked 
to the presence of coronary artery disease (CAD) and peripheral artery disease [5–10]. 
The measurement of postprandial lipemia is time-consuming, requiring postprandial 
measurements during several hours after an oral fat loading test [11]. It has been sug-
gested that fasting apolipoprotein (apo) B48 may be used as a surrogate marker for 
postprandial lipemia [11,12].
Diet-ingested lipids are transported to the circulation in chylomicrons. In the circula-
tion, triglycerides present in the chylomicrons are rapidly hydrolyzed by the enzyme 
lipoprotein lipase, and chylomicron remnants are formed [13]. Each chylomicron carries 
a single apo B48 molecule on its surface [14]. Since apo B48 is synthesized exclusively 
in the intestine, the level of apo B48 represents the total amount of circulating chylo-
microns and their remnants. Chylomicron remnants can migrate into the arterial wall, 
where they can induce foam cell formation without the need of prior oxidation or other 
modifications [15,16]. Although the infiltration rate into arterial tissue is approximately 
10 times lower than that of low-density lipoprotein (LDL) particles, their efflux rate is also 
approximately 20 times lower [17]. Thus, chylomicron remnants are more easily retained 
in the subendothelial space than LDL particles. It has been postulated that chylomicron 
remnants are mainly involved in the early stages of atherogenesis, and fasting apo B48 
levels have been associated with the development of atherosclerosis [18–21]. Carotid 
intima media thickness, a marker of subclinical atherosclerosis, was positively associ-
ated with fasting apo B48 [19]. In addition, fasting apo B48 was higher in patients with 
peripheral artery disease [20], and predicted the risk of coronary events independent of 
LDL cholesterol [21].
Chylomicrons may not only be directly involved in the development of atherosclerosis, 
but also indirectly, by stimulating inflammation following interaction with circulating 
leukocytes [1,2]. The aim of this study was to evaluate the relationship between apo B48 
and leukocyte activation markers in the fasting and the postprandial situation.
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MATEriALs ANd METhods
Participants
In order to assess the relationship between fasting apo B48 and markers of leukocyte 
activation, subjects who were scheduled to undergo a diagnostic coronary angiography 
were included. The design of this case-control study has been described extensively 
elsewhere [22]. Exclusion criteria were the presence of inflammatory disorders, plasma 
C-reactive protein above 10 mg/L, and disorders of kidney, liver and thyroid function. To 
investigate the role of postprandial apo B48 on leukocyte activation, a second group of 
healthy volunteers underwent an oral fat loading test. The design of this postprandial 
study has been described elsewhere [23]. The Institutional Review Board of the Sint 
Franciscus Gasthuis Rotterdam and the regional independent medical ethics committee 
of the Maasstad Hospital Rotterdam approved both studies. All participants gave writ-
ten informed consent.
study design
For the case-control study, anthropometric measures, the use of medication and cardio-
vascular history were recorded on the day of the angiography. Shortly before coronary 
angiography, fasting venous blood was obtained from a peripheral vein of the forearm. 
Blood samples were collected in tubes containing EDTA (1 mg/mL) and kept on ice until 
processed for determination of leukocyte activation markers. Coronary angiography 
images were scored by an independent cardiologist.
For the postprandial study, volunteers visited the hospital after an overnight fast. 
A fasting venous blood sample was drawn. After venipuncture, volunteers ingested 
fresh cream in a concentration of 50 grams of fat per square meter body surface. Blood 
samples were obtained at 2-hourly intervals, for up to 8 hours after fat ingestion.
Analytical methods
Parameters for glucose, C-reactive protein, total cholesterol, high-density lipoprotein 
(HDL) cholesterol and triglycerides were determined using Synchron LX-20 analyzers 
(Beckman Coulter, Brea, CA, USA) according to standard procedures in our laboratory. 
LDL cholesterol values were calculated using the Friedewald formula. Apo A-I and B 
were determined by rate nephelometry using an IMMAGE analyzer (Beckman Coulter). 
Blood cell counts were determined using LH750 analyzers (Beckman Coulter, Miami, FL, 
USA). The leukocyte differentiation was determined as a five-part differentiation on the 
same instruments. Apo B48 was measured using a high-sensitivity commercial ELISA 
(Shibayagi Co Ltd, Ishihara, Japan) [24]. Two plates with 4 replicates per plate of a low 
value internal quality serum control (mean 2.96 mg/L) were run. The mean intra-assay 
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coefficient of variation (CV) at this low concentration was 8.7%, the total CV for both 
assays was 10.3%. The inter-assay CV was (Geometric substract) 5.5%.
Leukocyte activation markers
Blood samples for the measurement of leukocyte activation markers were collected in 
EDTA and were determined by flow cytometry on the same day. The expression of leu-
kocyte activation markers on the cell surface was determined using fluorescent labeled 
monoclonal antibodies (Beckman Coulter). Antibodies against CD66b were labeled with 
fluorescein isothiocynate (FITC). Antibodies against CD11b were labeled with phyco-
erythrin (PE). Antibodies against CD45 labeled with PE-Texas Red (ECD) were used to 
differentiate leukocytes from erythrocytes and platelets. Whole blood was added to a 
combination of CD66b-FITC, CD11b-PE and CD45-ECD antibodies. Cells were incubated 
for 15 minutes in the dark at room temperature. In parallel, blood was incubated with 
FITC- and PE-conjugated mouse IgG1 as isotype control to correct for nonspecific bind-
ing. Erythrocytes were lysed by adding ice-cold isotonic erythrocyte lysing solution 
(NH4Cl 0.19 M; KHCO3 0.01 M; Na2EDTA.2H2O 0.12 M, pH 7.2) for 15 minutes. For the 
cross-sectional study, a Coulter Epics XL-MCL flow cytometer with a 488 nm Argon ion 
laser and EXPO 32 software were used for measurement and analysis. For the postpran-
dial study, a Navios flow cytometer (Beckman Coulter) was used for measurement and 
Kaluza software version 1.2 (Beckman Coulter) was used for analysis. The fluorescent 
intensity of each cell was expressed as the mean fluorescent intensity, given in arbitrary 
units (au). Lymphocytes, monocytes and granulocytes were identified based on their 
side scatter and the level of CD45 on their cell surface.
statistical analysis
Data are given as mean ± SD in the text, tables and figures. Baseline differences between 
the groups were tested with Independent Samples T Test for normally distributed con-
tinuous variables and with Mann-Whitney U Test for continuous variables with skewed 
distributions (apo B48, triglycerides, monocyte CD11b, neutrophil CD11b and CD66b). 
Differences between fasting and postprandial values were tested with Wilcoxon Signed 
Rank Test. Correlation analysis was carried out using Spearman correlation statistics. The 
total area under the curve (AUC) and the AUC corrected for baseline values (dAUC) were 
calculated by the trapezoidal rule using Graphpad Prism version 5.0 (LA, USA). Statistical 
analysis was carried out with PASW statistics version 22.0 (IBM SPSS Statistics, New York, 
United States). P-values <0.05 (2-tailed) were considered statistically significant.
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rEsuLTs
Baseline characteristics
A total of 80 patients participated in the cross-sectional study. Their baseline charac-
teristics are listed in Table 4.1. The CAD group consisted of older patients and included 
more males. They had higher body mass index, systolic blood pressure and fasting 
triglycerides. Plasma apo A-I, LDL cholesterol and HDL cholesterol were lower than in 
subjects without CAD. Fasting apo B48 was significantly higher in patients with CAD (8.1 
± 5.2 mg/L) than in subjects without CAD (5.9 ± 3.9 mg/L, p=0.022). Data suggested a 
trend for higher expression of leukocyte activation markers in patients with CAD. The 
use of medication by all subjects, and of those with and without CAD separately, are 
Table 4.1 Baseline characteristics of participants (n=80) in the cross-sectional study
Total group (n=80) CAD+ (n=47) CAD- (n=33) P-value
Age (years) 60 ± 15 66 ± 11 51 ± 16 <0.001
Male gender, n (%) 46 (58%) 33 (70%) 13 (40%) 0.011
Smoking, n (%) 12 (15%) 5 (11%) 7 (21%) 0.218
Diabetes mellitus, n (%) 18 (23%) 14 (30%) 4 (12%) 0.101
Body mass index (kg/m2) 26.8 ± 4.8 27.8 ± 4.2 25.4 ± 5.3 0.033
Waist circumference (meters) 1.07 ± 0.12 1.09 ± 0.11 1.00 ± 0.13 0.055
Carotid intima media thickness 
(mm)
0.719 ± 0.108 0.728 ± 0.100 0.690 ± 0.134 0.466
Systolic blood pressure (mmHg) 139 ± 23 147 ± 22 127 ± 21 <0.001
Diastolic blood pressure (mmHg) 79 ± 12 80 ± 9 78 ± 16 0.636
Glucose (mmol/L) 6.4 ± 1.8 6.6 ± 1.7 6.1 ± 1.9 0.164
Apolipoprotein A-I (g/L) 1.47 ± 0.37 1.34 ± 0.33 1.66 ± 0.34 <0.001
Apolipoprotein B (g/L) 0.94 ± 0.29 0.93 ± 0.28 0.96 ± 0.30 0.620
Apolipoprotein B48 (mg/L) 7.2 ± 4.8 8.1 ± 5.2 5.9 ± 3.9 0.022
Triglycerides (mmol/L) 1.58 ± 1.07 1.86 ± 1.19 1.18 ± 0.69 0.001
Total cholesterol (mmol/L) 4.8 ± 1.1 4.7 ± 1.1 5.1 ± 1.0 0.087
HDL cholesterol (mmol/L) 1.3 ± 0.4 1.2 ± 0.3 1.5 ± 0.4 0.002
LDL cholesterol (mmol/L) 2.8 ± 1.0 2.6 ± 1.0 3.1 ± 0.8 0.020
C-reactive protein (mg/L) 2 ± 2 3 ± 2 2 ± 2 0.555
Complement C3 (g/L) 1.20 ± 0.25 1.23 ± 0.21 1.17 ± 0.30 0.293
Leukocyte count (109 cells/L) 7.0 ± 1.8 7.1 ± 1.7 6.8 ± 1.9 0.430
Lymphocyte count (109 cells/L) 1.9 ± 0.6 2.0 ± 0.6 1.9 ± 0.6 0.355
Monocyte count (109 cells/L) 0.6 ± 0.2 0.6 ± 0.2 0.5 ± 0.2 0.057
Neutrophil count (109 cells/L) 4.3 ± 1.4 4.3 ± 1.3 4.3 ± 1.6 0.942
Monocyte CD11b (au) 30.5 ± 11.8 32.1 ± 9.6 28.2 ± 14.3 0.054
Neutrophil CD11b (au) 30.2 ± 11.3 31.5 ± 11.5 28.3 ± 10.7 0.263
Neutrophil CD66b (au) 6.59 ± 2.63 7.44 ± 2.44 5.39 ± 2.46 <0.001
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listed in Table 4.2. The use of statins, acetylsalicylic acid and calcium channel antagonists 
was significantly higher in the CAD group.
fasting apo B48 and triglycerides in relation to fasting leukocyte activation 
(figure 4.1)
There was a strong positive correlation between fasting apo B48 and fasting triglycerides 
(Spearman rho: 0.708, p<0.001). Weak but significant positive correlations were found 
between fasting apo B48 and fasting monocyte CD11b expression (rho: 0.261, p=0.019, 
Figure 4.1A), and between fasting apo B48 and fasting neutrophil CD66b expression (rho: 
Table 4.2 Use of medication by participants (n=80) in the cross-sectional study
Total group (n=80) CAD+ (n=47) CAD- (n=33) P-value
Use of statins, n (%) 47 (59%) 38 (81%) 9 (27%) <0.001
Use of acetylsalicylic acid, n (%) 43 (59%) 36 (77%) 7 (21%) <0.001
Use of beta blockers, n (%) 37 (46%) 26 (55%) 11 (33%) 0.069
Use of diuretics, n (%) 23 (29%) 15 (32%) 8 (24%) 0.616
Use of ACE-inhibitors, n (%) 22 (28%) 13 (28%) 9 (27%) 1.000
Use of angiotensin II receptor 
antagonists, n (%)
16 (20%) 12 (26%) 4 (12%) 0.166
Use of calcium channel 
antagonists, n (%)
22 (28%) 20 (36%) 5 (13%) 0.011
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figure 4.1. Fasting apo B48 and triglycerides in relation to fasting leukocyte activation
Correlation graphs between fasting lipid parameters and fasting leukocyte activation in patients with CAD 
(n=47, circles) and patients without CAD (n=33, triangles). Fasting apo B48 in relation to fasting monocyte 
CD11b expression (A). Fasting apo B48 in relation to fasting neutrophil CD66b expression (B). Fasting triglycer-
ides in relation to fasting monocyte CD11b expression (C). Fasting triglycerides in relation to fasting neutrophil 
CD66b expression (D).
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0.334, p=0.002, Figure 4.1B). Triglycerides correlated positively with fasting monocyte 
CD11b (rho: 0.381, p<0.001, Figure 4.1C) and neutrophil CD66b expression (rho: 0.418, 
p<0.001, Figure 4.1D). After exclusion of two outliers with triglycerides >5 mmol/L, the 
associations with monocyte CD11b and neutrophil CD66b remained significant (rho: 
0.347, p=0.002 and rho: 0.389, p<0.001, respectively). When CAD+ and CAD- subjects 
were analyzed separately, the association between fasting triglycerides and leukocyte 
activation remained significant in both groups. For apo B48, significance was lost in 
the CAD+ group, while there was a trend for an association in the CAD- group. Plasma 
total apo B correlated positively with fasting neutrophil CD66b (rho: 0.243, p=0.030) but 
not with monocyte CD11b expression (data not shown). No correlations were found 
between these leukocyte activation markers and LDL cholesterol.
fasting and postprandial apo B48 and triglycerides in relation to postprandial 
leukocyte activation (figures 4.2 and 4.3)
Twelve healthy volunteers participated in the postprandial study. Plasma apo B48 in-
creased after an oral fat load, with the maximal increase after 2 hours, from 3.6 ± 1.9 
mg/L to 6.4 ± 3.1 mg/L (p=0.002, Figure 4.2A). Plasma triglycerides increased from 0.71 
± 0.24 mmol/L to 1.62 ± 0.70 mmol/L after 4 hours (p=0.002, Figure 4.2B). Monocyte 
CD11b expression tended to increase after 4 hours, from 14.8 ± 2.3 au to 16.5 ± 2.2 au 
(p=0.06, Figure 4.2C). Neutrophil CD66b expression increased after 4 hours, from 3.63 ± 
1.10 au to 4.16 ± 1.22 au (p=0.019, Figure 4.2D).
Fasting apo B48 and the total postprandial apo B48 area under the curve correlated 
positively with postprandial monocyte CD11b area under the curve corrected for base-
line values (rho: 0.595, p=0.041 and rho: 0.615, p=0.033, respectively, Figures 4.3A and 
4.3B). The correlation between fasting apo B48 and postprandial monocyte CD11b was 
lost after exclusion of one outlier with high fasting apo B48 (rho: 0.474, p=0.121). No 
correlations were found between fasting or postprandial apo B48 and neutrophil CD11b 
or CD66b (data not shown). No correlations were found between fasting or postprandial 
triglycerides and postprandial leukocyte activation markers (Figures 4.3C and 4.3D).
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figure 4.2. Postprandial response during an oral fat loading test in 12 healthy volunteers
Postprandial apo B48 (A), postprandial triglycerides (B), postprandial monocyte CD11b (C) and postprandial 
neutrophil CD66b (D). Data are given as mean ± SD. * p<0.05 compared to t=0; ** p<0.01 compared to t=0
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figure 4.3. Fasting and postprandial apo B48 and triglycerides in relation to postprandial leukocyte acti-
vation
Fasting apo B48 in relation to postprandial monocyte CD11b (A). Postprandial apo B48 in relation to postpran-
dial monocyte CD11b (B). Fasting triglycerides in relation to postprandial monocyte CD11b (C). Postprandial 
triglycerides in relation to postprandial monocyte CD11b (D).
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discussioN
To the best of our knowledge, this is the first study describing a relationship between 
chylomicron remnants and postprandial leukocyte activation. Interestingly, this rela-
tionship was not found for plasma triglycerides. These data suggest that postprandial 
chylomicrons and their remnants may induce leukocyte activation in the circulation. 
The importance of these observations lies in the fact that both leukocyte activation 
and postprandial lipemia have been linked to the presence and the development of 
atherosclerosis [6,8–11,25–27].
In the present study, fasting apo B48 and triglycerides were positively associated 
with fasting leukocyte activation. The observed correlations were stronger for fasting 
triglycerides than for apo B48. We have previously demonstrated ex vivo that incuba-
tion of human monocytes in lipid emulsions in the hypertriglyceridemic range resulted 
in an increased expression of CD11b on monocytes and neutrophils [1]. Collectively, 
these data suggest that in the fasting situation and ex vivo, both the total triglyceride 
concentration and chylomicrons and their remnants may induce leukocyte activation. It 
should be noted however, that the association between fasting apo B48 and leukocyte 
activation was weakened when CAD+ and CAD- patients were analyzed separately, es-
pecially in the CAD+ group. This could be due to the relatively small number of subjects 
included, but it could also indicate that in patients with CAD, other factors than chylo-
micron remnants may be involved in fasting leukocyte activation, such as CRP. Although 
CRP levels did not significantly differ between both groups, we did not measure hsCRP.
Several studies have shown that postprandial lipemia induces leukocyte activation 
[1–3]. In vivo, ingestion of an oral fat load by healthy volunteers resulted in increased 
expression of several activation markers on monocytes and neutrophils [1–3,23]. Our 
data suggest that this postprandial leukocyte activation in the circulation may not per 
se be the result of increased triglycerides postprandially, but rather an effect of circu-
lating chylomicrons and their remnants. According to current concepts, chylomicron 
remnants induce atherosclerosis by migrating to the subendothelial space, where they 
induce leukocyte activation and foam cell formation [16]. We propose that in addition, 
chylomicron remnants may contribute to atherogenesis by activating leukocytes in the 
circulation. Thus chylomicron remnants may facilitate the adhesion of these activated 
leukocytes to the intact endothelium. This theory is supported by an in vitro study, in 
which chylomicron remnant-like particles induced monocyte activation and enhanced 
monocyte migration towards the chemokine monocyte chemoattractant protein-1 [28]. 
Furthermore, also postprandial neutrophils show increased migration to chemokines 
[29]. It should be noted that the observed correlation between fasting apo B48 and post-
prandial monocyte CD11b expression seemed to be depending on one outlier. However, 
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the correlation between postprandial monocyte CD11b with postprandial apo B48 was 
stronger than with fasting apo B48, and this is consistent with our hypothesis.
The observed association between leukocyte activation and postprandial chylomi-
crons may be the result of binding and uptake of these lipoproteins by leukocytes via 
the apo B48-receptor. A postprandial study in healthy volunteers has demonstrated 
that circulating monocytes accumulate postprandial lipids, while simultaneously apo 
B48-receptor and CD11b mRNA expression increased [30]. This apo B48-receptor and 
CD11b transcriptional activity decreased in the late postprandial phase, paralleling the 
decrease of apo B48-containing lipoproteins [30]. Another candidate receptor for the 
binding and uptake of chylomicrons is the LDL related protein-1. It has been shown that 
monocytes take up triglyceride-rich lipoproteins via this receptor, resulting in increased 
CD11b expression [2]. In addition, we have recently demonstrated that the complement 
receptor 1 may be involved in the binding of lipoproteins by circulating leukocytes [31].
A possible confounding factor in our study may have been the higher use of statins 
by CAD patients, since it has been suggested that statins may have anti-inflammatory 
effects [32,33]. We have previously investigated the effect of statin use on fasting leuko-
cyte activation. Six weeks of statin discontinuation in 54 hyperlipidemic subjects did not 
result in significant changes in fasting expression of monocyte CD11b, neutrophil CD11b 
or neutrophil CD66b [34]. Moreover, we have previously shown that the postprandial 
changes of these markers are not influenced by statin use in patients with CAD and 
combined hyperlipidemia [29]. Therefore, we believe that statin use did not influence 
the results of the current study.
Whether the observed relationship between postprandial chylomicron remnants and 
leukocyte activation in healthy subjects is relevant in CAD patients, which are known 
to have increased postprandial lipemia [11,27], remains to be investigated. Although 
the pattern of postprandial expression of leukocyte activation markers in CAD patients 
[29] does not seem to be very different from that observed in healthy controls [23], no 
studies have directly compared the postprandial inflammatory response in patients with 
and without CAD. Another limitation is that this is a clinical study, and that the described 
association between chylomicron remnants and inflammation does not necessarily 
demonstrate causality. Further mechanistic studies are needed in order to investigate 
the causality of the association.
In conclusion, our in vivo study suggests that chylomicron remnants may be re-
sponsible for postprandial leukocyte activation in the circulation. The postprandial 
chylomicron response may be a stronger mediator of postprandial inflammation than 
postprandial triglyceridemia.
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ABsTrAcT
context: Cholecalciferol (vitamin D3) may improve vascular function and reduce inflam-
mation, potentially providing an explanation for the proposed cardiovascular protection 
by vitamin D.
objective: We investigated whether cholecalciferol supplementation reduces post-
prandial arterial dysfunction and inflammation.
design: This was a randomized 1:1, double blind trial.
setting: The study was conducted in the Diabetes and Vascular Center of the Franciscus 
Gasthuis, Rotterdam, The Netherlands.
Patients: Twenty-four healthy premenopausal, overweight or obese, vitamin D deficient 
women.
interventions: A single high (300 000 IU) or low dose (75 000 IU) cholecalciferol.
Main outcome measures: The effect of low and high dose cholecalciferol on postpran-
dial leukocyte activation markers, pulse wave velocity (PWV) and augmentation index 
(AIx) during an oral fat loading test, expressed as area under the curve (AUC).
results: High and low dose supplementation increased vitamin D by 163 ± 134%, 
p<0.001 and 66 ± 59%, p<0.001, respectively. Monocyte CD11b-AUC slightly increased 
after low but not high dose (+6 ± 2%, p=0.012 and +4 ± 1%, p=0.339 respectively). There 
were no significant effects on postprandial PWV or AIx by high or low dose vitamin D. 
Fasting complement component 3 (C3) levels decreased by 5.9% (p=0.004) in the high 
dose, and by 4.0% (p=0.018) in the low dose group.
conclusions: A single dose of vitamin D does not seem to reduce arterial stiffness and 
leukocyte activation in overweight, vitamin D deficient women. Fasting C3 may decrease 
by vitamin D. Possibly, higher vitamin D concentrations may be needed to decrease 
inflammation and improve vascular function in overweight or obese vitamin D deficient 
women.
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iNTroducTioN
Postprandial lipemia, associated with acute inflammatory changes [1], negatively af-
fects endothelial function [2] and potentially promotes atherosclerosis [3]. Postprandial 
lipemia is characterized by the secretion of intestinal chylomicrons and hepatic very 
low-density lipoproteins (VLDL) into the circulation. Chylomicrons transport dietary fat-
soluble vitamins (A, D, E and K) to tissues in the body. Recently, vitamin D has received 
major interest in relation to cardiovascular disease, and vitamin D deficiency has been 
linked to increased cardiovascular mortality [4]. The proposed effects of vitamin D are 
numerous, and include modulation of vascular smooth muscle cell proliferation, cytokine 
production and monocyte and macrophage function [5]. Vitamin D supplementation 
has been associated with improvement of endothelial function [6], decreased cytokine 
production [7] and reduction of oxidative stress [8].
Leukocyte activation has been linked to atherosclerosis [9]. Activated neutrophils and 
monocytes express integrins, such as CD11b and CD66b on their cell surface, facilitat-
ing the binding of these leukocytes to the intact endothelium [10]. Arterial stiffness is 
associated with atherogenesis and reflects vascular health [11]. In a recent pilot study 
by our group, a single cholecalciferol dose of 100 000 IU reduced arterial stiffness and 
postprandial leukocyte activation in healthy, lean subjects [12]. Interestingly, the effects 
of cholecalciferol on leukocyte activation were solely observed in the females with 
relatively high vitamin D levels at baseline, although vascular function also improved 
in males.
The aim of the current double-blind randomized study was to further explore the ef-
fect of different doses of vitamin D3 on postprandial inflammation and arterial stiffness, 
in order to enhance our insight into the mechanisms behind the association between 
vitamin D deficiency and atherosclerosis. We hypothesized that vitamin D3 may reduce 
postprandial inflammation in premenopausal women and therefore improve arterial 
elasticity.
MATEriALs ANd METhods
subjects and study design
The study was designed as a 1:1 randomized, double-blind trial comparing high (300 
000 IU) and low (75 000 IU) dose vitamin D3 supplementation. The Institutional Review 
Board of the Franciscus Gasthuis Rotterdam and the regional independent medical eth-
ics committee of the Maasstad Hospital Rotterdam approved the study. All participants 
gave written informed consent. The study was registered at Clinicaltrials.gov under 
clinical trial number NCT01967459.
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Healthy overweight or obese women, who are known to have low vitamin D levels, 
were recruited by advertisement. Inclusion criteria were an age above 18 years, a 
premenopausal status, a body mass index (BMI) of 25 kg/m2 or above and vitamin D 
deficiency, defined by a 25-hydroxyvitamin D (25OHD) below 50 nmol/L. Exclusion 
criteria were the use of any kind of medication except for oral contraceptives, smoking, 
pregnancy, participation in a clinical study less than 6 months before inclusion and the 
use of vitamin supplements.
Assessed for eligibility
(n=106)
Randomized (n=24)
Excluded (n=82)
- Not meeting inclusion criteria (n=78)
- Declined to participate (n=4)
High dose group
Allocated to intervention (n=12)
Received allocated intervention (n=12)
Low dose group
Allocated to intervention (n=12)
Received allocated intervention (n=12)
Study day 1
1. Fasting blood sampling and arterial 
stiffness measurements
2. Ingestion of cream 50 g / m2 body 
surface
3. Blood sampling 2, 4, 6 and 8 hours
after cream ingestion
4. Administration of 300 000 IU of 
cholecalciferol
Study day 1
1. Fasting blood sampling and arterial 
stiffness measurements
2. Ingestion of cream 50 g / m2 body 
surface
3. Blood sampling 2, 4, 6 and 8 hours
after cream ingestion
4. Administration of 75000 IU of 
cholecalciferol
Study day 8
1. Fasting blood sampling and arterial 
stiffness measurements
2. Ingestion of cream 50 g / m2 body 
surface
3. Blood sampling 2, 4, 6 and 8 hours 
after cream ingestion
Study day 8
1. Fasting blood sampling and arterial 
stiffness measurements
2. Ingestion of cream 50 g / m2 body 
surface
3. Blood sampling 2, 4, 6 and 8 hours 
after cream ingestion
Analyzed (n=12) Analyzed (n=12)
figure 5.1. Study flowchart
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Volunteers interested in study participation were screened for eligibility. During 
screening, anthropometric parameters and the medical and family history were re-
corded. The level of 25OHD was determined in a nonfasting blood sample.
All subjects visited the hospital after a 10-hour overnight fast. A fasting blood sample 
was obtained and baseline arterial stiffness measurements were performed after 5 to 
10 minutes of rest. Fresh cream was ingested, in a concentration of 50 grams of fat per 
square meter body surface. Blood samples and arterial stiffness measurements were 
obtained at 2-hourly intervals, for up to 8 hours after fat ingestion. During this time, 
subjects were asked to rest, and they were not allowed to eat or drink, except for water. 
At the end of the first oral fat loading test (OFLT), volunteers received a single high or 
low dose of cholecalciferol. The OFLT was repeated after 7 days. After the second OFLT, 
no cholecalciferol was administered. An overview of the study design is given in Figure 
5.1.
outcome measures
The endpoint of the study was the differential effect of 75 000 IU low dose versus 300 
000 IU high dose vitamin D3 on postprandial leukocyte activation markers CD11b 
(primary endpoint), CD66b, CD35 and CD36, and vascular function, measured by pulse 
wave velocity (PWV) and augmentation index (AIx) (secondary endpoints).
Pulse wave velocity (PWV) and augmentation index (Aix)
PWV and AIx were measured and calculated with the SphygmoCor Electronics Module 
MM3 (AtCor Medical, West Ryde, Australia) and SphygmoCor CvMS Software Suite ver-
sion 8.0 (AtCor Medical, West Ryde, Australia). PWV is considered the gold standard to 
measure arterial stiffness as a marker for endothelial function [11]. The velocity of the 
pulse wave increases when the aortic stiffness increases. The PWV was measured using 
a noninvasive tonometry at the carotid and femoral artery. The distance between the 
carotid and femoral artery was measured with a measuring tape. The AIx, adjusted to a 
heart rate of 75 beats per minute (AIx@75), represents both macrovascular and micro-
vascular function. The radial artery was used to measure the AIx. Both the PWV and AIx 
were measured in duplicate at each time interval.
Analytical methods
Laboratory measurements were carried out according to standard procedures in our labo-
ratory [13–15]. Parameters for glucose, C-reactive protein, total cholesterol, high-density 
lipoprotein (HDL)-cholesterol, triglycerides and PTH were determined using Synchron 
DxC analyzers (Beckman Coulter, Brea, CA, USA). LDL-cholesterol values were calculated 
using the Friedewald formula. Apolipoproteins (apo) AI and B were determined by rate 
nephelometry using an IMMAGE analyzer (Beckman Coulter). Blood cell counts were 
72 Chapter 5
determined using DxH800 analyzers (Beckman Coulter). The leukocyte differentiation 
was determined as a five-part differentiation on the same instruments. Vitamin D status 
was determined by measuring 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 on 
serum, using a direct competitive chemiluminescence immunoassay (Liaison, DiaSorin, 
Saluggia, Italy). Serum complement component 3 (C3) was measured by nephelometry 
using an IMMAGE instrument (Beckman Coulter).
Blood samples for the measurement of leukocyte activation markers were collected 
in EDTA, and the flow cytometric measurement protocol was commenced within 30 
minutes, as described previously [15]. The expression of leukocyte activation markers 
on the cell surface was determined using fluorescent labeled monoclonal antibodies 
(Beckman Coulter). Antibodies against CD66b and CD36 were labeled with fluorescein 
isothiocynate (FITC). Antibodies against CD11b and CD35 were labeled with phyco-
erythrin (PE). Antibodies against CD45 labeled with PE-Texas Red (ECD) were used to 
differentiate leukocytes from erythrocytes and platelets. Whole blood was added to a 
combination of CD66b-FITC, CD11b-PE and CD45-ECD antibodies, or CD36-FITC, CD35-
PE and CD45-ECD antibodies. Cells were incubated for 15 minutes in the dark at room 
temperature. In parallel, blood was incubated with FITC- and PE-conjugated mouse IgG1 
as isotype control to correct for nonspecific binding. Erythrocytes were lysed by add-
ing isotonic erythrocyte lysing solution (NH4Cl 0.19 M; KHCO3 0.01 M; Na2EDTA.2H2O 
0.12 M, pH 7.2) for 15 minutes. A Navios flow cytometer (Beckman Coulter) was used for 
measurement and Kaluza software version 1.3 (Beckman Coulter) was used for analysis. 
Lymphocytes, monocytes and neutrophil granulocytes were identified based on their 
side scatter and the level of CD45 on their cell surface. The fluorescent intensity of each 
cell was expressed as the mean fluorescent intensity in arbitrary units (au).
sample size calculation
Sample size calculation was based on the results of a pilot study performed by our group 
[14]. In the female participants of that study, postprandial monocyte CD11b expression 
was 132.3 ± 6.2 MFI*h before and 118.4 ± 14.2 MFI*h after receiving cholecalciferol in 
a dose of 100 000 IU. To demonstrate a difference of 13.85 ± 9.52 MFI*h in monocyte 
CD11b expression between subjects receiving low and high dose cholecalciferol, at 
least 2 x 11 subjects had to be included (type I error 0.05, two sided, type II error 0.20, 
randomization ratio 1:1). We included 2 x 12 subjects to adjust for possible dropout.
statistics
Data are given as mean ± standard deviation for normally distributed variables, and as 
median (interquartile range) for variables with skewed distribution (CRP, C3 and PWV). 
Differences within groups before and after vitamin D3 supplementation, for the high 
and low dose group separately and for pooled data for both groups, were determined by 
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paired Student’s t-test or Wilcoxon matched pairs signed ranks test, where appropriate. 
Differences between groups were tested by independent Student’s t-test or Mann-
Whitney U test, where appropriate. The total area under the curve (AUC) was calculated 
by the trapezoidal rule using Graphpad Prism version 5.0 (LA, USA). Statistical analysis 
was carried out with PASW statistics version 22.0 (IBM SPSS Statistics, New York, United 
States). P-values <0.05 (2-tailed) were considered statistically significant.
rEsuLTs
Baseline characteristics
A total of 106 women responded to the advertisement. At first screening, 62 did not 
meet the inclusion criteria, due to use of medication, established vitamin D sufficiency 
or comorbidity. The remaining 44 women were invited for screening. Fifteen women 
were not vitamin D deficient and were therefore excluded. Four women decided not to 
participate in the study, and one was excluded due to a BMI below 25. The remaining 24 
women were included and randomized to the high dose (n=12) or the low dose vitamin 
D3 group (n=12). An overview of participant recruitment and randomization is given 
in Figure 5.1. The baseline characteristics of the study participants, for the total group 
and for the high and low dose groups separately, are listed in Table 5.1. The groups were 
comparable in baseline characteristics, except for a higher leukocyte count in the high 
dose vitamin D3 group, due to a higher neutrophil count.
Table 5.1 Baseline characteristics of study participants (n=24)
Total (n=24) High dose (n=12) Low dose (n=12) P-value
Age (years) 28 ± 9 27 ± 7 29 ± 10 0.60
BMI (kg/m2) 32.1 ± 4.0 33.0 ± 3.5 31.2 ± 4.4 0.28
SBP (mmHg) 119 ± 12 116 ± 13 121 ± 10 0.28
DPB (mmHg) 74 ± 9 73 ± 10 74 ± 9 0.70
Waist (cm) 99 ± 11 101 ± 9 98 ± 13 0.50
PWV (m/s) 6.6 (6.0-7.3) 6.7 (6.1-7.3) 6.1 (6.0-7.3) 0.95
AIx (%) 5.0 ± 12.4 5.8 ± 9.8 4.2 ± 15.0 0.76
Glucose (mmol/l) 5.2 ± 0.4 5.2 ± 0.4 5.2 ± 0.5 >0.99
25OHD (nmol/l) 27.1 ± 13.8 26.8 ± 12.4 27.3 ± 15.6 0.94
PTH (pmol/l) 6.2 ± 2.8 6.2 ± 2.8 6.2 ± 2.9 0.98
TC (mmol/l) 5.2 ± 0.9 5.3 ± 1.2 5.1 ± 0.7 0.61
HDL-C (mmol/l) 1.4 ± 0.4 1.4 ± 0.4 1.5 ± 0.3 0.24
LDL-C (mmol/l) 3.2 ± 0.9 3.4 ± 0.9 3.1 ± 0.8 0.47
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Effect of vitamin d3 supplementation on fasting measurements
The effects of vitamin D3 on fasting parameters are listed in Table 5.2. Both high and low 
dose vitamin D3 supplementation resulted in a significant increase in serum 25OHD, 
although the increase in the high dose group was larger. PTH levels decreased in the 
high dose group only. Fasting plasma C3 levels decreased by 5.9% (p=0.004) in the high 
dose group, and by 4.0% (p=0.018) in the low dose group. Serum CRP, leukocyte counts, 
plasma triglycerides and the measurements of arterial stiffness did not change signifi-
cantly after vitamin D3 supplementation. The expression of fasting leukocyte activation 
markers was not significantly influenced by vitamin D3 supplementation, except for a 
higher expression of CD35 on monocytes after supplementation for the total group.
Table 5.1 Baseline characteristics of study participants (n=24) (continued)
Total (n=24) High dose (n=12) Low dose (n=12) P-value
TG (mmol/l) 1.00 (0.88-1.44) 1.25 (0.91-1.84) 0.99 (0.66-1.09) 0.090
Apo A-I (g/l) 1.60± 0.32 1.61 ± 0.36 1.60 ± 0.30 0.95
Apo B (g/l) 1.14 ± 0.26 1.17 ± 0.28 1.12 ± 0.26 0.68
CRP (mg/l) 4.0 (2.0-7.8) 6.0 (3.0-8.0) 3.0 (2.0-6.3) 0.21
C3 (g/l) 1.30 (1.16-1.47) 1.35 (1.26-1.53) 1.17 (1.09-1.36) 0.15
Leuko count (109/l) 7.3 ± 1.8 8.1 ± 2.0 6.6 ± 1.2 0.031
Mono count (109/l) 0.5 ± 0.2 0.5 ± 0.1 0.5 ± 0.2 0.72
Neutro count (109/l) 3.9 ± 1.3 4.4 ± 1.4 3.4 ± 0.9 0.040
Data are given as mean ± standard deviation or median (interquartile range). BMI: body mass index; SBP: sys-
tolic blood pressure; DPB: diastolic blood pressure; AIx: augmentation index; PWV: pulse wave velocity; 25OHD: 
25-hydroxyvitamin D; PTH: parathyroid hormone; TC: total cholesterol; HDL-C: high-density lipoprotein choles-
terol; LDL-C: low-density lipoprotein cholesterol; TG: triglycerides; Apo: apolipoprotein; CRP: C-reactive protein; 
C3: complement component 3; leuko count: leukocyte count; mono count: monocyte count; neutro count: 
neutrophil count.
P-value for difference between high and low dose vitamin D3 group.
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Effect of vitamin d3 supplementation on postprandial lipids and inflammation
Postprandial plasma triglycerides, arterial stiffness and leukocyte activation before and 
after vitamin D3 supplementation are listed in Table 5.3.
Vitamin D3 supplementation in low or high dose did not alter the postprandial plasma 
triglyceride response, which was comparable between both groups (Figure 5.2A and 
Table 5.3). Vitamin D3 did not influence postprandial PWV or AIx (Table 5.3). Postprandial 
arterial stiffness was similar in both groups before vitamin D3 supplementation, and the 
change in PWV and AIx was comparable between the high and low dose vitamin D3 
supplementation groups (Figure 5.2B and 5.2C and Table 5.3).
Table 5.3 Postprandial measurements before (baseline) and after supplementation (vitamin D3)
Total (n=24) High dose (n=12) Low dose (n=12) P-value P-value
Baseline Vitamin D3 Baseline Vitamin D3 Change Baseline Vitamin D3 Change Baseline Between groups# After Vitamin D between groups†
TG-AUC (mmol/l*h) 11.56 (9.49 - 17.27) 12.44 (9.55 - 18.53) 13.60 (11.10 - 19.79) 13.43 (10.00 - 19.28) 0.33 (-1.28 - 2.28) 10.05 (8.86 - 15.05) 11.86 (8.20 - 14.10) -0.49 (-1.85 - 2.24) 0.114 0.235
PWV-AUC (m/s*h) 51.8 (47.4 - 58.2) 49.4 (47.9 - 57.9) 54.7 (50.3 - 58.9) 54.5 (49.0 - 60.3) -0.5 (-3.2 - 3.1) 49.2 (46.7 - 55.2) 48.7 (45.7 - 57.0) -0.7 (-4.7 - 1.7) 0.288 0.566
AIx-AUC (%*h) 213.7 ± 85.6 212.2 ± 85.0 215.2 ± 73.9 223.8 ± 78.1 8.7 ± 22.1 212.3 ± 99.3 200.6 ± 93.4 -11.7 ± 33.9 0.936 0.096
C3-AUC (g/l*h) 9.65 (9.16 - 10.70) 9.78 (8.86 - 10.51) 11.09 (9.79 - 11.81) 10.63 (9.74 - 11.67) -0.10 (-0.70 - 0.11) 9.65 (9.16 - 10.70) 9.78 (8.86 - 10.51) -0.25 (-0.95 - 0.08) 0.143 0.590
mCD11b-AUC (MFI*h) 147.3 ± 27.8 154.8 ± 31.5* 140.3 ± 24.5 145.5 ± 32.7 5.2 ± 18.1 154.2 ± 30.2 164.1 ± 28.6 9.9 ± 11.4 0.229 0.456
nCD11b-AUC (MFI*h) 224.0 ± 46.9 227.6 ± 53.3 230.6 ± 37.6 226.7 ± 35.6 -4.0 ± 19.1 217.4 ± 55.5 228.6 ± 68.4 11.2 ± 26.2 0.501 0.120
nCD66b-AUC (MFI*h) 50.3 ± 16.8 50.7 ± 16.7 51.7 ± 20.0 51.6 ± 18.8 -0.1 ± 3.5 49.0 ± 13.5 49.8 ± 15.0 0.8 ± 5.0 0.709 0.632
mCD36-AUC (MFI*h) 407.5 ± 172.0 448.9 ± 208.3 327.7 ± 136.1 395.2 ± 208.2 67.4 ± 138.6 487.3 ± 171.5 502.6 ± 202.8 15.3 ± 119.5 0.019 0.335
mCD35-AUC (MFI*h) 40.1 ± 16.7 40.7 ± 16.0 40.1 ± 16.4 40.5 ± 16.3 0.5 ± 6.3 40.1 ± 17.7 40.9 ± 16.3 0.8 ± 5.5 0.993 0.891
nCD35-AUC (MFI*h) 68.4 ± 28.3 66.5 ± 28.4 70.7 ± 27.1 65.7 ± 26.0 -5.0 ± 7.9 66.2 ± 30.5 67.3 ± 31.8 1.1 ± 14.0 0.706 0.201
Area under the curve (AUC) as median (interquartile range) or mean ± standard deviation.
*P<0.05 for difference between before (control) and after vitamin D3 supplementation (vitamin D3) (paired 
Student’s t-test or Wilcoxon matched pairs signed ranks test)
**P<0.01 for difference between before (control) and after vitamin D3 supplementation (vitamin D3) (paired 
Student’s t-test or Wilcoxon matched pairs signed ranks test)
#P-value testing the difference between the high and low dose group before supplementation (independent 
Student’s t-test or Mann-Whitney U test)
†P-value testing the difference (intrapersonal change, after vs. before supplementation) between the high and 
low dose group (independent Student’s t-test or Mann-Whitney U test)
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In the total group, vitamin D3 supplementation resulted in a slight increase in postpran-
dial monocyte CD11b expression (AUC 147.3 ± 27.8 MFI*h before and 154.8 ± 31.5 after 
supplementation, p=0.021, Table 5.3). The change in monocyte CD11b expression did 
not differ between the high and low dose groups (Figure 5.3A and Table 5.3).
The expression of CD11b, CD66b and CD35 on neutrophils and CD36 and CD35 on 
monocytes did not change after vitamin D3 supplementation in the total group (Table 
5.3). Before vitamin D3, the postprandial monocyte CD36 expression was lower in the 
high dose group than in the low dose group (327.7 ± 136.1 and 487.3 ± 171.5 MFI*h, 
respectively, p=0.019). The expression of the other leukocyte activation markers did not 
differ between both groups before supplementation. There was no differential effect 
of high or low dose vitamin D3 supplementation on any of the investigated leukocyte 
activation markers (Figures 5.3B-F and Table 5.3). Postprandial C3 levels did not change, 
and were unaffected by vitamin D3 supplementation.
Table 5.3 Postprandial measurements before (baseline) and after supplementation (vitamin D3)
Total (n=24) High dose (n=12) Low dose (n=12) P-value P-value
Baseline Vitamin D3 Baseline Vitamin D3 Change Baseline Vitamin D3 Change Baseline Between groups# After Vitamin D between groups†
TG-AUC (mmol/l*h) 11.56 (9.49 - 17.27) 12.44 (9.55 - 18.53) 13.60 (11.10 - 19.79) 13.43 (10.00 - 19.28) 0.33 (-1.28 - 2.28) 10.05 (8.86 - 15.05) 11.86 (8.20 - 14.10) -0.49 (-1.85 - 2.24) 0.114 0.235
PWV-AUC (m/s*h) 51.8 (47.4 - 58.2) 49.4 (47.9 - 57.9) 54.7 (50.3 - 58.9) 54.5 (49.0 - 60.3) -0.5 (-3.2 - 3.1) 49.2 (46.7 - 55.2) 48.7 (45.7 - 57.0) -0.7 (-4.7 - 1.7) 0.288 0.566
AIx-AUC (%*h) 213.7 ± 85.6 212.2 ± 85.0 215.2 ± 73.9 223.8 ± 78.1 8.7 ± 22.1 212.3 ± 99.3 200.6 ± 93.4 -11.7 ± 33.9 0.936 0.096
C3-AUC (g/l*h) 9.65 (9.16 - 10.70) 9.78 (8.86 - 10.51) 11.09 (9.79 - 11.81) 10.63 (9.74 - 11.67) -0.10 (-0.70 - 0.11) 9.65 (9.16 - 10.70) 9.78 (8.86 - 10.51) -0.25 (-0.95 - 0.08) 0.143 0.590
mCD11b-AUC (MFI*h) 147.3 ± 27.8 154.8 ± 31.5* 140.3 ± 24.5 145.5 ± 32.7 5.2 ± 18.1 154.2 ± 30.2 164.1 ± 28.6 9.9 ± 11.4 0.229 0.456
nCD11b-AUC (MFI*h) 224.0 ± 46.9 227.6 ± 53.3 230.6 ± 37.6 226.7 ± 35.6 -4.0 ± 19.1 217.4 ± 55.5 228.6 ± 68.4 11.2 ± 26.2 0.501 0.120
nCD66b-AUC (MFI*h) 50.3 ± 16.8 50.7 ± 16.7 51.7 ± 20.0 51.6 ± 18.8 -0.1 ± 3.5 49.0 ± 13.5 49.8 ± 15.0 0.8 ± 5.0 0.709 0.632
mCD36-AUC (MFI*h) 407.5 ± 172.0 448.9 ± 208.3 327.7 ± 136.1 395.2 ± 208.2 67.4 ± 138.6 487.3 ± 171.5 502.6 ± 202.8 15.3 ± 119.5 0.019 0.335
mCD35-AUC (MFI*h) 40.1 ± 16.7 40.7 ± 16.0 40.1 ± 16.4 40.5 ± 16.3 0.5 ± 6.3 40.1 ± 17.7 40.9 ± 16.3 0.8 ± 5.5 0.993 0.891
nCD35-AUC (MFI*h) 68.4 ± 28.3 66.5 ± 28.4 70.7 ± 27.1 65.7 ± 26.0 -5.0 ± 7.9 66.2 ± 30.5 67.3 ± 31.8 1.1 ± 14.0 0.706 0.201
Area under the curve (AUC) as median (interquartile range) or mean ± standard deviation.
*P<0.05 for difference between before (control) and after vitamin D3 supplementation (vitamin D3) (paired 
Student’s t-test or Wilcoxon matched pairs signed ranks test)
**P<0.01 for difference between before (control) and after vitamin D3 supplementation (vitamin D3) (paired 
Student’s t-test or Wilcoxon matched pairs signed ranks test)
#P-value testing the difference between the high and low dose group before supplementation (independent 
Student’s t-test or Mann-Whitney U test)
†P-value testing the difference (intrapersonal change, after vs. before supplementation) between the high and 
low dose group (independent Student’s t-test or Mann-Whitney U test)
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figure 5.2. Triglycerides and arterial stiffness after an oral fat load
Mean (SEM) triglycerides (A), pulse wave velocity (B) and augmentation index (C) in the high dose group before 
(open square and dotted line) and after vitamin D3 supplementation (closed square and continuous line) and 
in the low dose group before (open triangle and dotted line) and after supplementation (closed triangle and 
continuous line) during an oral fat load.
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figure 5.3. Leukocyte activation after an oral fat load
Mean (SEM) expression of monocyte CD11b (A), neutrophil CD11b (B), monocyte CD35 (C), neutrophil CD35 (D), 
monocyte CD36 (E) and neutrophil CD66b (F) in the high dose group before (open square and dotted line) and 
after vitamin D3 supplementation (closed square and continuous line) and in the low dose group before (open 
triangle and dotted line) and after supplementation (closed triangle and continuous line) during an oral fat load.
80 Chapter 5
discussioN
In this paper, we describe the effect of a single high and low dose of vitamin D3 on post-
prandial arterial stiffness and leukocyte activation markers in healthy premenopausal 
overweight and obese women. Contrary to our hypothesis, a single dose of either 300 
000 or 75 000 IU cholecalciferol did not reduce postprandial arterial stiffness or leuko-
cyte activation.
Obesity is associated with increased arterial stiffness [16] and with vitamin D defi-
ciency [17]. We exclusively included premenopausal overweight and obese women, 
who usually have vascular dysfunction and vitamin D deficiency. Therefore, vitamin D 
was expected to provide more pronounced results in this human model.
The present results are in contrast with our previous pilot study [12]. Several differenc-
es in participant characteristics may explain this discrepancy. Firstly, participants in the 
current study were on average 8 years younger than the female participants of the pilot 
study. Secondly, the volunteers in the present study were either overweight or obese, 
with an average BMI of 32 kg/m2, in contrast to the lean female participants in the previ-
ous study. Thirdly, while the increase in vitamin D after supplementation was comparable 
(in both studies vitamin D increased by approximately 30 nmol/l), vitamin D levels after 
supplementation were approximately twice as high in the pilot study (109 nmol/l versus 
58 nmol/l in the present study). We cannot exclude that higher vitamin D levels must be 
reached to obtain beneficial vascular and anti-inflammatory effects as found earlier [12]. 
This assumption is underlined by a comparison of several randomized-controlled trials 
investigating the effect of vitamin D3 supplementation on vascular function and inflam-
mation, where trials observing a positive effect [6,7,12,18,19] reported higher vitamin D 
levels after supplementation (range 80 to 380 nmol/L) than studies in which vitamin D 
had no beneficial effect [20–23] (range 70-110 nmol/L).
The lack of a vitamin D effect on the augmentation index may possibly be due to the 
low baseline values measured in the present study. The augmentation index is known 
to increase with age [24], and it has been suggested that the augmentation index de-
creases with increasing body mass index [25]. The volunteers in this study were relatively 
young and either overweight or obese.
The expression of all measured leukocyte activation markers was higher in the present 
study than reported earlier [12], most likely due to systemic inflammation in obesity [26]. 
We speculate that in this condition, higher vitamin D levels may be needed to achieve 
anti-inflammatory effects.
Although several cross-sectional studies have shown that vitamin D levels may be in-
versely associated with fasting arterial stiffness [27,28], studies on the effect of vitamin D 
supplementation on PWV and augmentation index have shown conflicting results. Some 
studies using high doses of cholecalciferol demonstrated a beneficial effect on arterial 
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stiffness after four months [19] and after one year [29], while other studies reported no 
effect [20,21]. Trials investigating inflammation after vitamin D supplementation report 
contrasting results as well. While some investigators reported a cytokine profile shift to 
an anti-inflammatory profile [7] and reduced oxidative stress, assessed by malondialde-
hyde, nitric oxide and protein carbonyl groups [8], others found no effect on CRP [20,21], 
interleukin-6 or tumor necrosis factor-alpha levels [20]. To the best of our knowledge, 
besides the pilot study by our group [12], no other previous studies have investigated 
postprandial arterial stiffness and leukocyte activation after vitamin D administration.
Strikingly, in our overweight and obese female study participants, fasting C3 levels 
were comparable to the levels observed in familial combined hyperlipidemia and 
metabolic syndrome patients [30,31]. Increased C3 has been associated with metabolic 
syndrome [31] and cardiovascular disease [32]. Interestingly, both high and low dose vi-
tamin D3 supplementation reduced fasting C3 levels. C3 is mainly produced in the liver 
[33], but also by adipose tissue [34]. Vitamin D has been shown to reduce adipose tissue 
cytokine secretion and inflammation [35]. Possibly, vitamin D may also reduce adipocyte 
C3 secretion. We speculate that the observed effect could be a transcription effect. It has 
been suggested that vitamin D downregulates the transcription of pro-inflammatory 
genes [36]. Whether this is also the case for C3 remains to be investigated. C3 is not 
only involved in the immune system, but it also has an endocrine effect as precursor of 
acylation-stimulating protein (ASP), a hormone produced by adipose tissue [37]. ASP 
increases fat storage by stimulating lipogenesis in adipocytes and by inhibiting lipolysis 
[37], and it stimulates glucose transport through increased translocation of glucose 
transporters [37]. Possibly, a decrease in C3 levels may lead to increased sensitivity for 
the C3/ASP effect on fatty acid metabolism in the adipose tissue. The concept of C3/
ASP resistance has been proposed previously [30,34]. In healthy lean subjects, adipose 
tissue C3 and ASP production increases after a fatty meal, largely due to stimulation 
of adipocytes by chylomicrons [34], resulting in a postprandial increase of plasma C3 
levels [30,31,38]. In subjects with a high level of apolipoprotein B-containing lipopro-
teins, binding of ASP to the ASP receptor on adipocytes may be impaired, which makes 
adipocytes less sensitive to the effects of ASP, resulting in enhanced ASP secretion [39]. 
It has indeed been demonstrated that fasting C3 levels are increased in subjects with 
cardiometabolic diseases, such as familial combined hyperlipidemia [30], the metabolic 
syndrome [31] and type 2 diabetes mellitus [38]. In these subjects, in contrast to lean 
healthy individuals, C3 levels do not (or only slightly) increase postprandially [30,31,38]. 
The increased C3 levels in obesity may be explained by C3/ASP resistance as well [40]. 
Indeed, C3 levels are higher in obese than in lean subjects [40], and C3 decreases after 
weight loss [40].
This study has several strengths. This is the first double-blind randomized trial to 
investigate the effect of a single dose of vitamin D3 on postprandial leukocyte activa-
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tion and arterial elasticity. Furthermore, the study seemed to be well-powered, based on 
results of a pilot study, and there was no drop-out of subjects or loss of data.
However, several limitations apply as well. Firstly, we investigated a selected group 
of subjects, i.e. premenopausal vitamin D deficient overweight and obese women. 
Therefore, the results in this study population may not be representative for the gen-
eral population. Secondly, the study sample was relatively small. While the number of 
included subjects was based on a sample size calculation based on our pilot study, a 
larger sample size may have resulted in a different outcome. Contrary to our pilot study, 
there was a mild but significant increase in postprandial monocyte CD11b expression 
after vitamin D supplementation. This slight increase may not be clinically relevant and 
is contra-intuitive, and may possibly be due to the relatively small sample size. Thirdly, 
no placebo group was included, which could have emphasized any potential effect of 
vitamin D. Finally, we studied the effect of a single dose of vitamin D3 with one week 
between measurements. We cannot exclude that a longer duration of supplementation 
and higher vitamin D levels may have had positive effects on postprandial arterial stiff-
ness and inflammation, especially since 42% of the study subjects remained vitamin D 
deficient (<50 nmol/L) after supplementation.
In conclusion, this study suggests reduced fasting C3 levels after vitamin D3 supple-
mentation, most likely by an effect on the adipose tissue, but it does not provide evi-
dence for a short-term beneficial effect of a single dose of 75 000 or 300 000 vitamin 
D3 on arterial function or leukocyte activation in vitamin D deficient women. Possibly, 
higher vitamin D levels must be achieved for a positive effect on arterial elasticity and 
inflammation.
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ABsTrAcT
Background: Leukocyte activation has been linked to atherogenesis, but there is little in 
vivo evidence for its role in the progression of atherosclerosis. We evaluated the predic-
tive value of leukocyte activation markers in the coronary circulation for progression of 
coronary artery disease (CAD).
Methods: Monocyte and neutrophil CD11b, neutrophil CD66b expression and intracel-
lular neutrophil myeloperoxidase (MPO) in the coronary arteries was determined by 
flow cytometry in patients undergoing coronary angiography. The primary outcome 
included fatal and nonfatal myocardial infarction or arterial vascular intervention due 
to unstable angina pectoris.
results: In total 99 subjects were included, 70 had CAD at inclusion (26 patients had sin-
gle-vessel disease, 18 patients had two-vessel disease and 26 patients had three-vessel 
disease). The median follow-up duration was 2242 days (interquartile range: 2142-2358). 
During follow-up, 13 patients (13%) developed progression of CAD. Monocyte CD11b, 
neutrophil CD11b and CD66b expression and intracellular MPO measured in blood 
obtained from the coronary arteries were not associated with the progression of CAD.
conclusion: These data indicate that coronary monocyte CD11b, neutrophil CD11b and 
CD66b expression and intracellular MPO do not predict the risk of progression of CAD.
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iNTroducTioN
Classical risk factors used to predict cardiovascular risk include hyperlipidemia, hyper-
tension, smoking, obesity and diabetes mellitus [1]. In the past decades, it has become 
evident that atherosclerosis is an inflammatory disease [2]. Therefore, attention has 
shifted to inflammatory markers as predictors of future cardiovascular events. Total 
leukocyte count, C-reactive protein (CRP) and the third component of complement (C3) 
are predictors of cardiovascular risk [3–5]. In this respect, besides leukocyte count, also 
the level of leukocyte activation may be an interesting marker. Leukocytes can become 
activated by several stimuli, such as lipids and glucose [6–10]. Activated neutrophils 
and monocytes express integrins on their cell surface, facilitating the binding of these 
leukocytes to the intact endothelium [11,12]. One of these integrins, CD11b, is pres-
ent on the surface of activated monocytes and neutrophils and binds to intercellular 
adhesion molecule-1 on endothelial cells [11]. It has been demonstrated in vitro that 
increased expression of CD11b on monocytes and neutrophils is accompanied by en-
hanced leukocyte adhesion to the endothelium [13–15]. CD66b is a marker of neutrophil 
degranulation [16]. Myeloperoxidase (MPO) is an important enzyme in neutrophil host 
defense, as it inactivates bacterial toxins [17]. Activated neutrophils release MPO from 
their granules and therefore, intracellular MPO levels are a negative marker of neutrophil 
activation, with low levels representing increased activation [17]. When bound to the 
endothelium, activated leukocytes migrate to the subendothelial space. Monocytes 
bind modified lipoproteins and form foam cells, and the development of the atheroscle-
rotic plaque is initiated [2].
Several lines of evidence suggest that increased leukocyte activation is linked to the 
presence of ischemic heart disease and peripheral artery disease [18–21]. The expression 
of monocyte and neutrophil CD11b is higher in patients with multiple risk factors for 
atherothrombosis than in those with none or only one risk factor [22]. Intracellular MPO 
is reduced in patients presenting with acute coronary syndromes [23]. Finally, increased 
leukocyte activation has been associated with the presence of microvascular diabetic 
complications [24,25].
We have previously described an inflammatory gradient of intracellular MPO in pa-
tients with stable coronary artery disease (CAD), with the highest level of neutrophil 
activation in the coronary arteries, suggesting focal inflammation in CAD [26]. In healthy 
controls, this gradient was observed as well, although levels of neutrophil activation 
were lower than in patients with CAD [26]. For monocyte CD11b and neutrophil CD11b 
and CD66b expression, this gradient was not present [26].
Although the current literature underlines an association between leukocyte activa-
tion and CAD, no studies have evaluated the use of leukocyte activation markers CD11b 
and CD66b and intracellular MPO as possible indicators of future coronary events. The 
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aim of the current study was to assess whether levels of leukocyte activation in the coro-
nary circulation may help to predict which patients are at risk of progression of CAD, in 
patients undergoing elective coronary angiography (CAG).
METhods
study design and study population
The design of the study has been described extensively and published elsewhere [26]. 
The study was designed as a prospective follow-up study. Briefly, subjects who visited the 
outpatient clinic of the Department of Cardiology, Sint Franciscus Gasthuis, Rotterdam, 
The Netherlands, between July 2007 and September 2008 and who were scheduled to 
undergo a diagnostic CAG were invited to participate. Their indications for CAG were 
typical chest pain and a positive cycle ergometry.
Exclusion criteria were the presence of inflammatory disorders such as rheumatoid 
arthritis, systemic lupus erythematosus and infections, a plasma CRP level above 10 
mg/L, and disorders of kidney, liver and thyroid function. The study was conducted 
according to the Declaration of Helsinki. The Institutional Review Board of the Sint 
Franciscus Gasthuis Rotterdam and the regional independent medical ethics committee 
of the Maasstad Hospital Rotterdam approved the study. The study was registered at 
clinicaltrials.gov under clinical trial number NCT02376738. All participants gave written 
informed consent.
On the day of the angiography, anthropometric measures, the use of medication and 
cardiovascular history were recorded. Shortly before CAG, venous blood was obtained 
from a peripheral vein of the forearm. During the angiography, blood samples were 
obtained from each coronary artery. In addition, blood was collected from the femoral 
artery and midway from the abdominal aorta. The first 2 mL were discarded to avoid 
contamination with contrast. Subsequently, blood samples were collected in tubes con-
taining EDTA (1 mg/mL) and kept on ice until processed for determination of leukocyte 
activation markers. CAG images were scored by an independent cardiologist.
scoring of coronary events
The primary outcome was defined as progression of CAD, evaluated by an independent 
investigator at approximately six years follow-up. This endpoint included fatal and non-
fatal myocardial infarction and any arterial vascular intervention that had not already 
been planned at the time of inclusion (e.g. coronary bypass, percutaneous coronary 
intervention, peripheral vascular surgery or angioplasty/stenting).
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Analytical methods
Parameters for renal and liver function, glucose, CRP, total cholesterol, high-density 
lipoprotein (HDL) cholesterol and triglycerides were determined using Synchron LX-20 
analyzers (Beckman Coulter, Brea, CA, USA) according to standard procedures in our 
laboratory. Low-density lipoprotein (LDL) cholesterol values were calculated using the 
Friedewald formula. Apolipoproteins A-I and B were determined by rate nephelometry 
using an IMMAGE analyzer (Beckman Coulter). Blood cell counts were determined using 
LH750 analyzers (Beckman Coulter, Miami, FL, USA).
Leukocyte activation markers
The expression of leukocyte activation markers on the cell surface was determined 
using fluorescent labeled monoclonal antibodies (Immunotech Coulter, Marseille, 
France). Antibodies for CD66b were labeled with fluorescein isothiocynate (FITC) and 
were diluted 10 times from their stock concentration. Antibodies for CD11b were la-
beled with phycoerythrin (PE) and were diluted 40 times. Antibodies for CD45 labeled 
with PE-Texas Red (ECD) were used in order to be able to differentiate leukocytes from 
erythrocytes and platelets. Twenty microliters of blood from an EDTA-anticoagulated 
blood sample were added to 2.5 µL of each CD66b-FITC, CD11b-PE and CD45-ECD. Cells 
were incubated for 15 minutes in the dark at room temperature. Erythrocytes were lysed 
by adding 300 µL of ice-cold isotonic erythrocyte lysing solution (NH4Cl 0.19 M; KHCO3 
0.01 M; Na2EDTA.2H2O 0.12 M, pH 7.2) for 15 minutes.
Antibodies against MPO (Beckman Coulter) were FITC-conjugated. Membrane per-
meabilization was performed with Intraprep (Beckman Coulter). To each blood sample 
of 20 µL, 2.5 µL of titrated anti-MPO (2 times diluted) was added. Cells were incubated 
for 15 minutes in the dark at room temperature.
A Coulter Epics XL-MCL flow cytometer with a 488 nm Argon ion laser and EXPO 32 
software were used for measurement and analysis. Fluorescent intensity of each cell was 
expressed as the mean fluorescent intensity (MFI), given in arbitrary units (au). Lympho-
cytes, monocytes and granulocytes were identified based on their side scatter and the 
level of CD45 on their cell surface.
Patients were considered to have high leukocyte activation if the level of monocyte 
CD11b, neutrophil CD11b or CD66b expression was above, or intracellular MPO was 
below, the median of the total group.
statistical analysis
Data are given as mean ± standard deviation (SD) for continuous variables with a 
normal distribution, and median (interquartile range (IQR)) for continuous variables 
with a skewed distribution (triglycerides, CRP, leukocyte count, C3, monocyte CD11b 
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expression, neutrophil CD11b and CD66b expression and MPO). Differences in leukocyte 
activation between groups were tested with the Mann Whitney-U test.
A Cox-regression analysis was performed to study the impact of leukocyte activa-
tion markers on the progression of CAD, using a two-step approach. First, a univariate 
analysis was performed with several known cardiovascular risk factors as factor, using 
progression of CAD as event, and time to event as the time to coronary event since CAG 
at inclusion. The presence of CAD at CAG at inclusion was found to predict progres-
sion of CAD, while age (above or below the median of 65 years) and gender did not. In 
the second step, leukocyte activation markers in the coronary arteries were added to 
the Cox-regression model, with the presence of CAD entered into the model and the 
individual markers entered as additional variables. A p-value <0.05 (two-sided) was 
regarded as statistically significant. All statistical analyses were performed using PASW 
statistics version 22.0 (IBM SPSS Statistics, New York, United States).
rEsuLTs
General characteristics
A total of 99 subjects were included. Their baseline characteristics are listed in Table 6.1. 
The median duration of follow-up was 2242 days (IQR: 2142-2358). At the time of inclu-
sion, 37 (37%) patients had a history of CAD. In 70 patients (71%), CAD was established 
by CAG at inclusion, resulting in 33 new diagnoses of CAD: 26 patients had single-vessel 
disease, 18 patients had two-vessel disease and 26 patients had three-vessel disease. In 
the remaining 29 patients, no significant coronary stenosis was established by CAG, and 
none of these patients had a history of clinical CAD.
Presence of cAd at inclusion predicts progression of cAd
During follow-up, 13 patients (13%) showed progression of CAD: 10 patients developed 
unstable angina pectoris requiring intervention (percutaneous coronary intervention 
or bypass surgery) and 3 patients developed fatal myocardial infarction. A comparison 
between the baseline characteristics of those with progression of CAD, and those re-
maining free of progression, is given in Table 6.1. All patients with progression of CAD 
had significant coronary stenosis by CAG at inclusion. In a univariate analysis, only the 
presence of CAD, established by CAG at inclusion, predicted the progression of CAD 
(Log Rank Test p=0.014).
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coronary leukocyte activation and risk of progression of cAd
In a Cox-regression analysis, none of the investigated leukocyte activation markers in 
the coronary circulation contributed significantly to the predictive power of progression 
of CAD in addition to CAD at inclusion (Table 6.2). Monocyte CD11b, neutrophil CD11b 
and CD66b and MPO in the other vascular regions (peripheral vein, femoral artery and 
abdominal aorta) did not increase the predictive power of progression of CAD either 
(data not shown).
Table 6.1 Baseline characteristics of study participants (n=99)
Total group (n=99) Progression CAD 
(n=13)
No progression CAD 
(n=86)
P-value
Age (years) 65 ± 12 67 ± 11 64 ± 12 0.50
Gender (% male) 60 62 60 >0.99
CAD (%) 71 100 66 0.009
DM (%) 28 15 30 0.34
Smoking (%) 14 15 14 >0.99
Statin use (%) 68 92 64 0.06
ASA use (%) 67 92 63 0.06
ACE-i use (%) 33 23 35 0.54
BMI (kg/m2) 27.6 ± 4.1 25.5 ± 4.6 27.9 ± 4.0 0.06
SBP (mmHg) 144 ± 22 154 ± 27 143 ± 21 0.09
Glucose (mmol/L) 6.8 ± 1.7 6.5 ± 1.3 6.8 ± 1.8 0.59
LDL-c (mmol/L) 2.8 ± 1.0 2.8 ± 1.2 2.8 ± 1.0 0.95
HDL-c (mmol/L) 1.3 ± 0.3 1.3 ± 0.3 1.2 ± 0.3 0.56
Triglycerides (mmol/L) 1.55 (1.07-2.19) 1.46 (0.90-1.78) 1.56 (1.08-2.25) 0.43
CRP (mg/L) 2.0 (1.0-4.0) 1.0 (1.0-5.0) 2.0 (1.0-4.0) 0.64
Leukocyte count (109/L) 7.1 (6.0-8.3) 7.1 (5.6-7.7) 7.1 (6.1-8.4) 0.32
Complement C3 (g/L) 1.23 ± 0.24 1.28 ± 0.24 1.22 ± 0.24 0.39
Mono CD11b LCA (au) 31.8 (25.5-40.8) 28.9 (21.0-42.4) 32.2 (25.6-40.7) 0.66
Mono CD11b RCA (au) 32.2 (26.5-41.8) 29.8 (23.0-42.0) 32.2 (26.7-41.7) 0.56
Neutro CD11b LCA (au) 30.9 (24.3-38.6) 29.0 (22.2-38.8) 31.8 (24.4-38.6) 0.51
Neutro CD11b RCA (au) 31.5 (25.6-37.6) 23.7 (20.0-43.8) 31.8 (26.2-37.6) 0.26
Neutro CD66b LCA (au) 7.2 (6.0-9.0) 7.6 (5.5-9.8) 7.1 (6.1-8.9) 0.70
Neutro CD66b RCA (au) 7.3 (5.8-9.3) 7.7 (5.0-11.3) 7.3 (5.8-9.0) 0.72
MPO LCA (au) 162.5 (130.2-202.9) 160.4 (136.4-169.4) 169.6 (129.8-205.0) 0.69
MPO RCA (au) 165.3 (130.1-194.7) 166.9 (147.1-177.3) 164.0 (129.3-196.5) 0.99
Data are given as mean ± SD, median (IQR) or as percentage. P-value for difference between groups. ACE-i: 
angiotensin-converting enzyme inhibitor; ASA: acetylsalicylic acid; au: arbitrary units; BMI: body mass index; 
CAD: coronary artery disease; CRP: C-reactive protein; DM: diabetes mellitus; LCA: left coronary artery; mono: 
monocyte; neutro: neutrophil; RCA: right coronary artery; SBP: systolic blood pressure.
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discussioN
This is the first prospective study investigating the value of coronary monocyte CD11b, 
neutrophil CD11b and CD66b expression and intracellular MPO in the prediction of fu-
ture coronary events. In the present study, in patients scheduled for CAG due to typical 
chest pain or positive cycle ergometry, these leukocyte activation markers measured 
in the coronary circulation, or in other vascular regions, did not predict the risk of CAD 
progression.
We have previously published the baseline values of the investigated leukocyte 
activation markers in the coronary arteries in this study population [26]. While MPO 
was significantly lower in patients with CAD, the expression of CD11b and CD66b in the 
coronary circulation was similar in patients with and without CAD [26].
Several studies have pointed at a role for leukocyte activation in the development of 
CAD. Neutrophil infiltration has been associated with acute coronary syndromes, and 
autopsy studies have shown that ruptured plaques contained more neutral endopep-
tidase positive neutrophils than eroded plaques [27]. In survivors of non-ST elevation 
myocardial infarction, plasma MPO was associated with short-term risk (<30 days) of 
recurrent acute coronary syndrome and myocardial infarction, but this association was 
lost after 180 days [28]. In a large prospective study among patients without previous 
CAD, plasma MPO in peripheral blood was associated with increased risk of future coro-
nary heart disease in men but not in women [29]. In addition, the level of neopterin, 
a marker of monocyte activation, in the peripheral circulation was an independent 
predictor of future cardiovascular events in patients with and without CAD, indicating 
the presence of systemic leukocyte activation in CAD [30,31].
Table 6.2 Coronary leukocyte activation and risk of future CAD
HR (95% CI) P-value
Monocyte CD11b in LCA 0.97 (0.94 – 1.04) 0.61
Monocyte CD11b in RCA 0.97 (0.90 – 1.04) 0.42
Neutrophil CD11b in LCA 1.00 (0.94 – 1.06) 0.87
Neutrophil CD11b in RCA 0.97 (0.90 – 1.04) 0.38
Neutrophil CD66b in LCA 1.10 (0.86 – 1.34) 0.45
Neutrophil CD66b in RCA 1.06 (0.82 – 1.37) 0.65
Myeloperoxidase in LCA 1.00 (0.99 – 1.01) 0.95
Myeloperoxidase in RCA 1.00 (0.99 – 1.01) 0.70
Hazard ratios (HR) with 95% confidence interval (CI) for progression of coronary artery disease in patients per 
coronary leukocyte activation marker for each point increase in arbitrary units, as additional factor in a Cox Re-
gression analysis with presence of CAD as covariate.
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The effect of reducing leukocyte activation on CAD has been investigated in animal 
studies. In rats, treatment with antibodies selectively blocking CD11b or CD18 reduced 
leukocyte adhesion to endothelial cells [13]. Treatment with anti-CD11b or CD18 
reduced myocardial infarct size after regional myocardial ischemia in dogs [14,32]. How-
ever, studies on the effect of these blocking antibodies on myocardial infarction size or 
on risk of future coronary events in humans are lacking.
The lack of an association with the presently investigated leukocyte activation mark-
ers may possibly be explained by the nature of these markers. The integrins CD11b and 
CD66b can bind to various selectins on the endothelial surface [12–15,33]. Moreover, 
activated neutrophils transfer MPO to endothelial cells via the CD11b integrin, contrib-
uting further to endothelial cell activation and leukocyte adhesion [34]. Therefore, the 
measurement of these integrins on the leukocyte surface in blood samples may in fact 
be an underestimation of the true level of leukocyte activation, since activated leuko-
cytes expressing these integrins, adhere to the endothelial surface and may be missed 
by blood sampling.
Some limitations of the present study are the relatively small number of patients 
included, the low number of reported coronary events, the relatively short duration of 
follow-up and the heterogeneity of the included patients. Our study group comprised 
patients with and without a history of CAD, and many of the study subjects already 
received intensive treatment for primary or secondary intervention purposes. All of 
the study subjects with progression already had significant coronary sclerosis at inclu-
sion, and the number of patients without clinical coronary sclerosis at inclusion was 
low. Therefore, no conclusions can be drawn regarding the value of coronary leukocyte 
activation in the prediction of future CAD in healthy subjects. A strength of the present 
study is that this is the first study to investigate coronary leukocyte activation in the 
progression of CAD in vivo in humans.
In conclusion, expression of monocyte and neutrophil activation markers CD11b and 
CD66b, and intracellular MPO in the coronary arteries was not associated with the risk 
of progression of CAD.
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ABsTrAcT
Background: Apolipoprotein (apo) B bound to circulating erythrocytes (ery-apoB) has 
been associated with less atherosclerosis. We evaluated the clinical characteristics of 
subjects with different levels of ery-apoB.
Methods: Ery-apoB was measured by flow cytometry in 427 subjects, expressed as 
mean fluorescent intensity in arbitrary units. Metabolic syndrome criteria were scored.
results: Ery-apoB was inversely associated with CRP (Spearman’s rho -0.169, p=0.001) 
and complement C3 (rho -0.162, p=0.001), and was lower in patients with hypertri-
glyceridemia (p=0.029), hypertension (p=0.031), abdominal obesity (p=0.007) and low 
HDL-C (p=0.05). Ery-apoB decreased with increasing metabolic syndrome criteria num-
ber (p=0.025). Median ery-apoB was higher in subjects with the wildtype His1208Arg 
complement receptor 1 (CR1) polymorphism (n=82) than in the mutated allele (n=42) 
(1.1 (IQR 0.4-2.0) versus 0.6 (IQR 0.2-1.5), p=0.036). In multivariate analysis, markers of 
inflammation, cardiometabolic factors, ABO blood group and CR1 polymorphism signifi-
cantly predicted ery-apoB (adjusted R2=0.35, p<0.001). Without ABO blood group, the R2 
decreased to adjusted R2 =0.16, p=0.004.
conclusions: Apo B bound to circulating erythrocytes is associated with several 
characteristics of the metabolic syndrome, inflammation, ABO blood group and CR1-
polymorphism. These data may help to better understand the mechanisms involved in 
the binding of atherogenic lipoproteins to erythrocytes and its clinical relevance.
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iNTroducTioN
Apolipoprotein (apo) B is the structural protein present on the surface of all atherogenic 
lipoproteins, including very low-density lipoprotein, low-density lipoprotein (LDL), 
intermediate-density lipoprotein, chylomicrons and their respective remnants [1,2]. 
Plasma apo B is a sensitive marker of cardiovascular risk, and recent reports indicate that 
it may even be a better indicator of cardiovascular risk than LDL-cholesterol [3,4]. The 
migration of apo B-containing lipoproteins and their remnants to the subendothelial 
space is a major contributor to the development of atherosclerosis. Once in the intima, 
these lipoproteins can be taken up by macrophages, either in their native form [5] or 
after (oxidative) modification [6]. This macrophage-lipoprotein interaction may result in 
the formation of foam cells, causing an inflammatory response which further contrib-
utes to the development of atherosclerosis [7].
Apo B-containing lipoproteins are not only present in plasma or serum, but it has been 
postulated that there is also a ‘marginated pool’ of lipoproteins attached to the surface 
of several types of cells, such as endothelial cells [8]. In addition, already in the 1980’s 
it was shown that human erythrocytes bind LDL particles [9]. Our group has confirmed 
the presence of apo B-containing lipoproteins on circulating erythrocytes (ery-apoB) in 
vivo, using fluorescent labeled antibodies [10,11]. Interestingly, ery-apoB was inversely 
associated with the presence of clinical and subclinical atherosclerosis [10,11].
We have previously shown that ery-apoB was higher in subjects with blood group O, 
than those with blood group A, B or AB [11]. However, much is still unknown about the 
mechanisms involved in the binding of apo B-containing lipoproteins to erythrocytes. 
In the present study, we aimed to further explore the determinants of ery-apoB in an 
outpatient setting and to determine their impact on ery-apoB.
MATEriALs ANd METhods
study design and participants
Subjects were recruited from the Department of Cardiology and the Diabetes and Vas-
cular Center of the Franciscus Gasthuis in Rotterdam between 2009 and 2013 [10,11]. 
In addition, a group of healthy volunteers was recruited among hospital employees. 
Subjects were included if they were 18 years or older, and if they had no disorders of 
kidney, liver and thyroid function. The study was approved by the independent Regional 
Medical Ethics Committee, Maasstad Hospital Rotterdam, the Netherlands. All subjects 
gave informed consent. Anthropometric measurements, clinical history and use of 
medication were recorded. Carotid intima media thickness (cIMT) was measured with 
the ART-LAB (Esaote, Italy) [10].
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In order to investigate the effect of the prandial state on ery-apoB, measurements 
were carried out in healthy volunteers before and after an oral fat loading test in a sepa-
rate cohort [12]. Healthy volunteers received an oral fat load using fresh cream in a dose 
of 50 grams of fat per square meter body surface. Blood samples were drawn fasting and 
4 and 8 hours after the fat load.
Laboratory measurements
Parameters for glucose, C-reactive protein (CRP), total cholesterol, high-density lipopro-
tein (HDL) cholesterol and triglycerides were determined using Synchron LX-20 or DxC 
analyzers (Beckman Coulter, Brea, CA, USA), according to standard procedures in our 
laboratory. Low-density lipoprotein (LDL) cholesterol values were calculated using the 
Friedewald formula. Complement component 3 (C3) and serum apolipoproteins A1 an 
B were measured by nephelometry using an IMMAGE instrument (Beckman Coulter). 
The ABO blood group was determined by standard procedures using agglutination 
techniques (Galileo Echo; Immucor Gamma, Heppignies, Belgium).
Measurement of ery-apoB
The procedure of the measurement of ery-apoB has been described in detail previously 
[10,11]. In short, a nonfasting blood sample was obtained from a peripheral vein of 
the forearm. The presence of apo B on the erythrocyte surface was determined using 
a polyclonal goat antibody directed against human apo B (catalogue number AB742, 
Millipore, Billerica, MA, USA), with a rabbit-anti-goat antibody conjugated with fluores-
cein isothiocynate (FITC) (Nordic Immunological Laboratories, Tilburg, the Netherlands) 
as secondary antibody. As a control for background staining, in parallel a sample was 
stained with FITC-labeled rabbit-anti-goat, but without the apo B antibody. Ery-apoB 
was expressed as mean fluorescent intensity in arbitrary units (au) of the signal obtained 
with the apo B antibody, minus the background signal.
complement receptor 1 single nucleotide polymorphism selection and 
genotyping
Genomic DNA was extracted from leukocytes obtained from EDTA-treated whole blood 
by the standard procedure. The most studied three single nucleotide polymorphisms of 
the CR1 gene are His1208Arg (rs2274567), intron 27 HindIII (rs11118133) and Pro1827Arg 
(rs3811381). Moreover, these three polymorphisms are in strong linkage disequilibrium.
His1208Arg was analyzed by restriction fragment length polymorphism technique. 
Primers were designed with the Primer3 software (http://biotools.umassmed.edu/bio-
apps/primer3_www.cgi) as following; forward 5’-TTC ACA TTG GAT AGC CAG AGC-3’and 
reverse 5’- CCA GAG GTT TAA TCT CCC TGG A-3’ and where used to amplify a 682bp 
fragment. Amplifications were performed in a final volume of 23 µl containing 10 ng of 
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DNA template using the AmpliTaq Gold 360 Master Mix (Applied Biosystems, Madrid, 
Spain). A Verity Thermal Cycler (Applied Biosystems, Madrid, Spain) was used for the 
PCR. PCR conditions were as follows: 5 min at 95˚C; 40 cycles at 95˚C for 30 s, 57˚C for 30 
s and 72˚C for 30 s; and, finally, 72˚C for 7 min. Rsa I restriction enzyme (New England 
Biolabs, Ipswich, UK) was used for digestion of the amplification product. Hydrolysis of 
the PCR product with the restriction enzyme was conducted for one hour at 37ºC. The 
RFLP product containing segments with 520bp and 162bp was identified as wild type 
(WT) alleles, product containing segments with 520bp, 458bp, 162bp and 62bp was 
identified as heterozygote and product containing segments with 458bp, 162bp and 
62bp was identified as recessive homozygote. RFLP products were analyzed by a 12% 
polyacrylamide gel electrophoresis.
scoring of the metabolic syndrome
The presence of the metabolic syndrome was determined by using the adapted Na-
tional Cholesterol Education Program (NCEP) criteria [13]. Since no fasting measure-
ments were available in our study population, nonfasting measurements were used. 
Metabolic syndrome was defined as the presence of at least 3 of the following 5 criteria: 
abdominal obesity (defined as a waist circumference >102 cm for men and >88 cm for 
women), hypertriglyceridemia (defined as nonfasting triglycerides >2.5 mmol/L or the 
use of fibrates), low HDL-C (defined as HDL-C <1.0 mmol/L for men and <1.3 mmol/L 
for women or the use of lipid-lowering drugs), hypertension (defined as office systolic 
blood pressure >130 mmHg, diastolic blood pressure >85 or the use of antihypertensive 
drugs due to a history of hypertension) and insulin resistance (defined as nonfasting 
glucose >11 mmol/L or the use of glucose lowering drugs).
statistics
For normally distributed continuous variables, data are given as mean ± standard devia-
tion in the text, tables and figures. The distribution of ery-apoB, triglycerides, CRP and C3 
was skewed. Therefore, these variables were logarithmically transformed before analysis, 
and data are given as median (interquartile range (IQR)). For clarity, the non-transformed 
data are shown in tables and figures. Differences between groups were tested with the 
Independent Samples T test for continuous variables and Chi-square test for binary vari-
ables. Differences in ery-apoB in subjects with different numbers of metabolic syndrome 
criteria were tested with one-way analysis of variance (ANOVA). Differences between 
fasting and postprandial ery-apoB levels were tested with repeated measures ANOVA 
with Dunnett’s Multiple Comparison Test as post hoc analysis. Correlation analysis was 
carried out using Spearman correlation statistics.
A multiple regression analysis was carried out with logarithmically transformed 
ery-apoB as dependent variable, and a history of coronary artery disease, cIMT, HDL-
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cholesterol, waist circumference, systolic and diastolic blood pressure, ABO blood group 
and logarithmically transformed triglycerides, CRP and complement C3 as independent 
variables, using the enter method. The multiple regression analysis was then repeated 
without ABO blood group as independent variable.
Statistical analysis was carried out with PASW statistics version 18.0 (IBM SPSS Statis-
tics, New York, United States). P-values below 0.05 (2-tailed) were considered statistically 
significant.
rEsuLTs
Baseline characteristics (Table 7.1)
A total of 427 patients were included, their baseline characteristics are listed in Table 7.1. 
Median ery-apoB was 0.9 (IQR 0.4 – 1.6). The distribution of ery-apoB values ranged from 
0.0 to 5.5 au and was skewed, with skewness being 1.29 and kurtosis 2.19. The variance 
of ery-apoB values was 0.74 au.
Table 7.1 Baseline characteristics of study participants (n=417). For total group, and for those with meta-
bolic syndrome (MetS+) and without MetS (Mets-)
Total (n=417) Mets+ (n=165) Mets- (n=252) P-value
Age (years) 58 ± 12 62 ± 9 56 ± 13 <0.001
Male gender, n (%) 229 (54) 103 (60) 126 (50) 0.048
History of CAD, n (%) 183 (43) 122 (71) 61 (24) <0.001
DM, n (%) 73 (17) 70 (41) 3 (1) <0.001
Smoking, n (%) 76 (18) 33 (19) 43 (17) 0.608
BMI (kg/m2) 27.1 ± 4.7 30.0 ± 4.7 25.2 ± 3.5 <0.001
Waist (cm) 98 ± 14 108 ± 13 91 ± 11 <0.001
Systolic BP (mmHg) 132 ± 18 139 ± 19 128 ± 16 <0.001
Use of statin, n (%) 218 (51) 150 (87) 68 (27) <0.001
Use of ACE-I, n (%) 106 (25) 73 (42) 33 (13) <0.001
Use of ASA, n (%) 182 (43) 109 (63) 73 (29) <0.001
Glucose (mmol/L) 6.2 ± 2.3 7.4 ± 2.9 5.5 ± 1.3 <0.001
TG (mmol/L) 1.29 (0.88 - 1.94) 1.77 (1.15 - 2.68) 1.12 (0.77 - 1.58) <0.001
LDL-C (mmol/L) 2.8 ± 1.0 2.3 ± 0.8 3.1 ± 1.0 <0.001
HDL-C (mmol/L) 1.39 ± 0.41 1.24 ± 0.35 1.50 ± 0.41 <0.001
Apo A-I (g/L) 1.55 ± 0.31 1.47 ± 0.29 1.60 ± 0.31 <0.001
Apo B (g/L) 0.93 ± 0.27 0.87 ± 0.24 0.96 ± 0.29 0.001
CRP (mg/L) 2.0 (1.0 - 3.0) 2.0 (1.0 - 4.0) 1.0 (1.0 - 3.0) <0.001
C3 (g/L) 1.2 (1.0 - 1.4) 1.3 (1.2 - 1.5) 1.1 (1.0 - 1.3) <0.001
cIMT (mm) 0.648 ± 0.143 0.697 ± 0.129 0.616 ± 0.142 <0.001
Ery-apoB (au) 0.9 (0.4 - 1.6) 0.7 (0.4 - 1.3) 0.9 (0.5 - 1.8) 0.002
ASA: acetylsalicylic acid; ACE-i: angiotensin-converting enzyme inhibitor; BMI: body mass index; BP: blood pres-
sure; CAD: coronary artery disease; DM: diabetes mellitus; TG: triglycerides.
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Ery-apoB in relation to inflammation and cardiometabolic factors (figures 7.1-
3)
Ery-apoB was inversely associated with CRP (Spearman’s rho -0.169, p=0.001, Figure 
7.1A) and with C3 (rho -0.162, p=0.001, Figure 7.1B). Ery-apoB was lower in patients with 
hypertriglyceridemia (p=0.029, Figure 7.2A) and tended to be lower in patients with low 
HDL-C (p=0.05, Figure 7.2B). Ery-apoB was lower in patients with hypertension (p=0.031, 
Figure 7.2C) and in subjects with abdominal obesity (p=0.007, Figure 7.2D). Median 
ery-apoB decreased with increasing number of metabolic syndrome criteria (p=0.025, 
Figure 7.3). Ery-apoB was similar in men (0.9, IQR 0.4-1.4) and women (0.9, IQR 0.4-1.8; 
p=0.43). Ery-apoB did not correlate with age (rho -0.067, p=0.18) or with plasma apo B 
(rho -0.071, p=0.15).
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figure 7.1. Ery-apoB in relation to markers of inflammation
Ery-apoB is inversely correlated with CRP (Spearman’s rho -0.172, p=0.001) (A) and with complement C3 (Spear-
man’s rho -0.165, p=0.001) (B).
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figure 7.2. Ery-apoB in relation to several cardiometabolic factors
Ery-apoB is lower in patients with hypertriglyceridemia (nonfasting triglycerides >2.5 mmol/L or the use of 
fibrates) (A), ery-apoB tends to be lower in subjects with low HDL-C (HDL-C <1.0 mmol/L for men and <1.3 
mmol/L for women or the use of lipid-lowering drugs) (B), ery-apoB is lower in patients with hypertension (of-
fice systolic blood pressure >130 mm/Hg, diastolic blood pressure >85 or the use of antihypertensive drugs due 
to a history of hypertension) (C) and ery-apo is lower in subjects with abdominal obesity (waist circumference 
>102 cm for men and >88 cm for women) (D). Data are given as median with IQR, with the whiskers depicting 
minimal and maximal values.
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figure 7.3. Ery-apoB and metabolic syndrome
Ery-apoB decreases with increasing number of adapted NCEP criteria for metabolic syndrome (MetS). Data are 
given as median with IQR, with the whiskers depicting minimal and maximal values.
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Ery-apoB in relation to ABo blood group
Data on ABO blood group was available in 135 subjects. Ery-apoB was almost threefold 
higher in subjects with blood group O (n=65) than in those with a non-O blood group 
(n=70) (1.3 (IQR 0.8-2.1) versus 0.5 (IQR 0.1-1.1), p<0.001).
Ery-apoB in relation to cr1 polymorphism
The His1208Arg CR1 polymorphism was determined in 124 subjects. The minor allele 
frequency of His1208Arg was 0.18 and the genotype distribution was in Hardy-Weinberg 
equilibrium. Median ery-apoB was significantly higher in subjects with the wildtype 
polymorphism (n=82) than in those with a mutated allele (n=42) (1.1 (IQR 0.4-2.0) versus 
0.6 (IQR 0.2-1.5), p=0.036, Figure 7.4).
fasting and postprandial ery-apoB levels
To explore the effect of the prandial state on ery-apoB, 12 healthy volunteers underwent 
an oral fat loading test. Median ery-apoB was 1.1 (0.4-1.9) fasting, 1.2 (0.5-1.8) 4 hours 
after fat ingestion and 1.4 (0.6-1.9) 8 hours after fat ingestion (p=0.50).
Multiple regression analysis
In a multiple regression analysis, with ery-apoB as dependent variable and a history of 
coronary artery disease, cIMT, triglycerides, HDL-cholesterol, CRP, complement C3, waist 
circumference, systolic and diastolic blood pressure, CR1 polymorphism and ABO blood 
group as independent variables, the entered variables combined significantly predicted 
ery-apoB: adjusted R2 = 0.35, p<0.001. When the multiple regression analysis was carried 
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figure 7.4. Ery-apoB and CR1 gene polymorphism
Ery-apoB is significantly lower in those with the minor His1208Arg CR1 allele (heterozygous or homozygous) 
than those with the wildtype allele.
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out without ABO blood group as independent variable, the strength of the regression 
decreased, to adjusted R2 = 0.16, p=0.004. Without both ABO blood group and CR1 
polymorphism, the explained variance decreased even further, to adjusted R2 = 0.049, 
p=0.002.
discussioN
The binding of atherogenic apo B-containing lipoproteins to erythrocytes in the circula-
tion may represent a protective mechanism against atherosclerosis. In the current paper 
we describe that ery-apoB is associated with several cardiometabolic factors, such as 
abdominal obesity, hypertriglyceridemia, hypertension and inflammation, all of them 
closely associated to the metabolic syndrome. Ery-apoB decreased with increasing 
number of criteria for the metabolic syndrome. Furthermore, ery-apoB was associated 
with CR1 polymorphisms.
As we have postulated before [14], the binding of apo B-containing lipoproteins to 
circulating erythrocytes may protect the vessel wall from interaction with these lipopro-
teins, and contribute to clearance of these particles from the circulation. The concept of 
the removal of harmful particles from the circulation by erythrocytes is not new. Eryth-
rocytes bind immune complexes, which they can transfer to phagocytic cells in the liver 
and spleen [15]. This process is known as ‘immune adherence’ [16]. Immune adherence 
is dependent on the complement system, and the major receptor on the erythrocyte 
membrane involved is the complement receptor 1 (CR1) [16]. A similar mechanism may 
be involved in the phenomenon of ery-apoB, in which atherogenic lipoproteins bind 
to erythrocytes. These apo B-containing lipoproteins may then be detached from the 
erythrocyte in the liver.
Our group is not the first to demonstrate the binding of lipoproteins to human eryth-
rocytes. Already in the 1980’s Hui et al. described the binding of LDL to red blood cells 
[9]. Recently, Hung et al. demonstrated in mice that transfusion of cholesterol-labeled 
erythrocytes resulted in delivery of cholesterol to the feces [17]. This study supports the 
hypothesis of reverse cholesterol transport by erythrocytes, which in fact shows many 
similarities to the apo B-mediated immune adherence to erythrocytes proposed by our 
group. The authors postulated a working model, in which lipoprotein-free cholesterol is 
transferred to erythrocytes in the circulation, and then carried to the liver. Whether this 
binding of lipoproteins to red blood cells contributes to reverse cholesterol transport in 
humans needs to be investigated.
In the current study, there was no relation between ery-apoB and plasma apo B, as 
we have published previously [10,11]. Furthermore, ery-apoB did not change in the 
postprandial state in healthy subjects. In addition, we have previously shown that dis-
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continuation of statin use during six weeks did not affect ery-apoB [11]. This indicates 
that the metabolism of apo B-containing lipoproteins bound to circulating blood cells 
differs from that of atherogenic lipoproteins in plasma.
The binding mechanism of atherogenic lipoproteins to circulating erythrocytes is 
slowly being elucidated. Since erythrocytes do not express classical lipoprotein recep-
tors, such as the LDL-receptor [18], other mechanisms must be involved. We have recently 
shown in vitro and ex vivo in humans that CR1, the receptor involved in the transport 
of immune complexes by erythrocytes, is also involved in the binding of lipoproteins 
to blood cells, and that this binding is mediated by the classical and the alternative 
pathways of complement activation [19]. Results from the current study underline the 
involvement of CR1 in apo B-binding to erythrocytes. Ery-apoB was significantly higher 
in subjects with the wildtype variant of the His1208Arg CR1 polymorphism, which is 
associated with higher expression of CR1 on erythrocytes [20]. In a multivariate analysis, 
CR1 polymorphisms contributed to 11% of the explained variance in ery-apoB.
Results from our multiple linear regression analysis indicate that the level of ery-apoB is 
determined by many different factors. The set of 11 variables tested here only explained 
35% of the variation in ery-apoB. Therefore, other yet still unidentified factors must be 
involved as well. Interestingly, the variable with the strongest association with ery-apoB 
was the O blood group. In this extended dataset, in line with our previous findings [11], 
ery-apoB was almost threefold higher in those with blood group O, as opposed to sub-
jects with a non-O blood group. In this paper, we focused on the additional value of ABO 
blood group in the prediction of ery-apoB. Result from our multiple regression analysis 
indicate that approximately 19% of the explained variance in ery-apoB is due to ABO 
blood group. Currently, we cannot explain this association. It is tempting to speculate 
that the presence of A and B antigens on the erythrocyte surface may interfere with the 
binding of lipoproteins to the cell, but mechanistic studies are warranted. Subjects with 
a non-O blood group are known to have a higher cardiovascular risk than those with 
blood group O [21,22]. Previous reports have suggested that this increased risk may be 
attributed to differences in plasma Von Willebrand factor and factor VIII levels [22–24]. 
Interestingly, differences in ery-apoB may partly explain the increased cardiovascular 
risk in these subjects as well.
A limitation of the present study is the cross-sectional design. Correlation analyses do 
not prove causality, and therefore, mechanistic and interventional studies are needed to 
further investigate the impact of inflammation, metabolic syndrome, CR1 polymorphism 
and ABO blood group on ery-apoB. In addition, our results need to be confirmed in an 
independent cohort. Finally, prospective data on the value of ery-apoB in the prediction 
of cardiovascular risk are lacking. A prospective study by our research group investigat-
ing ery-apoB in relation to cardiovascular risk is ongoing.
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Before ery-apoB can be used as a potential novel cardiovascular risk marker, the 
measurement of ery-apoB should be standardized and validated. Quantification of the 
number of apo B molecules on erythrocyte surface is needed. Previous experiments 
with 125I-labeled LDL have indicated that human erythrocytes have approximately 200 
binding sites for LDL particles [9]. In addition, it needs to be established what type 
of lipoproteins are present on the erythrocyte surface. The polyclonal antibody used 
for the ery-apoB measurement recognizes both apo B48 and apo B100. Therefore, we 
cannot distinguish between apo B100-containing LDL, very low-density lipoprotein 
and intermediate-density lipoprotein particles, and apo B48-containing chylomicrons 
and their remnants. Unpublished results from our group, with antibodies exclusively 
directed against apo B48 [25], and against apo B100 [26], indicate that the apo B isoform 
detected with the present measurement technique is predominantly apo B100 and not 
apo B48.
In conclusion, apo B bound to circulating erythrocytes is associated with several 
characteristics of the metabolic syndrome, inflammation, CR1 polymorphism and ABO 
blood group. These data may give clues into the mechanisms involved in the binding 
of atherogenic lipoproteins to erythrocytes, and may shed new light on lipoprotein 
metabolism in humans. Ery-apoB could potentially serve as a novel cardiovascular risk 
marker or pharmacological target.
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ABsTrAcT
Background: The binding of apolipoprotein (apo) B-containing lipoproteins to cir-
culating erythrocytes (ery-apoB) has been associated with a decreased prevalence of 
atherosclerosis. In this study, we evaluated ery-apoB as a possible prognostic factor in 
cardiovascular events and all-cause mortality, in a prospective cohort study.
Methods: Ery-apoB was measured by flow cytometry in subjects with and without 
cardiovascular disease (CVD). The primary endpoint was the cardiovascular event rate. 
Secondary endpoints were all-cause mortality and the combined endpoint of all-cause 
mortality and cardiovascular events (any event rate). A Cox-regression analysis with a 
univariate and multivariate analysis and Kaplan Meier survival analysis was performed.
results: Follow-up data were available of 384 subjects. Subjects were divided according 
to high (>2.0 au, n=60), intermediate (0.2-2.0 au, n=274) or low (<0.2 au, n=50) ery-apoB. 
Median follow-up was 1767 days (IQR 1564–2001). In univariate analysis, low ery-apoB 
was associated with increased all-cause mortality (HR 9.9 (1.2-79.0), p=0.031) and any 
event rate (HR 3.4 (95% CI 1.3-8.7), p=0.012). In a Cox regression analysis, only a history 
of CVD was significantly associated with any event rate (HR 3.6 (1.6-8.0), p=0.002), while 
low ery-apoB showed a trend (HR 2.4 (0.9-6.4), p=0.07). In a subgroup analysis, in sub-
jects with a history of CVD, ery-apoB was significantly associated with all-cause mortality 
(Log Rank p=0.021) and any event rate (Log Rank p=0.009).
conclusion: Low ery-apoB is associated with increased mortality and cardiovascular 
risk, especially in patients with a prior history of CVD. These subjects may benefit from 
more aggressive secondary prevention treatment.
Erythrocyte-bound apolipoprotein B predicts mortality and cardiovascular events 121
8
iNTroducTioN
Cardiovascular disease (CVD) is one of the major causes of mortality and morbidity 
in the general population. The most important contributor to CVD is atherosclerosis 
[1]. Lipids and fibrous elements accumulate in the large arteries and narrow the ves-
sel lumen [1]. This is accompanied by an ongoing inflammatory response [1–3]. All 
atherogenic lipoproteins, including low density lipoprotein (LDL), intermediate density 
lipoprotein (IDL), very low density lipoprotein (VLDL), chylomicrons and their remnants, 
have a single apolipoprotein (apo) B molecule as their structural protein [4–6]. Apo B 
remains with the lipoprotein particle from the moment of formation in the intestine or 
liver until catabolization and cellular uptake [7]. Apo B yields the best current estimate 
of the total number of circulating atherogenic particles, representing the atherogenic 
burden caused by atherogenic lipoproteins [8]. Serum apo B has proved to be a strong 
predictor of CVD [9].
Studies on apo B as a predictor of CVD have always focused on apo B present in plasma 
or serum. Our research group has demonstrated that apo B is also present on circulating 
erythrocytes [2,10,11]. In two cross-sectional studies, a low level of erythrocyte-bound 
apo B (ery-apoB) was associated with an increased prevalence of CVD and with an in-
creased carotid intima media thickness [10,11]. This may indicate that a high adherence 
of apo B to erythrocytes reflects a protective situation against atherosclerosis, whereas 
low ery-apoB seems atherogenic. An explanation for this phenomenon may be that the 
binding of atherogenic apo B-containing lipoproteins to blood cells prevents their inter-
action with the endothelium [2]. In addition, high ery-apoB may indicate the presence of 
an alternative blood-cell mediated lipoprotein transport system in the circulation [2,11].
However, a limitation of previous studies investigating ery-apoB in relation to CVD is 
their cross-sectional design [10,11]. The aim of the present study was to examine the 
role of ery-apoB as a possible prognostic factor in all-cause mortality and cardiovascular 
events, in a prospective cohort study.
MATEriALs ANd METhods
study design and subjects
The study design was a prospective follow-up study of patients and healthy volunteers. 
Subjects older than 18 years, who visited the outpatient clinics of the Diabetes and 
Vascular Center and the Department of Cardiology of the Franciscus Gasthuis, Rotter-
dam, the Netherlands, and the healthy volunteers, were included between July 2009 
and February 2013 [10,11]. Exclusion criteria for both patients and healthy controls were 
the use of any experimental medication or drugs and the use of more than two units of 
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alcohol per day. The use of statins was not an exclusion criterion, because these drugs 
do not affect ery-apoB levels [11]. The study was approved by the independent Regional 
Medical Ethics Committee, Maasstad Hospital Rotterdam, the Netherlands. All study par-
ticipants gave written informed consent. At baseline, subjects were divided according to 
low ery-apoB (<0.2 au), intermediate ery-apoB (0.2-2.0 au) and high ery-apoB (>2.0 au), 
as has been defined previously [11].
Analytical methods
Anthropometric parameters and cardiovascular history were recorded. Laboratory mea-
surements were carried out according to standard procedures in our laboratory for clini-
cal chemistry [10,11]. Glucose, C-reactive protein (CRP), total cholesterol, high-density 
lipoprotein cholesterol (HDL-C) and triglycerides were determined using Synchron LX-20 
or DxC analyzers (Beckman Coulter, Brea, CA, USA). Low-density lipoprotein cholesterol 
(LDL-C) was calculated using the Friedewald formula. Complement component 3 (C3) 
and serum apo B were measured by nephelometry using an IMMAGE instrument (Beck-
man Coulter). Blood cell counts were determined using LH750 or DxH800 analyzers 
(Beckman Coulter).
Measurement of erythrocyte-bound apo B
The method of the in vivo measurement of ery-apoB has been described in detail previ-
ously [10–13]. In short, a nonfasting blood sample was obtained from a peripheral vein 
of the forearm. The presence of apo B on the erythrocyte surface was determined using 
a polyclonal goat antibody directed against human apo B (catalogue number AB742, 
Millipore, Billerica, MA, USA), with a rabbit-anti-goat antibody conjugated with fluores-
cein isothiocynate (FITC) (Nordic Immunological Laboratories, Tilburg, the Netherlands) 
as secondary antibody. As a control for background staining, a sample was stained in 
parallel with FITC-labeled rabbit-anti-goat, but without the apo B antibody. Ery-apoB 
was expressed as mean fluorescent intensity (MFI) in arbitrary units (au) of the signal 
obtained with the apo B antibody, minus the background signal. The intra-individual 
coefficient of variation for the measurement of ery-apoB is 9.4% (unpublished data).
Primary and secondary outcomes
Follow-up data were derived from the digital hospital information system and/or from 
questionnaires by telephone. If a study participant had experienced any event, the type 
of event was verified by review of medical records with the participant’s permission. The 
primary outcome was the cardiovascular event rate. The secondary endpoints were all-
cause mortality and the combined endpoint of all-cause mortality and cardiovascular 
events (any event rate). The endpoints were evaluated by an independent investiga-
tor at approximately 5 years follow-up. A cardiovascular event was defined as fatal or 
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nonfatal myocardial infarction, any arterial vascular intervention that had not already 
been planned at the time of inclusion (e.g. coronary bypass, percutaneous coronary 
intervention, peripheral vascular surgery or angioplasty/stenting), ischemic stroke, 
transient ischemic attack, amaurosis fugax, transient global amnesia or hospitalization 
due to unstable angina pectoris.
statistics
For normally distributed continuous variables, data are given as mean ± standard de-
viation (SD) in the text, tables and figure. The distributions of ery-apoB, triglycerides, 
CRP and complement C3 were skewed. Therefore, these variables were logarithmically 
transformed before analysis. For sake of clarity, the non-transformed data are shown in 
tables and figure, and data are given as median (interquartile range (IQR)). Differences 
between the low, intermediate and high ery-apoB groups were tested with one-way 
analysis of variance (ANOVA) for continuous variables, with the Bonferroni test as post-
hoc analysis, or with Pearson’s chi-square test for dichotomous variables.
A Cox-regression analysis was performed to study the impact of ery-apoB and 
other covariates on mortality, cardiovascular events and any event, using a two-step 
approach. First, the impact of ery-apoB and other variables related to cardiovascular risk 
on all-cause mortality, cardiovascular events and any event was assessed in a univariate 
survival analysis for each outcome measure separately, using the outcome measure as 
event, and time to outcome measure as the time to event since inclusion. Significance 
was assessed with the Log Rank test, a significant effect being p<0.10. In the second 
step, only the significant variables from the univariate analysis differing significantly 
between with patients with high, intermediate and low ery-apoB, i.e. a history of CVD, 
the presence of the metabolic syndrome and HDL-C levels, were added as covariates to 
a Cox-regression model. A p-value <0.05 (two-sided) was regarded as statistically signifi-
cant. All statistical analyses were performed using PASW statistics version 22.0 (IBM SPSS 
Statistics, New York, United States). The analyses were performed in the total group, and 
in the subgroups of subjects without prior CVD and patients with a prior history of CVD.
rEsuLTs
Baseline characteristics
The total cohort consisted of 392 subjects. In 8 subjects, no baseline ery-apoB value 
was present due to technical difficulties during measurement. Therefore, analyses were 
performed on 384 subjects. Subjects were divided according to high (>2.0 au, n=60), 
intermediate (0.2-2.0 au, n=274) or low (<0.2 au, n=50) ery-apoB levels. The median 
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follow-up was 1767 days (IQR 1564 – 2001). Table 8.1 shows the baseline characteristics 
of the total group, and for each of the ery-apoB classes.
Compared to subjects with high ery-apoB, subjects with low ery-apoB more often had 
metabolic syndrome, lower HDL-C and higher C3 levels. Subjects with low or interme-
diate ery-apoB had higher waist circumference, triglycerides and CRP than those with 
high ery-apoB. Those with low ery-apoB more often had a history of CVD, used statins 
more often and had higher leukocyte counts than subjects with intermediate or high 
ery-apoB. Subjects with low ery-apoB more often used acetylsalicylic acid than those 
with intermediate ery-apoB.
Mortality and cardiovascular events
During follow-up, a cardiovascular event occurred in 9% (n=35): 13 subjects developed 
unstable angina pectoris requiring intervention (percutaneous coronary intervention or 
bypass surgery), 11 developed fatal or nonfatal myocardial infarction, 6 subjects suf-
fered from nonfatal ischemic stroke, 3 had a transient ischemic attack, 1 subject had an 
episode of amaurosis fugax and 1 subject experienced transient global amnesia.
Death occurred in 7% (n=26) of the subjects: 3 died of fatal myocardial infarction, 2 of 
cancer, 1 of end-stage chronic obstructive pulmonary disease, 1 of pneumonia, and in 19 
subjects the cause of death was not specified in the medical records.
A total of 14% (n=53) of the subjects reached the combined endpoint of death or 
cardiovascular event: 27 patients had a nonfatal cardiovascular event and were alive at 
the end of follow-up, 3 patients had a fatal cardiovascular event and 23 patients died of 
non-cardiovascular causes.
univariate survival analysis
In univariate analysis, a history of CVD, age above 60 years, low HDL-C, hypertension, 
the presence of the metabolic syndrome and diabetes mellitus were associated with 
increased risk of any event (death or cardiovascular event). A history of CVD, age above 
60 years, low HDL-C and diabetes mellitus were associated with increased risk of mor-
tality. A history of CVD, age above 60 years, low HDL-C, hypertension and presence of 
the metabolic syndrome were associated with increased risk of future cardiovascular 
events. Gender, abdominal obesity and hypertriglyceridemia were neither associated 
with mortality nor with the cardiovascular event rate. Of these factors, the history of 
CVD, the presence of the metabolic syndrome and HDL-C levels differed significantly 
between patients with high, intermediate and low ery-apoB (Table 8.1).
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The Kaplan Meier survival curves for the three endpoints are shown in Figure 8.1. The 
cardiovascular event rate differed significantly between groups (Log Rank p=0.039, 
Figure 8.1A). However, the hazard ratio for a cardiovascular event was not significantly 
different between those with low and high ery-apoB (Table 8.2). All-cause mortality 
and the any event rate were significantly different between the three groups (Log Rank 
p=0.015 and p=0.002, respectively, Figure 8.1B and 8.1C). Subjects with low ery-apoB 
had significantly higher risk of death and any event than subjects with high ery-apoB 
(Table 8.2).
Table 8.2 Univariate survival analysis
CVE Death Death/CVE
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
History of CVD 6.2 (2.5-15.2) <0.001 3.2 (1.4-7.7) 0.008 4.6 (2.4-8.8) <0.001
Age above 60 years 2.7 (1.1-4.7) 0.028 8.2 (2.5-27.6) 0.001 3.5 (1.9-6.5) <0.001
Low HDL-C 2.8 (1.2-6.5) 0.016 3.8 (1.3-11.0) 0.014 3.2 (1.6-6.4) 0.001
Presence of hypertension 5.2 (1.6-17.2) 0.007 1.5 (0.6-3.8) 0.355 2.9 (1.3-6.1) 0.006
Presence of metabolic 
syndrome
2.1 (1.0-4.2) 0.040 1.9 (0.9-4.2) 0.102 2.1 (1.2-3.7) 0.007
Presence of diabetes mellitus 1.4 (0.6-3.2) 0.387 2.7 (1.2-5.9) 0.015 2.1 (1.2-3.7) 0.013
Low ery-apoB 2.4 (0.8-7.2) 0.112 9.9 (1.2-79.0) 0.031 3.4 (1.3-8.7) 0.012
Intermediate ery-apoB 0.9 (0.3-2.5) 0.860 4.1 (0.5-30.5) 0.174 1.3 (0.6-3.1) 0.572
The table shows the results of univariate Kaplan Meier analysis of the impact of several factors on risk of car-
diovascular event (CVE), mortality or the combined endpoint of death or CVE as hazard ratio (HR) with 95% 
confidence interval (CI) for: history of cardiovascular disease (CVD as binary variable), age above 60 years (as 
binary variable), low HDL-C (as binary variable as outlined by NCEP criteria), presence of hypertension (as binary 
variable as outlined by NCEP criteria), presence of metabolic syndrome (as binary variable as outlined by NCEP 
criteria), presence of diabetes mellitus (as binary variable), low and intermediate ery-apoB represent the impact 
compared to subjects with high ery-apoB as reference.
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figure 8.1. Univariate survival analysis (Kaplan Meier curves) for cardiovascular event (CVE)-free survival 
(A), overall survival (B) and the combined endpoint of death or CVE (C), in subjects with high ery-apoB (con-
tinuous black line), intermediate ery-apoB (dotted dark grey line) and low ery-apoB (striped light grey line).
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In a subgroup analysis, in subjects with a history of CVD, ery-apoB was not significantly 
associated with cardiovascular event rate (Log Rank p=0.14). However, all-cause mor-
tality (Log Rank p=0.021) and any event rate (Log Rank p=0.009) differed significantly 
between the three groups in subjects with prior CVD. The hazard ratios for subjects with 
low ery-apoB, compared to those with high ery-apoB, for mortality (HR 5.8 (0.7-46.7), 
p=0.098) and any event (HR 2.2 (0.8-6.2), p=0.13), were not significant.
In subjects without a history of CVD, ery-apoB was not associated with cardiovascular 
event rate, all-cause mortality or any event rate (HR 2.1 (0.1-33.3), p=0.60, HR 1.0 (0.0-
1.9·106), p>0.99 and HR 2.1 (0.1-33.5), p=0.60; for low ery-apoB compared to high ery-
apoB, respectively). The baseline characteristics of both subgroups are listed in Table 8.3.
cox regression analysis
A Cox regression analysis was carried out with ery-apoB, a history of CVD, metabolic 
syndrome and HDL-C as covariates for the any event rate (Table 8.4). In this model, a 
history of CVD was associated with an increased any event rate (HR 3.6 (95% CI 1.6-
8.0), p=0.002). Low ery-apoB tended to be associated with an increased any event rate 
(HR 2.4 (95% CI 0.9-6.4), p=0.07). In contrast, HDL-C and the metabolic syndrome were 
not significantly associated with mortality or cardiovascular events in this multivariate 
analysis. No Cox regression analysis was carried out in the subgroups of subjects with or 
without prior CVD, due to the limited event rate.
discussioN
This is the first cohort study to report that the binding of apo B-containing lipoproteins 
to circulating erythrocytes is associated with all-cause mortality and future cardiovas-
cular events. These results are in line with previous cross-sectional observations [10,11], 
Table 8.4 Cox regression analysis
HR (95% CI) p-value
History of CVD 3.6 (1.6-8.0) 0.002
Low HDL-C 1.3 (0.5-3.2) 0.583
Presence of metabolic syndrome 1.0 (0.6 -2.0) 0.883
Low ery-apoB 2.4 (0.9-6.4) 0.070
Intermediate ery-apoB 1.1 (0.5-2.7) 0.808
The table shows the results of the Cox regression analysis, with the hazard ratio (HR) and 95% confidence in-
terval (CI) for the primary outcome measure (any event, i.e. all-cause mortality or cardiovascular event): history 
of CVD (as binary variable), HDL-C (as binary variable as outlined by NCEP criteria), presence of metabolic syn-
drome (as binary variable as outlined by NCEP criteria), low and intermediate ery-apoB represent the impact 
compared to subjects with high ery-apoB as reference.
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and suggest that the binding of apo B-containing lipoproteins to erythrocytes in the 
circulation may be a protective mechanism against atherosclerosis and mortality.
The first report about the phenomenon of LDL bound to the surface of erythrocytes 
dates back to the 1980s, when Hui and colleagues performed a study investigating 
chemically modified and native LDL exchanging cholesterol with erythrocytes, which 
lack the capacity of whole lipoprotein internalization [14,15]. They described that LDL 
could bind to freshly isolated human erythrocytes, and that this binding resulted in an 
altered morphology [16,17]. The binding of 125I-labeled LDL to erythrocytes, measured by 
spectrometry, appeared to be temperature-independent and concentration-dependent 
until a plateau was reached. About 200 LDL particles were associated with each eryth-
rocyte at saturation [14].
Roughly thirty years later, our research group developed a flow cytometric method 
to measure blood cell-bound apo B [2,10–12]. We demonstrated an inverse relationship 
between ery-apoB and clinical and subclinical atherosclerosis [10,11] and we formulated 
a new hypothesis on the mechanism of action, proposing similarities with the process 
of ‘immune adherence’ [2].
Immune adherence is a well-documented phenomenon: erythrocytes bind immune 
complexes via the complement receptor 1 (CR1) and carry them from the circulation to 
the liver and spleen for elimination [18,19]. This mechanism may possibly be involved 
in elimination of atherogenic lipoproteins from the circulation as well, possibly through 
uptake by hepatocytes, followed by biliary excretion [2]. Mechanistic studies of the 
molecular mechanisms involved in the binding of apo B-containing lipoproteins to 
circulating erythrocytes are needed. The absence of a correlation between plasma apo B 
and ery-apoB, and the observation that plasma apo B is normal in subjects with low ery-
apoB, suggests that the binding mechanism may be independent of lipid metabolism. 
Since erythrocytes do not carry classical lipoprotein receptors, such as the LDL-receptor 
or LRP-1 [13,14,16,20], a different receptor must be involved. CR1 is one of the candi-
dates. We have shown in vitro that binding of apo B to human leukocytes and to Chinese 
hamster ovarian cells is, at least in part, mediated by CR1 [13]. This binding seems to be 
dependent on activation of the complement system. We demonstrated that the binding 
of native LDL to CR1 is mediated via the classical pathway, and the binding of modified 
LDL is mediated via both the classical and alternative pathways [13].
The observed association of high ery-apoB and lower cardiovascular event rate could 
be of clinical relevance. These results imply that ery-apoB may be a valuable additional 
parameter in the assessment of cardiovascular risk, especially in high-risk subjects. 
Moreover, if ery-apoB is indeed causally associated with cardiovascular risk, and ery-
apoB is found to be modifiable, this would be an interesting target for future therapy. 
In the present study, ery-apoB did not seem to predict cardiovascular risk or mortality 
in subjects without a prior history of CVD. This could be due to lack of power, since 
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only 12 events occurred in this group. Therefore, no conclusions can be drawn on the 
additional value of ery-apoB in primary prevention strategies. Results of the subgroup 
analysis in patients with a cardiovascular history suggest that ery-apoB may indeed be 
a valuable marker in the identification of subjects with a very high risk of recurrent CVD 
or death. As long as we do not know the precise mechanism by which ery-apoB may 
protect against atherosclerosis or how to modulate ery-apoB, this measurement may 
help to select patients who may benefit from intensive secondary prevention strategies.
Despite aggressive statin treatment for secondary prevention, about one in five 
patients experiences a major cardiovascular event within five years [21]. This residual 
cardiovascular risk has been attributed to increased plasma apo B, age, body mass index, 
male gender and diabetes mellitus [22]. Perhaps low ery-apoB is partly involved in this 
residual cardiovascular risk as well, since most patients with CVD in our cohort were on 
statins or other lipid lowering drugs.
However, before ery-apoB can be regarded as a marker or a target for cardiovascular 
risk reduction strategies, certain conditions must be met. For instance, it needs to be 
established whether the measurement of ery-apoB has consequences for outcomes 
such as CVD and death when applied on top of the parameters currently used in com-
mon practice, requiring further validation studies. Furthermore, the current method 
for ery-apoB measurement is a time-consuming two-step staining procedure, which 
makes implementation on large scale difficult. Therefore, the development of a faster 
and easier measurement procedure is warranted. In addition, no longitudinal data on 
ery-apoB measurement are available. The average life span of an erythrocyte is 127 days 
[23]. We cannot exclude that ery-apoB may change over the course of several years, for 
instance under the influence of lifestyle changes. This is now being investigated by our 
group.
The main limitation of this study is the heterogeneity in classic cardiovascular risk 
factors between our groups at baseline. While age, blood pressure and diabetes mel-
litus did not significantly differ between groups, the higher prevalence of metabolic 
syndrome, a history of CVD and lower HDL-C in subjects with low ery-apoB may have 
been a confounder in our study. Results from the multivariate analysis showed that a 
history of CVD was the most powerful predictor of future cardiovascular events or death. 
However, in patients with a history of CVD, low ery-apoB was significantly associated 
with the risk of death or cardiovascular events. In addition, in this subgroup of patients 
with prior CVD, the prevalence of the metabolic syndrome and levels of HDL-C did not 
significantly differ between subjects with low, intermediate or high ery-apoB. These data 
indicate that the association between ery-apoB and the risk of mortality and CVD may 
be independent from such traditional risk factors as prior CVD, the metabolic syndrome 
and low HDL-C.
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Another limitation is the relatively small number of study subjects and the number of 
events, despite a median follow-up of 4.8 years. Therefore, correction for other variables 
was difficult in this cohort. The results need to be confirmed in an independent cohort.
In conclusion, ery-apoB may be a novel cardiovascular risk marker in high-risk subjects. 
These subjects may benefit from more aggressive secondary prevention treatment.
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ABsTrAcT
Background: Atherosclerosis is a pro-inflammatory condition, in which leukocyte 
activation plays an important role. The interaction between circulating leukocytes and 
apolipoprotein (apo) B-containing lipoproteins results in pro-inflammatory changes of 
these cells. We aimed to evaluate the relationship between apo B bound to circulating 
leukocytes and atherosclerosis.
Methods: Apo B on circulating leukocytes was measured by flow cytometry in subjects 
with and without cardiovascular disease (CVD), expressed as mean fluorescent intensity 
in arbitrary units (au). Carotid intima media thickness (cIMT) was measured using B-
mode ultrasound. Data are given as median (interquartile range).
results: 396 subjects were included, of whom 183 had a history of CVD. Compared to 
subjects without CVD, patients with CVD had lower apo B bound to neutrophils (12.7 
au (9.8-16.2) and 14.2 au (10.1-17.5), respectively, p=0.038) and to monocytes (2.5 
au (1.7-3.1) and 2.7 (1.9-3.6) au, respectively, p=0.025). No differences were found for 
lymphocyte-bound apo B. Neutrophil- and monocyte-bound apo B were inversely cor-
related with cIMT (Spearman’s rho: -0.123, p=0.017 and -0.108, p=0.035, respectively). 
Both monocyte- and neutrophil-bound apo B were inversely associated to different 
factors related to the metabolic syndrome, such as body mass index, triglycerides and 
complement C3. There was a positive association between erythrocyte-bound apo B and 
apo B bound to each of the leukocyte classes, possibly reflecting a similar mechanism. 
Discontinuation of statins in 54 subjects did not influence leukocyte-bound apo B.
conclusion: Unexpectedly, the presence of non-internalized apo B-containing lipopro-
teins on circulating neutrophil and monocyte membranes may represent a protective 
mechanism against atherosclerosis.
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iNTroducTioN
The development of atherosclerosis starts when leukocytes and endothelial cells are 
activated by different well-described stimuli, such as lipoproteins, oxidative stress and 
glucose [1–5]. According to classical concepts, circulating leukocytes can adhere to the 
intact endothelium and migrate to the subendothelial space [6]. Subendothelial mono-
cytes mature into macrophages and take up modified lipoproteins, with the risk of foam 
cell formation [6]. Evidence also suggests a pathophysiological role for lymphocytes and 
neutrophils in atherogenesis [7,8]. It has been shown in vivo in mice that reduced leuko-
cyte adhesion to the endothelium is associated with a reduced atherosclerotic plaque 
size [9]. These data underscore the importance of the interaction between leukocytes 
and the endothelium in the development of atherosclerosis.
All atherogenic lipoproteins carry a single apolipoprotein (apo) B molecule [10]. The 
level of plasma apo B is a strong predictor of cardiovascular risk [11,12]. However, not 
only plasma apo B, but also apo B-containing lipoproteins bound to circulating blood 
cells may be associated with cardiovascular disease (CVD). It has been demonstrated that 
circulating leukocytes interact with apo B-containing lipoproteins [2,13]. For example, 
these leukocytes internalize dietary fatty acids during the postprandial phase [2,13]. 
The interaction between leukocytes and lipids results in activation of these leukocytes 
[2,3,13,14].
We recently demonstrated that not only circulating leukocytes, but also circulating 
erythrocytes carry apo B-containing lipoproteins [15,16]. A higher level of erythrocyte-
bound apo B was associated with a lower prevalence of CVD and with less subclinical 
atherosclerosis, assessed by measurement of the carotid intima media thickness (cIMT) 
[15,16].
The aim of the present study was to investigate the relationship between leukocyte-
bound apo B-containing lipoproteins and the presence of atherosclerosis. We hypoth-
esized that apo B bound to circulating leukocytes may be positively associated with 
the presence of clinical and subclinical atherosclerosis, due to the fact that these cells 
become increasingly activated by these lipoproteins [2,3,13,14].
MATEriALs ANd METhods
subjects and study design
The study design was a cross-sectional study that has been described in detail previ-
ously [15,16]. Subjects aged 18 years or above, who visited the outpatient clinics of the 
Diabetes and Vascular Center or the Department of Cardiology of the Sint Franciscus 
Gasthuis in Rotterdam for cardiovascular risk assessment between July 2009 and Febru-
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ary 2013 were included. In addition, a group of hospital employees were included as 
healthy volunteers. Exclusion criteria were the use of any experimental medication or 
drugs and the use of more than two units of alcohol per day. Anthropometric parameters 
and cardiovascular history were recorded. A history of CVD was defined as the presence 
of one or more of the following conditions at time of inclusion: ischemic stroke, transient 
ischemic attack, myocardial infarction, percutaneous coronary intervention due to stable 
or unstable coronary artery disease, angina pectoris based on clinical characteristics or 
coronary artery disease based on coronary angiography.
The cIMT was measured with the ART-lab (Esaote, Italy), as described previously [15], 
by trained and experienced sonographers. ART-lab is based on dedicated ultrasound 
signal processing, using radio frequency ultrasound signals for automatic detection of 
the vessel wall [17]. Ultrasound scans were performed with the patient lying in a supine 
position with the head resting comfortably and the neck slightly hyperextended and 
rotated in the opposite direction of the probe. The ultrasound images were obtained 
of the distal 1 cm of the far wall of each common carotid artery (CCA) using B-mode 
ultrasound, producing two echogenic lines. These lines represent the combined thick-
ness of the intima and media layers of the arterial wall. Each CCA was imaged in three 
different projections: CCA right side 90-120-150 and CCA left side 210-240-270 degrees. 
The segments were measured semi-automated in triplicate. Laboratory measurements 
were carried out according to standard procedures in our laboratory for clinical chem-
istry [15,16].
In order to investigate the effect of statins on the binding of apo B-containing lipo-
proteins to leukocytes, a second group of subjects was selected. The design of this statin 
withdrawal substudy has been published elsewhere [16]. Briefly, subjects who were on 
statin therapy for primary or secondary prevention were invited to participate. These 
patients visited the outpatient clinic twice after an overnight fast. During the first visit, 
while on statins, a baseline lipid profile and neutrophil- and monocyte-bound apo B 
were determined. After the first visit, participants discontinued their statin use for 6 
weeks. After 6 weeks, participants returned to the outpatient clinic, and a fasting lipid 
profile and leukocyte-bound apo B were determined again. The effect of the withdrawal 
of statins on the fasting lipid profile in these subjects has previously been published 
[16]. The effect of statin withdrawal on monocyte- and neutrophil-bound apo B levels 
has not been reported previously.
Both studies were approved by the independent Regional Medical Ethics Commit-
tee, Maasstad Hospital Rotterdam, the Netherlands. All study participants gave written 
informed consent. Reporting of the study conforms to STROBE statement along with 
references to STROBE statement and the broader EQUATOR guidelines [18].
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Measurement of leukocyte-bound apolipoprotein B
The method of the in vivo measurement of leukocyte-bound apo B has been described 
in detail previously [2,19]. Nonfasting blood samples were collected in tubes containing 
5.4 mg K2 EDTA (Becton Dickinson, Plymouth, United Kingdom). We have previously 
shown that leukocyte-bound apo B is not influenced by the prandial state [2]. The stain-
ing procedure was started within one hour after venipuncture. One mL of blood was 
taken and erythrocytes were lysed by adding 10 mL of lysis solution (1.5 M ammonium 
chloride, 100 mM potassium hydrogen carbonate, 0.82 mM EDTA, pH 7.4), followed 
by 15 minutes of incubation. Samples were washed three times in PBS supplemented 
with 0.5% BSA (PBS-BSA). Leukocytes were resuspended in 1 mL of PBS-BSA. Twenty 
µL of leukocyte-suspension was added to tubes containing 2.5 µL of a 25-times diluted 
polyclonal goat antibody directed against human apo B (catalogue no. AB742, Millipore, 
Billerica, MA, USA), and 2.5 µL of 10-times diluted anti-CD45 (Beckman Coulter), and 
incubated for 30 minutes in the dark on ice. In case of a leukocyte count above 10 x 109 
cells/L, only 10 µL of leukocyte-suspension was added. The cells were washed once in 
1 mL PBS-BSA and the supernatant was drained away. The cells were then incubated 
with 2.5 µL of a 10-times diluted rabbit anti-goat antibody conjugated with fluorescein 
isothiocynate (RAG-FITC, Nordic Immunological Laboratories, Tilburg, The Netherlands) 
for an additional 30 minutes in the dark on ice. In order to determine background signal, 
each sample was incubated in parallel without the apo B antibody, but with RAG-FITC. To 
be able to differentiate between different types of leukocytes, a CD45 antibody labeled 
with PE-Texas Red (Beckman Coulter, Miami, USA) was added simultaneously with the 
apo B antibodies. Samples were kept in the dark on ice until measurement. A total of 
15000 leukocytes per sample were analyzed with an Epics XL-flow cytometer (Beckman 
Coulter). The different types of leukocytes (lymphocytes, monocytes and granulocytes) 
were identified based on their side scatter and the level of CD45 on their cell surface. 
The fluorescent intensity of each cell was expressed as the mean fluorescent intensity, 
given in arbitrary units (au). The mean fluorescent intensity of each leukocyte popula-
tion was determined by subtracting the background signal obtained with the RAG-FITC 
control from the signal measured with the apo B antibody. Erythrocyte-bound apo B was 
determined as has been described previously [15,16].
statistics
For normally distributed continuous variables, data are given as mean ± standard 
deviation in the text, tables and figures and differences between groups were tested 
with the Independent Samples T Test. Continuous variables with skewed distributions 
(triglycerides, C-reactive protein, neutrophil-, monocyte- and lymphocyte-bound apo 
B) are given as median (interquartile range (IQR)), and differences between groups were 
tested with the Mann Whitney-U test. Differences in neutrophil- and monocyte-bound 
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apo B before and after statin withdrawal were tested with the Wilcoxon Signed Ranks 
test. The Chi-square test was used to test for differences between groups for discrete 
variables. Correlations were determined with Spearman correlation statistics. Because 
of anticipated differences in baseline characteristics between patients with and without 
CVD, the influence of age, gender and waist circumference on neutrophil- and mono-
cyte-bound apo B was assessed in a multiple linear regression analysis. Age was found to 
be of significant influence, while gender and waist circumference were not. In addition, 
variables such as statin use, ACE-inhibitor use and chronic kidney disease did not influ-
ence leukocyte-bound apo B in multiple regression analysis. Results were therefore also 
stratified for age below or above 58 years. Statistical analysis was carried out with PASW 
statistics version 22.0 (IBM SPSS Statistics, New York, United States). P-values below 0.05 
(2-tailed) were considered statistically significant.
rEsuLTs
Baseline characteristics
Table 9.1 shows the baseline characteristics of the 396 included subjects, of whom 
183 (46%) had a history of CVD (CVD+) and 213 had no CVD (CVD-). The CVD+ group 
consisted of more males and more patients with diabetes mellitus. CVD+ patients were 
on average older, had higher body mass index, waist circumference, systolic blood 
pressure, fasting glucose, triglycerides, neutrophil count, monocyte count and cIMT 
than CVD- subjects. CVD+ subjects had lower low-density lipoprotein cholesterol, high-
density lipoprotein cholesterol, apo B and apo A-I than the CVD- subjects. The use of 
statins, antihypertensive drugs and acetylsalicylic acid was significantly higher in the 
CVD+ group. Subclinical atherosclerosis, defined as a cIMT above 0.700 mm, was present 
in 131 patients (mean age 65 years, range 44-81). In 252 patients (mean age 54 years, 
range 22-79), no subclinical atherosclerosis was observed. In the remaining 13 patients, 
no cIMT value was available, due to technical problems during measurement.
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Table 9.1 General characteristics of study participants (n=396)
cVd+ (n=183) cVd- (n=213) P-value
Male gender 127 (69) 81 (38) <0.001
Diabetes mellitus 51 (28) 19 (9) <0.001
Smoking 36 (20) 33 (16) 0.291
Age (years) 63 ± 9 54 ± 12 <0.001
Body mass index (kg/m2) 28.1 ± 4.7 26.0 ± 4.4 <0.001
Waist circumference (cm) 102 ± 13 93 ± 14 <0.001
Systolic blood pressure 
(mmHg)
136 ± 18 129 ± 17 <0.001
Diastolic blood pressure 
(mmHg)
78 ± 10 79 ± 10 0.362
Glucose (mmol/L) 6.8 ± 2.6 5.8 ± 1.9 <0.001
Triglycerides (mmol/L) 1.38 (0.99-2.18) 1.20 (0.86-1.77) 0.020
Total cholesterol (mmol/L) 4.4 ± 0.9 5.3 ± 1.2 <0.001
LDL cholesterol (mmol/L) 2.4 ± 0.8 3.2 ± 1.0 <0.001
HDL cholesterol (mmol/L) 1.3 ± 0.4 1.5 ± 0.4 <0.001
Apolipoprotein B (g/L) 0.85 ± 0.22 1.00 ± 0.28 <0.001
Apolipoprotein A-I (g/L) 1.48 ± 0.28 1.61 ± 0.32 <0.001
C-reactive protein (mg/L) 2.0 (1.0-4.0) 2.0 (1.0-4.0) 0.672
Leukocyte counts (109 
cells/L)
6.9 ± 1.9 6.4 ± 1.9 0.030
Neutrophil counts (109 
cells/L)
4.2 ± 1.6 3.8 ± 1.6 0.028
Monocyte counts (109 
cells/L)
0.60 ± .18 0.52 ± 0.17 <0.001
Lymphocyte counts (109 
cells/L)
1.89 ± 0.55 1.92 ± 0.59 0.608
Carotid intima media 
thickness (mm)
0.702 ± 0.134 0.592 ± 0.124 <0.001
Use of statins 165 (90) 35 (16) <0.001
Use of acetylsalicylic acid 150 (82) 22 (10) <0.001
Use of beta blockers 89 (49) 21 (10) <0.001
Use of diuretics 49 (27) 19 (9) <0.001
Use of ACE-inhibitors 84 (46) 10 (5) <0.001
Use of angiotensin II 
receptor antagonists
45 (25) 22 (10) <0.001
Use of calcium channel 
antagonists
55 (30) 7 (3) <0.001
Data are given as mean ± standard deviation for normally distributed continuous variables, as median (inter-
quartile range) for continuous variables with skewed distributions (triglycerides, C-reactive protein, erythrocyte-
bound apo B), or as number (percentage). P-value for difference between groups.
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Leukocyte-bound apolipoprotein B and clinical atherosclerosis
Compared to CVD- subjects, CVD+ patients had lower apo B bound to neutrophils (12.7 
au (9.8-16.2) and 14.2 au (10.1-17.5), respectively, p=0.038) and to monocytes (2.5 au 
(1.7-3.1) and 2.7 (1.9-3.6) au, respectively, p=0.025) (Figure 9.1). Lymphocyte-bound 
apo B did not differ between those with and without CVD (0.2 au (0.1-0.3) and 0.2 au 
(0.1-0.3), respectively, p=0.51). When stratified for age, for patients older than 58 years, 
monocyte-bound apo B remained significantly lower in patients with CVD (2.5 au (1.7-
3.0) and 3.1 au (2.2-3.7), p<0.001), with a trend for lower neutrophil-bound apo B (12.4 
au (9.4-16.0) and 13.5 au (10.4-17.3), p=0.092). Neutrophil- and monocyte-bound apo B 
were no longer significantly different between CVD+ and CVD- patients younger than 
58 years.
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figure 9.1. Neutrophil- and monocyte-bound apo B is lower in subjects with cardiovascular disease (CVD)
Boxplot showing the difference in neutrophil-bound apo B (A) and monocyte-bound apo B (B) between pa-
tients with a history of cardiovascular disease (CVD+, n=183, dark grey bars) and those without previous cardio-
vascular disease (CVD-, n=213, light grey bars). Data are shown as median with the 25th and 75th percentile, with 
the whiskers depicting minimal and maximal values. P-value for difference between both groups (Mann Whit-
ney-U test). Both neutrophil- and monocyte-bound apo B were lower in CVD+ patients than in CVD- patients.
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Leukocyte-bound apolipoprotein B and subclinical atherosclerosis
Neutrophil-bound apo B and cIMT as well as monocyte-bound apo B and cIMT were 
weakly inversely correlated (Figure 9.2). No significant correlation was observed between 
lymphocyte-bound apo B and cIMT. When stratified for age, correlations remained sig-
nificant for patients younger than 58 years (Spearman’s rho -0.173, p=0.020 for cIMT and 
monocyte-bound apo B; and rho -0.156, p=0.037 for cIMT and neutrophil-bound apo B). 
For patients older than 58 years, no significant correlations were found.
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figure 9.2. Neutrophil- and monocyte-bound apo B is inversely correlated with carotid intima media 
thickness (cIMT)
Correlation plot of neutrophil-bound apo B (A) and monocyte-bound apo B (B) with carotid intima media thick-
ness (cIMT), a marker of subclinical atherosclerosis (Spearman’s rho with corresponding p-value). Neutrophil- 
and monocyte-bound apo B both correlated inversely with cIMT.
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determinants of leukocyte-bound apo B
Table 9.2 shows the correlation statistics for monocyte- and neutrophil-bound apo 
B with apo B bound to erythrocytes and lymphocytes, as well as the correlation with 
several anthropometric and laboratory measurements. Monocyte-bound apo B was 
positively associated with apo B bound to neutrophils, lymphocytes and erythrocytes. 
Neutrophil-bound apo B correlated positively with monocyte-, lymphocyte- and 
erythrocyte-bound apo B. Monocyte and neutrophil-bound apo B were inversely associ-
ated with age, body mass index, waist circumference, triglycerides, C-reactive protein, 
complement C3 and total leukocyte count. We found no correlations between plasma 
apo B levels and leukocyte-bound apo B (data not shown).
Leukocyte-bound apo B after discontinuation of statins
In the separate statin withdrawal cohort, 54 subjects were included. Their baseline char-
acteristics have been published elsewhere [16]. No correlations were found between 
fasting plasma apo B and neutrophil- or monocyte-bound apo B (Spearman’s rho: 0.005, 
p=0.92 and 0.050, p=0.32, respectively). After statin withdrawal, plasma apo B increased 
by 59.3 ± 30.8% (p<0.001), while median neutrophil- and monocyte-bound apo B did 
not change significantly (-1.1 ± 0.6%, p=0.92, and +4.2 ± 4.1%, p=0.49, respectively).
Table 9.2 Determinants of leukocyte-bound apo B
Monocyte-bound apo B Neutrophil-bound apo B
Monocyte-bound apo B - 0.582 (<0.001)
Neutrophil-bound apo B 0.582 (<0.001) -
Lymphocyte-bound apo B 0.419 (<0.001) 0.376 (<0.001)
Erythrocyte-bound apo B 0.313 (<0.001) 0.190 (<0.001)
Age -0.037 (0.462) -0.136 (0.007)
BMI -0.133 (0.009) -0.081 (0.112)
Waist -0.147 (0.004) -0.098 (0.056)
Triglycerides -0.132 (0.009) -0.144 (0.004)
C-reactive protein -0.104 (0.045) -0.132 (0.011)
Complement C3 -0.100 (0.048) -0.094 (0.063)
Leukocyte count -0.027 (0.591) -0.139 (0.006)
Table with correlation statistics (Spearman’s rho and corresponding p-value), with monocyte- and neutrophil 
bound apo B in the vertical columns, and apo B bound to several cell types and anthropometric and laboratory 
measurements in the horizontal rows.
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discussioN
This is the first study describing an association between atherosclerosis and the 
decreased presence of apo B-containing lipoproteins on circulating neutrophils and 
monocytes. These results are in contrast with our hypothesis and with current concepts. 
Since the uptake of lipoproteins by leukocytes results in activation of these leukocytes 
[2,3,13,14], which has been associated with the development of atherosclerosis [20,21], 
we hypothesized that the binding of apo B-containing lipoproteins would result in a 
pro-atherogenic condition. Our data suggest the opposite.
It should be underlined that the observed differences in leukocyte-bound apo B are 
relatively small. However, the results are consistent across different cell lines (neutrophil 
granulocytes, monocytes and erythrocytes) and the results are in line with our previ-
ous finding of an inverse relationship between apo B-containing lipoproteins bound 
to circulating erythrocytes with the presence of atherosclerosis [15,16]. These in vivo 
data do not fit into the current concepts regarding the interaction between atherogenic 
lipoproteins and leukocytes and its effect on the arterial wall.
Atherosclerosis is considered to be an inflammatory disease, and it has been suggested 
that the uptake of apo B-containing lipoproteins by leukocytes in the subendothelial 
space is a pro-atherogenic process [6]. Increasing in vitro and in vivo evidence from dif-
ferent groups suggests that leukocytes also interact with atherogenic lipoproteins in 
the circulation [2,13]. A possible explanation for the paradoxical inverse relationship 
between leukocyte-bound apo B and atherosclerosis may be that the binding of ath-
erogenic apo B-containing lipoproteins to leukocytes in the circulation might prevent 
these lipoproteins from interacting with the endothelium. We assume that the bind-
ing of atherogenic apo B-containing lipoproteins to circulating leukocytes may lead 
to internalization and possibly catabolism in the fasting situation. It has been shown 
that interaction between endothelial cells and apo B-containing lipoproteins results in 
increased expression of cell-adhesion molecules on endothelial cells, thereby facilitat-
ing the binding of leukocytes to the endothelium, inducing a pro-inflammatory and 
pro-atherogenic state [22,23]. In this respect, leukocyte-lipoprotein interaction in the 
circulation may reflect a first line defense mechanism, protecting the vessel wall. This 
hypothesis is supported by the weak inverse correlation between leukocyte-bound apo 
B and markers of inflammation and cIMT.
At present, it is unknown how apo B-containing lipoproteins bind to leukocytes and 
erythrocytes. Multiple receptors for the binding of apo B-containing lipoproteins to cir-
culating leukocytes are known, including the LDL-receptor, LRP-1, the apo B48-receptor 
and LOX-1 [13,24–26]. We have recently demonstrated that the complement receptor 1 
(CR1) may also be involved in the binding of lipoproteins to blood cells [19]. The strong 
positive association between apo B bound to erythrocytes and to each of the leukocyte 
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classes suggests a common binding mechanism. Since CR1, in contrast to the afore-
mentioned lipoprotein receptors, is present both on erythrocytes and leukocytes, this 
may be a candidate receptor. In this respect we proposed a role for erythrocytes as an 
alternative transport system for atherogenic lipoproteins, whereby these lipoproteins 
may be cleared from the circulation when erythrocytes circulate through the liver. This 
is an established clearance mechanism for immune complexes and micro-organisms 
bound to CR1 on erythrocytes known as “immune adherence” [27]. Lipoproteins bound 
to leukocytes may follow the same pathway, which would explain the protective effect 
described here.
One of the main limitations of the present study is the heterogeneity of patients 
with and without CVD. Several factors associated with the metabolic syndrome, such 
as triglycerides, body mass index and C3, were inversely correlated to monocyte and 
neutrophil-bound apo B. With the design of the current study, we cannot determine 
whether leukocyte-bound apo B is affected by these factors. It would be interesting to 
investigate in an interventional study whether for instance weight loss or reduction of 
triglyceride levels positively influences leukocyte-bound apo B. In addition, it would be 
valuable to investigate the metabolism of leukocyte-bound apo B in a population with 
high neutrophil or monocyte count.
Another difference between patients with and without CVD in our study was the use of 
statins. We have shown previously that statins have no effect on erythrocyte-bound apo 
B [16]. We now demonstrate that also monocyte- and neutrophil-bound apo B did not 
change 6 weeks after discontinuation of statins in 54 subjects. We cannot exclude the 
possibility that statin discontinuation beyond six weeks could affect leukocyte-bound 
apo B, although this seems not very likely due to the dynamic metabolism of these cells.
We need to underline that the investigated population consisted mainly of a selected 
group of subjects visiting our hospital for cardiovascular risk assessment. Although the 
population also comprised some healthy volunteers, the observed results may not be 
representative for the general population.
In order to further establish the role of the binding of apo B-containing lipoproteins to 
circulating leukocytes in the development of atherosclerosis, large prospective studies 
are needed, and more detailed investigation of the mechanisms involved will be neces-
sary. The number of apo B-containing lipoproteins bound to monocytes and neutrophils 
at saturation needs to be established, so that the relative contribution of these cells to 
the lipoprotein metabolism may be estimated.
In conclusion, similarly to erythrocyte-bound apo B, the presence of clinical and sub-
clinical atherosclerosis was associated with a lower level of apo B bound to circulating 
monocytes and neutrophils. The binding of apo B-containing lipoproteins to the surface 
of circulating leukocytes may represent a protective mechanism against atherosclerosis.
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ABsTrAcT
Background: Inflammation plays a key role in atherosclerosis. The complement system 
is involved in atherogenesis, and the complement receptor 1 (CR1) plays a role in facilitat-
ing the clearance of immune complexes from the circulation. Limited evidence suggests 
that CR1 may be involved in cardiovascular disease. We investigated the relationship 
between CR1 gene polymorphisms and cardiovascular risk.
Methods: Single nucleotide polymorphisms (SNPs) within the CR1 region (n=73) on 
chromosome 1 were assessed in 5244 participants in PROSPER (PROspective Study of 
Pravastatin in the Elderly at Risk) (mean age 75.3 years), who had been randomized to 
pravastatin 40 mg/day or placebo and followed for a mean of 3.2 years. Logistic regres-
sion adjusted for gender, age, country and use of pravastatin was used to assess the 
association between the SNPs and cardiovascular disease.
results: All 73 SNPs within the genomic region of the CR1 gene on Chromosome 1 
were extracted. In this region, strong LD was present leading to the occurrence of two 
haploblocks. Twelve of the 73 investigated CR1 SNPs were significantly associated with 
the risk of fatal or nonfatal myocardial infarction (all p<0.05). Moreover, most of the as-
sociated SNPs were also associated with levels of serum C-reactive protein (CRP). The 
global p-value for the tail strength method to control for multiple testing was 0.0489, 
implying that the null hypothesis of no associated SNPs can be rejected.
conclusion: These data indicate that genetic variation within the CR1 gene is associated 
with inflammation and the risk of incident coronary artery disease.
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iNTroducTioN
Inflammation plays a key role in the development of atherosclerosis. Lipoproteins can 
migrate into the subendothelial space, where they can induce inflammation, foam cell 
formation and atherosclerotic plaque development [1,2]. Several inflammatory markers, 
such as C-reactive protein (CRP), interleukin-6 and leukocyte count have been associated 
with the risk of cardiovascular disease [3,4], and after myocardial infarction, levels of 
interleukin-6, CRP and leukocyte count increase [5]. Interleukin-6 is the main stimulant 
of the hepatic synthesis of acute phase proteins, such as CRP [6].
The complement system is involved in this inflammatory condition leading to athero-
genesis. The terminal complement complex, C5b-9, colocalizes with CRP in human ath-
erosclerotic lesions [7]. Furthermore, elevated levels of serum complement component 
3 (C3) have been associated with the presence of myocardial infarction, and predict the 
risk of future coronary events [8,9].
The complement receptor 1 (CR1) is found on the membranes of many types of cells, 
including erythrocytes, granulocytes, monocytes and macrophages [10]. CR1 is a recep-
tor for the complement proteins C3b and C4b [10]. Via this receptor, erythrocytes carry 
immune complexes from the circulation to the spleen and liver, where the immune 
complexes are transferred to phagocytic cells [11]. Recently, it has been postulated that 
CR1 on erythrocytes may also be involved in the clearance of atherogenic lipoproteins 
[12–14]. Besides a role in the clearance of immune complexes and lipoproteins, CR1 can 
also inhibit complement activation, by acting as a co-factor for the factor I-mediated 
breakdown of C3b into iC3b [10,15].
A large intra-individual variation in the number of CR1 molecules per erythrocyte has 
been described, with values ranging between less than 100 to 1200 molecules per cell 
[16,17]. Erythrocytes loose CR1 molecules during their aging process in the circulation 
[18]. Accelerated and sometimes reversible loss of erythrocyte-CR1 has been described 
in patients with several types of inflammatory and non-inflammatory diseases, such as 
severe acute respiratory syndrome [19], tuberculosis [20], insulin-dependent diabetes 
mellitus [21] and systemic lupus erythematosus [22]. In addition to these conditions, 
several polymorphisms in the CR1 gene have been related to erythrocyte CR1 expres-
sion, including the Pro1827Arg (C5507G, rs3811381) SNP in exon 33, the His1208Arg 
(A3650G, rs2274567) SNP in exon 22 and the HindIII restriction fragment length poly-
morphism (RFLP, T520C, rs11118133) in intron 27 [17,23,24]. These three polymorphisms 
are in strong linkage disequilibrium (LD) [25].
The role of the CR1 gene in cardiovascular disease and atherosclerosis remains un-
clear. The goal of the present study was to investigate the relationship between CR1 
polymorphisms and cardiovascular disease.
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MATEriALs ANd METhods
study population
All data come from the PROspective Study of Pravastatin in the Elderly at Risk (PROS-
PER). A detailed description of the study has been published elsewhere [26,27]. In 
short, elderly subjects (aged 70-82 years) with a history of vascular disease, or increased 
vascular risk, were enrolled in Scotland, Ireland and the Netherlands. The primary study 
endpoint was death from coronary heart disease, non-fatal myocardial infarction (MI), 
and fatal and non-fatal stroke. Secondary endpoints were the separate coronary and 
cerebrovascular components of the primary endpoint. The study protocol was approved 
by the medical ethics committees of each participating institution. All study subjects 
gave written informed consent. The study protocol conforms to the ethical guidelines of 
the 1975 Declaration of Helsinki.
Genotyping
In the PHASE project, whole genome wide screening has been performed, as has 
been described in detail previously [28]. From this GWAS study, we selected all single 
nucleotide polymorphisms within the CR1 region on chromosome 1 (n=73) with PLINK 
software. Taking a relatively stringent R2 threshold (>0.8), using LDlink (https://analysis-
tools.nci.nih.gov/LDlink/) [29], we observed three sets of SNPs. The R2-matrix for these 
12 SNPs is displayed in Table 10.1.
Laboratory measurements
All measurements were performed on samples stored at -80°C. CRP was measured by 
automated particle-enhanced immunoturbidimetric assay (Roche, UK). This method 
has an inter- and intra-assay coefficient of variation of 3%. IL-6 was determined using 
a high-sensitivity enzyme-linked immunosorbent assay (R&D Systems, Abingdon, UK) 
with inter- and intra-assay coefficients of variation of <6% and sensitivity of 0.16 pg/
mL. White blood cell count (WBC) was measured by a fully automated system Sysmex 
XE-2100 (TOA Medical Electronics, Kobe, Japan).
statistical analysis
Allele frequencies were estimated and pairwise LD between the investigated SNPs was 
estimated and plotted with the program Haploview. Associations between the CR1 SNPs 
and laboratory measurements were assessed with linear regression adjusted for sex, 
age, and country. Logistic regression was used to associate the CR1 SNPs with cardiovas-
cular outcomes adjusted for sex, age, country, and pravastatin treatment. All statistical 
analyses were performed with PLINK statistical software (http://pngu.mgh.harvard.
edu/~purcell/plink/download.shtml#download). To control for multiple testing, we 
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calculated global p-values using the tail strength method [30]. In short, the tail strength 
measures how much p-values in a set differ from the expected uniform distribution 
under the null hypothesis and sums up these differences into a single test statistics. 
The tail strength is powerful when many small effects exist in the data [30]. Since SNPs 
are not independent, empirical p-values were computed using permutations. SNPs were 
permuted as a block, keeping intact the relationship between covariates and outcome. 
Individual tests were based on a cox-model (coxph) and 2×104 permutations were used. 
Computations were parallelized using package parallelize.dynamic [31]. Global p-values 
were computed using R version 3.2.
rEsuLTs
Table 10.2 shows the baseline characteristics of the 5,244 participants of the PROSPER 
Study. Table 10.3 shows the characteristics of subjects who developed fatal or nonfatal 
myocardial infarction versus those without myocardial infarction. The mean age of the 
Table 10.2 Baseline characteristics of the 5,244 subjects of the PROSPER study
Participants
demographics
Female, n (%) 2,720 (51.9)
Age, years 75.3 ± 3.4
Current smoker, n (%) 1,392 (26.5)
Body Mass Index, kg/m2 26.8 ± 4.2
History of Diabetes, n (%) 544 (10.4)
History of Hypertension, n (%) 3,257 (62.1)
History of Myocardial infarction, n (%) 708 (13.5)
History of Stroke or TIA, n (%) 586 (11.2)
History of Vascular disease*, n (%) 2,336 (44.5)
Hyperlipidemia**, n (%) 1,424 (27.2)
Laboratory measurements
White blood cell count , x109/L 6.43 ± 1.62
C-reactive protein, LN transformed, mg/L 1.13 ± 1.13
Interleukin-6, LN transformed, ng/L 0.97 ± 0.66
LDL-cholesterol, mmol/L 3.79 ± 0.80
HDL-cholesterol, mmol/L 1.28 ± 0.35
Data are presented as number (percentage) or mean ± SD. *Any of stable angina, intermittent claudication, 
stroke, transient ischemic attack, myocardial infarction, peripheral artery disease surgery, or amputation for vas-
cular disease more than 6 months before study entry. **Hyperlipidemia was defined according to NCEP criteria 
as a total cholesterol > 6.21 mmol/L (240 mg/dL) or triglycerides > 5.5 mmol/L (400 mg/dL).
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participants was 75.3 years and approximately 50% were female. Due to the inclusion 
criteria of PROSPER, almost 50% of the participants had a history of vascular disease. 
Mean follow-up of study subjects was 3.2 years (range 2.8-4.0).
From the GWAS database including 2.5 million SNPs, we extracted all SNPs within the 
genomic region of the CR1 gene on Chromosome 1 (n=73). Figure 1 shows the CR1 gene 
structure with the location of the investigated SNPS. Strong LD is present within the 
genomic region of CR1 leading to the occurrence of two haploblocks as shown in Figure 
1. All SNPs were in Hardy Weinberg equilibrium (p>0.05).
Table 10.3 Baseline characteristics, stratified on occurrence of myocardial infarction during follow-up
No event (n=4654) Event (n=590)
demographics
Female, n (%) 2,486 (53.4) 234 (39.7)
Age, years 75.3 ± 3.3 75.7 ± 3.4
Current smoker, n (%) 1,240 (26.6) 152 (25.8)
Body Mass Index, kg/m2 26.8 ± 4.2 27.0 ± 4.1
History of Diabetes, n (%) 461 (9.9) 83 (14.1)
History of Hypertension, n (%) 2896 (62.2) 361 (61.2)
History of Myocardial infarction, n (%) 555 (11.9) 153 (25.9)
History of Stroke or TIA, n (%) 514 (11.0) 72 (12.2)
History of Vascular diseasea , n (%) 1,992 (42.8) 344 (58.3)
Hyperlipidemia 1283 (27.6) 141 (23.9)
Laboratory measurements
White blood cell count, x109/L 6.40 ± 1.61 6.64 ± 1.69
C-reactive protein, LN transformed, mg/L 1.11 ± 1.12 1.30 ± 1.12
Interleukin-6, LN transformed, ng/L 0.96 ± 0.66 1.06 ± 0.64
C-reactive protein, mg/L 5.90 ± 11.54 6.87 ± 10.23
Interleukin-6, ng/L 3.37 ± 3.09 3.63 ± 3.11
LDL-cholesterol, mmol/L 3.80 ± 0.81 3.74 ± 0.72
HDL-cholesterol, mmol/L 1.29 ± 0.35 1.24 ± 0.34
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During follow-up, 12.7% of the patients developed a fatal or nonfatal MI, 4.8% experi-
enced fatal or nonfatal stroke, 5.3% died from cardiovascular disease and the overall 
mortality was 11.7%.
Twelve of the 73 investigated CR1 SNPs were significantly associated with the risk of 
fatal or nonfatal MI. These SNPs, and their corresponding odds ratio for MI with 95% 
confidence intervals, are depicted in panel A of Figure 10.2. The minor allele frequency 
of the CR1 SNPs rs3886100, rs2274566, rs11118157, rs6691117, rs7519119, rs7542544, 
rs11803956, rs12041437, rs12034383 and rs11803366 was associated with a decreased 
risk of coronary artery disease, while the minor allele frequency of SNPs rs10127904 and 
rs17259038 were associated with increased risk. Seven out of 10 SNPs associated with 
decreased risk of MI, were also associated with lower levels of CRP. Hence, the two SNPs 
associated with an increased risk of MI showed an association with higher CRP levels, 
although not statistically significant. The 12 SNPs were not associated with leukocyte 
count or levels of Interleukin-6 (data not shown). The global p-value for the tail strength 
method to control for multiple testing was 0.0489, implying that the null hypothesis of 
no associated SNPs can be rejected.
A
B
figure 10.1. Details of the genomic region of the CR1 gene
Linkage disequilibrium (LD) between the single nucleotide polymorphisms examined. Two haploblocks are 
shown with strong LD (dark blocks present LD>95%), with the existing haplotypes with corresponding frequen-
cies.
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Figure 10.3 shows the association of the investigated SNPs with vascular and all-cause 
mortality and with fatal and nonfatal stroke. In line with the results for risk of MI, SNPs 
rs3886100 and rs2274566 were associated with decreased risk of vascular and all-cause 
mortality, while SNPs rs10127904 and rs17259038 were associated with increased vas-
cular and all-cause mortality. SNPs rs7542544, rs11803956, rs12041437 and rs12034383 
were associated with decreased vascular mortality, but not with all-cause mortality. 
None of the investigated SNPs were associated with the risk of stroke.
Further adjustments for smoking, diabetes, hypertension, average LDL cholesterol dur-
ing follow-up, history of MI, history of stroke, and log-transformed CRP did not materially 
change the results (data not shown).
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figure 10.2. CR1 SNPs in relation to risk of MI and CRP
The relationship all investigated SNPs significantly associated with risk of future fatal or nonfatal myocardial 
infarction (odds ratio with 95% confidence interval) (A). The relationship of these SNPs with serum C-reactive 
protein levels (beta-coefficient with 95% confidence interval) (B). There were three sets of SNPs, which are sepa-
rated by the dotted lines. *p<0.05
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discussioN
We investigated the relationship between CR1 polymorphisms and cardiovascular risk in 
PROSPER, a prospective randomized trial in which elderly subjects received pravastatin 
or placebo. After a mean follow-up of 3.2 years, 12 SNPs in the CR1 gene were associated 
with risk of fatal and nonfatal MI. In addition, several SNPs associated with decreased 
risk of MI were also associated with lower levels of CRP. Furthermore, many of the inves-
tigated SNPs were associated with the risk of vascular and all-cause mortality.
To date, two previous studies have investigated the relationship between CR1 poly-
morphisms and cardiovascular risk. Buraczynska et al found that the GG phenotype of 
the Pro1827Arg polymorphism, corresponding with decreased erythrocyte-CR1 expres-
sion [23,32], was more prevalent in end-stage renal disease patients with a history of 
cardiovascular disease than in those without cardiovascular disease [33]. In contrast, 
Boiocchi et al described a lower prevalence of the GG variant in hypercholesterolemic 
patients with a history of coronary artery disease than in healthy controls [34]. However, 
in that study, the total number of patients with the GG variant was only 20. Unfortu-
nately, this polymorphism was not present in the database of our GWAS.
No previous studies have assessed the relationship between the 12 presently described 
CR1 SNPs with cardiovascular disease. However, the minor alleles of the rs12034383 
and rs6691117 SNPs have been associated with lower erythrocyte sedimentation rate 
[35]. The lower risk of MI which we observed in carriers of the minor allele rs12034383 
and rs6691117, and lower levels of CRP in rs12034383, are in line with the previously 
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figure 10.3. CR1 SNPs in relation to risk of stroke and mortality
The investigated SNPs in relation to risk of vascular mortality (A), all-cause mortality (B), non-vascular mortality 
(C) and fatal or nonfatal stroke (D) (OR with 95% CI). There were three sets of SNPs, which are separated by the 
dotted lines. *p<0.05
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reported lower inflammation in these subjects [35]. Several markers of inflammation, 
including CRP [3], IL-6 [3] and white blood cell count [4], have been associated with 
increased cardiovascular risk. Several CR1 SNPs that were significantly associated with 
cardiovascular risk in the present study, were also associated with levels of CRP, but not 
with IL-6 or white blood cell count. CRP is synthesized in the liver, primarily in response 
to IL-6 [36]. When CRP binds to phosphocholine groups on the surface of for instance 
bacteria, this activates the complement system and induces an inflammatory cascade to 
destroy the ligand [37]. Complexes of CRP with soluble ligands may bind to CR1 on the 
erythrocyte surface and thus be cleared from the circulation [38]. This direct interaction 
between CRP and CR1 may explain the observed association with the CR1 SNPs. In the 
present study we found no evidence for a direct effect of CR1 gene polymorphisms on 
levels of IL-6 or leukocyte count.
We hypothesize that the mechanism behind the observed relationship between 
CR1 polymorphisms and the risk of coronary artery disease involves the level of CR1 
on circulating erythrocytes. This may affect cardiovascular risk in several ways. Firstly, 
polymorphisms leading to lower expression of CR1 on these cells may result in reduced 
clearance of immune complexes from the circulation, resulting in a pro-inflammatory 
and therefore, a pro-atherogenic situation. Secondly, lower erythrocyte-CR1 expression 
may be pro-atherogenic due to less binding of atherogenic lipoproteins to erythrocytes. 
We have previously demonstrated in vivo that circulating human erythrocytes are able 
to bind atherogenic apolipoprotein B-containing lipoproteins [12,39]. The binding of 
these lipoproteins by circulating blood cells was associated with a reduced prevalence 
of atherosclerosis [12,39]. Possibly, this binding of atherogenic particles by blood cells 
prevents their interaction with the endothelium, and we have speculated that erythro-
cytes contribute to removal of the lipoproteins from the circulation [40]. In vitro and ex 
vivo work from our group indicates that CR1 is a likely candidate receptor for the binding 
of lipoproteins to circulating blood cells [13].
A limitation of the present study is that we did not quantify erythrocyte-bound CR1 in 
our patients. We do not know whether these SNPs lead to functional changes in the CR1 
protein, although the observed relationship with CRP levels and the previously reported 
relationship with erythrocyte sedimentation rate suggest functionality. Another limita-
tion is that we did not correct for multiple testing with the more common Bonferroni 
correction. Due to the large number of SNPs analyzed, the Bonferroni adjusted p-value 
would have been 6.8x10-6 (0.05 / 73). However, we noticed by checking the haplotype 
structure within the gene, that there were only two major haploblocks with very strong 
LD. This indicates that the 73 investigated SNPs were not all independent of each other 
and that using the Bonferroni correction would have been too conservative. Instead we 
used the tail strength method to control for multiple testing, since this test is powerful 
for studies with strong LD (dependency) and with small effect sizes. Since we found 
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a significant p-value with this test as well, we consider our results to be valid and not 
false-positive. Another limitation is that these data were obtained in a single cohort, 
and these findings need to be confirmed in an independent cohort. In addition, we 
investigated a group of subjects aged 70 years and above. While the impact of CR1 
gene polymorphisms, and their influence on inflammation and atherosclerosis, may be 
most pronounced in a group of elderly individuals, if CR1 gene polymorphisms lead to 
premature death before the age of 70, we may underestimate the true effect of these 
polymorphisms. Furthermore, future studies investigating the functionality of these CR1 
SNPs are necessary.
In conclusion, genetic variation within the CR1 gene is associated with inflammation 
and risk of incident coronary artery disease. These data further strengthen the evidence 
for the role of the complement system in atherosclerosis.
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iNTroducTioN
Atherosclerosis, the underlying pathology of cardiovascular disease, is an inflammatory 
disease [1,2]. It is thought that especially inflammation induced by different stimuli, 
such as postprandial lipemia, oxidized lipoproteins leading to the production of radical 
oxygen species and many others, may be atherogenic. Since humans in Western coun-
tries are postprandial during most of the day, this postprandial inflammation may have 
a large impact on the risk of cardiovascular disease. In chapter 1, we reviewed the 
contribution of different nutrients on postprandial inflammation and endothelial dys-
function, and the effects of lifestyle and pharmaceutical interventions. After a high-fat 
meal, both triglyceride-rich lipoproteins and free fatty acids released upon hydrolysis of 
these particles may contribute to inflammation. This inflammation consists of increased 
expression of adhesion molecules on endothelial cells [3], neutrophils and monocytes 
[4–6], increased leukocyte count [7], the production of pro-inflammatory molecules [8], 
and leads to transient endothelial dysfunction [7]. Not only a high-fat meal, but also 
a meal containing glucose may induce inflammation and impair endothelial function 
[7,9,10]. Recent evidence suggests that this postprandial inflammation, considered to be 
pro-atherogenic and detrimental to endothelial function, can be reduced by a diet rich 
in anti-oxidants, which can be found in tomatoes [11], strawberries [12], black raspber-
ries [13], orange juice [14] and red wine [15], and monounsaturated fatty acids, such as 
in extra virgin olive oil [16,17]. In addition, weight loss [18,19] and the use of lipid and 
glucose lowering drugs [20,21] may be effective in reducing postprandial inflammation.
Despite this increasing evidence for the role of postprandial lipids in inflammation 
and atherosclerosis, many guidelines for cardiovascular risk management still advise to 
measure the lipid profile in the fasting state. However, since we are nonfasting for the 
major part of the day, a fasting measurement may not be representative. In addition, the 
need to be fasting for blood sampling imposes practical limitations for both patients 
and physicians. As we describe in chapter 2, a nonfasting lipid profile, i.e. measurement 
of apolipoprotein (apo) B and non-high-density lipoprotein cholesterol (non-HDL-C), is 
a sensitive indicator of cardiovascular risk and may even be superior in cardiovascular 
risk prediction to fasting low-density lipoprotein cholesterol measurement [22,23]. 
In addition, a nonfasting lipid profile is usually adequate in distinguishing between 
familial hypercholesterolemia (FH), familial combined hyperlipidemia (FCH) and familial 
hypertriglyceridemia (FHTG) [24–26]. We therefore, advocate the use of nonfasting lipid 
profile with apo B or non-HDL-C for cardiovascular risk assessment, evaluation of lipid 
lowering therapy and differentiation between primary lipid disorders. Very recently, this 
proposal has been implemented in the European Atherosclerosis Society guidelines.
In part 1 of this thesis, we further focused on inflammation in the postprandial situ-
ation, and specifically on the role of lipids and glucose in this inflammation. In part 2, 
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we investigated potentially beneficial effects of cell-bound atherogenic lipoproteins on 
atherosclerosis and mortality, and the role of inflammation in this process.
PosTPrANdiAL GLucosE ANd LiPids iNducE LEukocyTE AcTiVATioN
Glucose-induced leukocyte activation in different degrees of insulin-sensitivity
Although it has been shown that glucose may induce inflammation and leukocyte 
activation in both type 2 diabetes mellitus (T2DM) patients and in healthy controls 
[27,28], no previous studies have directly compared glucose-induced leukocyte activa-
tion between T2DM patients and healthy controls. In chapter 3, we investigated the 
effect of glucose ingestion on leukocyte activation in subjects with different degrees of 
insulin sensitivity. We included insulin-sensitive healthy subjects and insulin-resistant 
T2DM patients. In addition, we included a group of subjects with non-diabetic reduced 
insulin sensitivity, i.e. patients with FCH. We demonstrated that both fasting and post-
prandial leukocyte activation was highest in the most insulin-resistant subjects, the 
T2DM patients, intermediate in the reduced insulin-sensitive FCH patients and lowest 
in healthy, insulin-sensitive controls. Furthermore, both acute and chronic glycemia, 
assessed by measurement of glucose and HbA1c levels, were associated with fasting as 
well as postprandial leukocyte activation. Leukocyte activation has been linked to the 
development of diabetic complications, such as nephropathy [29] and retinopathy [30]. 
Therefore, our results may have implications for the prevention of diabetic microvascu-
lar complications, and underline the need for studies investigating the effect of different 
glucose lowering drugs or lifestyle interventions on fasting and postprandial leukocyte 
activation.
chylomicron remnants induce leukocyte activation
In chapter 4, we focused on a specific atherogenic lipoprotein, the chylomicron rem-
nant, in relation to inflammation. Chylomicrons are synthesized in the intestine. They 
transport diet-ingested lipids to the circulation, where triglycerides are removed from 
their content, and chylomicron remnants remain [31]. These remnants are known to be 
atherogenic, because they can penetrate the vessel wall, where they are trapped, and can 
induce foam cell formation, inflammation and atherosclerosis [32,33]. No previous stud-
ies have investigated whether circulating chylomicron remnants also induce leukocyte 
activation. We assessed the relation between these particles and leukocyte activation 
in the circulation. The measurement of apo B48 is a good indicator of the total number 
of chylomicron remnants, since each particle contains a single apo B48 protein [31]. We 
demonstrated that in patients with and without atherosclerosis, in the fasting situation, 
a high level of apo B48 is associated with increased leukocyte activation. Furthermore, 
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in a group of healthy volunteers, after a high-fat meal, both fasting and postprandial 
apo B48 were associated with postprandial leukocyte activation. Interestingly, this cor-
relation with postprandial infl ammation was not found for triglycerides. We therefore 
propose that chylomicron remnants not only directly contribute to atherosclerosis in 
the arterial wall, but also indirectly, by stimulating and activating leukocytes in the circu-
lation, resulting in leukocyte adhesion to the endothelium and transmigration, further 
stimulating atherosclerosis (Figure 11.1).
Vitamin d and postprandial leukocyte activation
In the fi rst chapters of this thesis, we have shown which factors elicit postprandial 
infl ammation, and which interventions may help to reduce this process. In addition to 
the factors mentioned in Chapter 1, in theory also vitamin D may have the potential to 
reduce postprandial infl ammation. An unblinded and uncontrolled pilot study by our 
group in healthy, lean subjects demonstrated that a single dose of 100 000 IU of chole-
calciferol (vitamin D3) improved postprandial arterial elasticity in both men and women, 
while postprandial leukocyte activation was only reduced in women [6]. In chapter 5, 
we describe the results of a randomized controlled double-blind trial, aiming to confi rm 
these data. In this trial, healthy pre-menopausal overweight or obese vitamin D defi cient 
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figure 11.1. Proposed pro-atherogenic mechanisms of chylomicron remnants
According to classical concepts, chylomicron remnants directly induce atherosclerosis by migrating to the sub-
endothelial space, where they induce monocyte activation and foam cell formation (white arrows). We propose 
that in addition, chylomicron remnants may also indirectly induce atherosclerosis, by stimulating and activating 
leukocytes in the circulation, resulting in leukocyte adhesion to the endothelium and transmigration, further 
stimulating atherosclerosis (dark arrows).
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women underwent an oral fat loading test, before and after a single low (75 000 IU) or 
high dose (300 000 IU) vitamin D3. In this select group of female subjects, in contrast to 
results of the pilot study [6], vitamin D3 did not reduce postprandial arterial stiffness or 
leukocyte activation. This discrepancy may have several causes. The young and obese 
volunteers of the randomized trial had higher fasting and postprandial inflammation, 
reflecting increased inflammation in obesity. This increased inflammation may be more 
difficult to improve with a single dose of vitamin D. In contrast, arterial stiffness in this 
study population was lower, in line with previous studies reporting decreased arterial 
stiffness in young and in obese subjects [34–36]. Although cholecalciferol supplementa-
tion increased vitamin D levels significantly in both groups, after vitamin D3 supple-
mentation, 42% of the study subjects still had a vitamin D level below 50 nmol/l. These 
data suggest that possibly higher vitamin D levels must be reached to achieve beneficial 
effects. A comparison of several trials investigating inflammation and vascular function 
after vitamin D supplementation supports this assumption, since in studies reporting 
positive effects [6,37–41], higher vitamin D levels were reached than in studies reporting 
no effect of vitamin D supplementation [42–45].
While no short-term beneficial effect of a single dose of 75 000 or 300 000 vitamin 
D3 on arterial function or leukocyte activation was observed, we found that vitamin D3 
may possibly affect complement C3 levels. Fasting complement C3 levels were strikingly 
high in the study population, and decreased after vitamin D3. This may be of clinical 
relevance, since C3 has been positively associated with CVD [46,47] and the metabolic 
syndrome [48]. We speculate that vitamin D reduces C3 secretion by adipocytes, and 
that this reduced C3 production may lead to increased sensitivity for the effect of the 
hormone acylation-stimulating hormone, which increases fat storage and glucose 
transport [49,50].
Leukocyte activation in the prediction of cardiovascular disease
In the first chapters of this thesis, we have shown that both lipids and glucose elicit 
leukocyte activation. Several inflammatory markers, including leukocyte count, CRP and 
C3, have been demonstrated to predict cardiovascular risk [47,51,52]. While increased 
leukocyte activation has been associated with the presence of CVD [53–56], and we 
have shown an inflammatory gradient of intracellular MPO towards the coronary cir-
culation in patients with stable CAD [57], little is known about the value of leukocyte 
activation markers in the prediction of cardiovascular risk in humans. In chapter 6, we 
describe the results of a prospective study investigating whether the measurement of 
leukocyte activation in the coronary circulation may help to identify which subjects are 
at increased risk of future coronary artery disease. We included 99 subjects, and after 
approximately six years of follow-up, coronary monocyte CD11b, neutrophil CD11b and 
CD66b and intracellular MPO did not predict progression of coronary artery disease. We 
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speculate that this negative outcome may be due to the fact that activated leukocytes, 
with high expression of CD11b or CD66b, more readily adhere to the endothelium and 
are therefore missed by blood sampling. Furthermore, activated neutrophils transfer 
MPO to endothelial cells. In this respect, the measurement of CD11b and CD66b on the 
leukocyte surface, and intracellular MPO, may in fact be an underestimation of the true 
level of leukocyte activation and inflammation. In addition, studies with larger number 
of patients and more events may be needed to firmly establish whether the measure-
ment of coronary leukocyte activation may help to predict cardiovascular risk.
Blood cell-bound apoloprotein B and atherosclerosis
In Part 1 of this thesis, we focused on the negative effects of inflammation. However, 
inflammation is a physiologic response and it is vital for survival. Inflammation is crucial 
in recovery from infections and trauma, such as severe burn injury [58]. Children with 
inherited severe combined immunodeficiencies (SCID), which are the result of a block in 
T lymphocyte differentiation, often die before the age of one [59]. In addition, inflamma-
tion has been demonstrated to be not only detrimental, but also beneficial in cardiovas-
cular disease. For instance, monocytes and macrophages have been proposed to be key 
regulators of the restoration of damaged myocardial tissue in myocardial infarction [60].
Another mechanism by which inflammation may have a beneficial effect, in this case 
on the development of atherosclerosis, is by facilitating the binding of atherogenic apo 
B-containing lipoproteins to erythrocytes (ery-apoB) in the circulation. The association 
between increased serum apo B and the development of atherosclerosis has been 
firmly established [23,61,62]. Our research group had developed a method to measure 
apo B bound to circulating erythrocytes and leukocytes by flow cytometry. We have 
shown that ery-apoB is inversely associated with the presence of clinical and subclinical 
atherosclerosis. We hypothesize that this inverse relationship may be due to decreased 
interaction between atherogenic particles and the endothelium, and increased removal 
of harmful particles from the circulation by erythrocytes. This process is very likely de-
pendent on inflammation, since the complement receptor 1 (CR1) is the main receptor 
involved in the binding of harmful particles, such as immune complexes, to circulating 
erythrocytes, a process known as ‘immune adherence’ [63]. Once bound to erythrocytes, 
these particles are transported to the liver and spleen, where they are detached from the 
erythrocyte surface. The harmful particles are then eliminated from the body, and the 
intact erythrocyte returns to the circulation.
Erythrocyte-bound apo B in relation to inflammation, cardiometabolic factors, 
ABo blood group and future cardiovascular disease
In Part 2 of this thesis, we have further investigated the phenomenon of blood cell-
bound apo B. In chapter 7, we describe the results of a clinical cross-sectional study, in 
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which we explored which factors possibly influence ery-apoB. We measured ery-apoB 
and several clinical factors in a group of 427 patients and healthy volunteers. We found 
that ery-apoB was inversely associated with levels of CRP, complement C3 and the pres-
ence of the metabolic syndrome.
Interestingly, a major determinant of ery-apoB was the ABO blood group, and subjects 
with the O blood group, which are known to have lower cardiovascular risk [64,65], had 
on average almost threefold higher ery-apoB than those with a non-O blood group. 
While this observation is in line with our results of decreased prevalence of atheroscle-
rosis in those with high ery-apoB [66,67], at this point we have no explanation for this 
association. We speculate that the presence of A or B antigens on the erythrocyte surface 
may prevent lipoproteins from interacting with the erythrocytes. All erythrocytes carry 
a chain of glycoproteins and glycolipids, of which the basis is the H antigen, consisting 
of a terminal galactose monosaccharide [68]. Blood group O, A, B and AB erythrocytes 
differ in the number and type of monosaccharides attached to the H antigen [68]. In 
blood group O, no additional antigens exist. Blood group A erythrocytes have an N-
acetylgalactosamine sugar linked to the H antigen, in blood group B this is sugar is galac-
tose. In blood group AB, a mix of both A and B chains are present [68]. Several enzymes 
capable of enzymatic conversion of blood group A and B erythrocytes to O erythrocytes 
have been developed [69]. These enzymes digest the N-acetylgalactosamine (A-zyme) 
of galactose (B-zyme), resulting in A and B erythrocytes with the phenotype of blood 
group O [69]. We conducted several experiments with erythrocytes treated with such 
enzymes, kindly provided by professor Martin Olsson, to test whether removal of A or 
B antigens affects the presence of apo B-containing lipoproteins on the erythrocyte 
surface. We tested the untreated and treated erythrocytes of several subjects with A, B 
and O blood group. In enzyme-treated erythrocytes of all blood groups, ery-apoB was 
higher than in untreated erythrocytes from the same donor (Figure 11.2A), suggesting 
that the enzyme itself rather than the removal of the A or B antigen may influence the 
binding of apo B to these cells. Simultaneously, we measured the expression of CR1. 
On enzyme-treated erythrocytes, CR1 expression decreased, which may implicate that 
the enzyme treatment affects more than just the N-acetylgalactosamine and galactose 
monosaccharides (Figure 11.2B). In conclusion, with these experiments we were unable 
to prove our hypothesis of impaired binding of apo B-containing lipoproteins to eryth-
rocytes due to the presence of A or B antigens on the erythrocyte surface.
In addition to the factors described above, CR1 polymorphism genotyping demonstrated 
that ery-apoB was higher in subjects with a genetic predisposition for a high expression 
of CR1 on erythrocytes. These data indicate that while increased inflammation in itself 
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figure 11.2. Effect of enzymatic conversion of erythrocytes on erythrocyte-bound apolipoprotein B and 
complement receptor 1
Erythrocyte-bound apo B (ery-apoB, mean of measurement in triplicate) (A) and erythrocyte CR1 expression 
(ery-CR1, mean of measurement in duplicate) (B) on native (white bars) and enzyme-treated (grey bars) eryth-
rocytes of several donors with blood group A1, A2, B and O.
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(high CRP or C3 levels) may be detrimental to health, the capacity of erythrocytes to 
utilize the complement system may protect against atherosclerosis.
Previous studies on ery-apoB have been based on cross-sectional data [66,67], or 
have focused on the mechanisms behind this phenomenon [70]. In chapter 8, we 
describe the results of the first prospective study investigating the role of ery-apoB in 
future cardiovascular disease and mortality. We assessed the occurrence of fatal and 
nonfatal cardiovascular events and all-cause mortality after a median follow-up of 4.8 
years in 384 subjects. Study participants were divided into three groups: those with 
low (<0.2 au), intermediate (0.2-2.0 au) and high (>2.0 au) ery-apoB. The occurrence of 
cardiovascular events differed significantly between subjects with low, intermediate 
and high ery-apoB. There was a trend for a higher cardiovascular event rate in the low 
ery-apoB group, although the hazard ratio did not reach significance, possibly due to 
lack of power. Subjects with low ery-apoB had a significantly higher risk of all-cause 
mortality or the occurrence of either death or a fatal or nonfatal cardiovascular event 
than those with high ery-apoB. The difference in all-cause mortality and cardiovascular 
disease between the three groups was also present in a subgroup analysis with only 
subjects with a history of prior CVD, but not in those without previous CVD. These data 
indicate that ery-apoB could potentially be used as a novel cardiovascular risk marker, 
especially for secondary prevention purposes.
Leukocyte-bound apo B in relation to cardiovascular disease
We have previously shown that not only erythrocytes, but also monocytes and neutro-
phil granulocytes carry apo B on their surface [71]. In Chapters 1 and 4 of this thesis, 
we described the pro-inflammatory effect of atherogenic apo B-containing lipoproteins 
on leukocytes, where these lipoproteins induce increased leukocyte activation [72] and 
the production of pro-inflammatory cytokines [7,8]. In addition, leukocyte-lipoprotein 
interaction may result in the uptake of free fatty acids by leukocytes [71]. We therefore 
hypothesized that increased binding of apo B to circulating leukocytes (leuko-apoB) 
would be a pro-atherogenic process. We investigated the relation between leuko-apoB 
and the presence of clinical and subclinical atherosclerosis in a group of 396 subjects. 
The results of this study are described in chapter 9. Contrary to our hypothesis, and to 
the current concepts of the effect of interaction between leukocytes and atherogenic 
lipoproteins, apo B bound to monocytes or neutrophils was lower in subjects with a 
history of cardiovascular disease, and was inversely associated with carotid intima media 
thickness, a measurement of subclinical atherosclerosis.
Both monocyte- and neutrophil-bound apo B were positively correlated with ery-
apoB. In addition, similar to the associations found for ery-apoB, as described in Chapter 
7, inverse associations were found between monocyte- and neutrophil-bound apo B 
with cardiometabolic and inflammatory factors, such as body mass index, waist circum-
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ference, triglycerides, CRP and complement C3. Combined, these data suggest that a 
similar binding mechanism may be involved in erythrocytes and leukocytes. A viable 
candidate receptor for this binding is CR1, since this is one of the few receptors present 
on both erythrocytes, monocytes and neutrophil granulocytes [4,70,73–75].
A possible explanation for the inverse relation between leuko-apoB and atheroscle-
rosis may be that the binding of atherogenic lipoproteins to circulating leukocytes 
may prevent interaction between these lipoproteins and the endothelium. Possibly, 
leukocytes contribute to immune adherence, similar to erythrocytes [76], and in this 
way remove harmful lipoproteins from the circulation. In addition, we speculate that 
binding of atherogenic lipoproteins to the leukocyte surface may lead to internalization 
and degradation of these lipoproteins.
complement receptor 1 gene polymorphisms are associated with 
cardiovascular risk
As we have mentioned previously, CR1 is very likely involved in the binding of apo 
B-containing lipoproteins to circulating erythrocytes and leukocytes. Several single 
nucleotide polymorphisms (SNPs) in the CR1 gene have been associated with eryth-
rocyte CR1 expression [77–79]. We therefore hypothesized that CR1 polymorphisms 
would be associated with cardiovascular disease, since both high erythrocyte- and 
leukocyte-bound apo B are associated with less cardiovascular disease. In chapter 10, 
we investigated the association between SNPs in the CR1 gene with the risk of future 
cardiovascular disease, in the PROSPER study, a prospective multicenter randomized 
trial investigating the effect of pravastatin treatment on major cardiovascular events. 
Data on CR1 SNPs were available in 5244 subjects. After a mean follow-up of 3.2 years, 
12 of the 73 investigated CR1 SNPs were significantly associated with the risk of fatal 
and nonfatal myocardial infarction, and several of these SNPs were also associated with 
vascular mortality and all-cause mortality. We speculate that this relationship may be 
(partly) due to differences in erythrocyte- or leukocyte-bound apo B between carriers of 
the major and minor allele frequencies. Unfortunately, the presence of apo B-containing 
lipoproteins nor CR1 expression on erythrocytes or leukocytes was quantified in this 
study. Furthermore, little is known about the functionality of the investigated SNPs, and 
if functionality is present, which allele frequency would be associated with increased 
CR1 expression. However, several of the SNPs associated with cardiovascular risk in this 
study were also associated with levels of CRP, and the minor alleles of two of these SNPs 
have previously been associated with reduced erythrocyte sedimentation rate [80], 
which suggests that these SNPs have consequences for levels of inflammation and pos-
sibly expression of CR1.
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cLiNicAL iMPLEMENTATioNs ANd fuTurE dirEcTioNs
In this thesis we have shown that inflammation may have both detrimental and beneficial 
effects on cardiovascular disease. While glucose and lipids induce inflammation in the 
postprandial phase, and this postprandial inflammation is linked to the development 
of atherosclerosis, to some extent inflammation may protect against atherosclerosis as 
well. In this thesis, we added data to the existing body of literature demonstrating that 
the binding of apo B-containing lipoproteins to circulating erythrocytes may convey 
protection against atherosclerosis. In addition, we have shown for the first time that 
the binding of apo B to circulating leukocytes may be atheroprotective as well. This 
process is very likely dependent on some level of inflammation, since the binding of 
native LDL to CR1 is mediated via the classical pathway of complement activation, which 
is dependent on IgM or IgG antibodies and CRP [70]. For the complement-mediated 
binding of immune complexes or lipids to CR1, opsonization is necessary [81]. Upon 
complement activation, C3 is cleaved into C3a and C3b [82], and C3b can then bind to 
target surfaces and to CR1, facilitating the binding of harmful particles to CR1 [81]. Thus, 
for the CR1-mediated beneficial effect of the binding of apolipoprotein-B containing 
lipoproteins to circulating erythrocytes and leukocytes, a low level of inflammation and 
complement activation is crucial.
Much more research is needed into the binding of apo B-containing lipoproteins to 
circulating blood cells. Mechanistic studies into the exact processes involved in this 
binding are necessary, as well as studies determining whether this binding can be 
influenced. The effect of for instance weight loss or glucose-lowering drugs on ery-apoB 
is currently under investigation. In addition, it needs to be established whether indeed 
ery-apoB contributes to the so-called ‘residual risk’: the occurrence of cardiovascular 
events despite aggressive lipid-lowering therapy [83]. While our data so far indicate that 
ery-apoB measurement may help to select patients who may benefit from intensive 
secondary prevention strategies, this needs to be established in an independent cohort 
and validated as a cardiovascular risk marker. If ery-apoB is found to be modifiable, stud-
ies investigating the causality of the association between ery-apoB and CVD or mortality 
are needed.
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NiEuWE Pro- EN ANTi-AThEroGENE EffEcTEN VAN APoLiPoProTEïNE 
B-BEVATTENdE LiPoProTEïNEN
iNLEidiNG
Hart- en vaatziekten zijn wereldwijd een groot gezondheidsprobleem. Naar schatting 
overleden in 2012 17,5 miljoen mensen aan de gevolgen van hart- en vaatziekten, dit 
was ongeveer 31% van alle sterfgevallen. De meeste mensen overleden aan de gevolgen 
van een hartinfarct of een beroerte. Hart- en vaatziekten zijn niet alleen een belangrijke 
doodsoorzaak, maar veroorzaken ook veel gezondheidsproblemen. Veel mensen leven 
met beperkingen die veroorzaakt worden door bijvoorbeeld coronaire hartziekten, 
verlamming na een beroerte of verminderde mobiliteit door perifeer vaatlijden. De 
onderliggende oorzaak van hart- en vaatziekten is aderverkalking, ofwel atherosclerose. 
Atherosclerose kan ontstaan onder invloed van meerdere risicofactoren. De belangrijk-
ste hiervan zijn roken, diabetes mellitus, hoog cholesterol, hoge bloeddruk, overgewicht, 
lichamelijke inactiviteit, een ongezond dieet (weinig fruit en groenten), alcoholgebruik 
en psychosociale factoren. 
Bij het ontstaan van atherosclerose speelt ontsteking, of inflammatie, een belangrijke 
rol. Vooral de inflammatie die in de bloedbaan ontstaat na het eten, postprandiale in-
flammatie, blijkt een ongunstig effect te hebben op atherosclerose. Dit is van groot 
belang, omdat we de hele dag door eten en dus niet nuchter zijn. In hoofdstuk 1 
hebben we literatuuronderzoek gedaan naar de bijdrage van allerlei verschillende 
voedingsstoffen op postprandiale inflammatie, en naar het effect van verschillende 
leefstijlveranderingen en medicijnen. Na een vetrijke maaltijd ontstaat inflammatie 
door het vrijkomen van vetten en vrije vetzuren, waardoor er meer en actievere witte 
bloedcellen (leukocyten) ontstaan. Ook krijgen endotheelcellen, die de binnenkant van 
de bloedvaten bedekken, meer moleculen op hun oppervlak waaraan deze leukocyten 
kunnen hechten, en worden er meer moleculen geproduceerd die inflammatie in de 
hand werken. Al deze veranderingen leiden tot tijdelijke achteruitgang van de vaatfunc-
tie. Niet alleen een vetrijke maaltijd, maar ook een maaltijd met veel glucose kan deze 
ontsteking en verslechterde vaatfunctie veroorzaken. Postprandiale inflammatie kan 
geremd worden door een dieet met veel antioxidanten, die onder andere in tomaten, 
190 Nederlandse samenvatting 
aardbeien, zwarte frambozen, sinaasappelsap en rode wijn zitten, en met meervoudig 
onverzadigde vetzuren, zoals in extra vergine olijfolie, maar ook door gewichtsverlies en 
het gebruik van cholesterol of glucose verlagende medicatie.  
Hoewel er dus veel bewijs is dat juist ontsteking in niet-nuchtere toestand bijdraagt aan 
het ontstaan van hart- en vaatziekten, adviseren veel internationale richtlijnen nog altijd 
om het lipiden profiel nuchter te bepalen. Deze nuchtere meting heeft verschillende 
nadelen. Ten eerste is deze meting geen goede afspiegeling van de rest van de dag, 
omdat we het grootste deel van de dag niet nuchter zijn. Ten tweede is het belastend 
voor patiënten om niet te mogen eten of drinken voor de bloedafname, en kan een 
arts niet op een willekeurig moment van de dag het lipiden profiel laten bepalen. In 
hoofdstuk 2 beschrijven we dat een niet-nuchtere meting van bepaalde onderdelen 
van het lipidenprofiel, namelijk het apolipoproteïne (apo) B en het non-HDL-cholesterol 
(non-HDL-c) een even goede, en misschien zelfs betere inschatting van het risico op 
hart- en vaatziekten mogelijk maakt dan een nuchtere meting van het LDL-cholesterol. 
Bovendien kan met een niet-nuchter lipiden profiel in de meeste gevallen goed onder-
scheid gemaakt worden tussen verschillende familiare aandoeningen die tot verhoogd 
cholesterol of triglyceriden leiden.  
In het eerste deel van dit proefschrift hebben we ons gericht op ontsteking na de 
maaltijd, vooral op het effect van glucose en verschillende typen lipiden hierop. In het 
tweede deel van het proefschrift beschrijven we de gunstige effecten van de binding 
van bepaalde lipoproteïnen (verbindingen van vetten en eiwitten) aan rode en witte 
bloedcellen op atherosclerose, en de rol van ontsteking hierbij. 
GLucosE EN LiPoProTEiNEN AcTiVErEN LEukocyTEN
Activatie van leukocyten door glucose
De activatie van leukocyten is geassocieerd met allerlei complicaties die kunnen 
optreden bij suikerziekte, zoals aandoeningen van de ogen en van de nieren. Eerder 
onderzoek heeft aangetoond dat inname van glucose ontsteking en activatie van leu-
kocyten veroorzaakt bij zowel patiënten met type 2 diabetes mellitus als bij gezonde 
proefpersonen, maar er was nog nooit onderzoek gedaan waarbij het effect van glucose 
op deze ontsteking werd vergeleken tussen deze groepen. In hoofdstuk 3 hebben 
we het effect van glucose inname op activatie van leukocyten onderzocht in verschil-
lende groepen: gezonde proefpersonen, een patiëntengroep die een verminderde 
gevoeligheid voor het hormoon insuline heeft (patiënten met familiaire gecombineerde 
hyperlipidemie) en patiënten met type 2 diabetes mellitus, die insuline ongevoelig zijn. 
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Met dit onderzoek hebben we laten zien dat de activatie van leukocyten na inname 
van glucose het grootst was bij de patiënten met suikerziekte, gemiddeld was bij de 
patiënten met familiaire gecombineerde hyperlipidemie en het laagst bij de gezonde 
proefpersonen. Het effect van glucose op ontsteking nam dus toe bij een toenemende 
mate van insuline-ongevoeligheid. Daarnaast was zowel een kortdurend als een lang-
durig hoog glucose geassocieerd met leukocyten activatie, zowel in nuchtere toestand 
als na de maaltijd. Dit onderzoek heeft mogelijk gevolgen voor het voorkomen van de 
complicaties van suikerziekte, en toont aan dat er meer onderzoek nodig is naar het 
effect van medicijnen die de bloedsuiker verlagen en leefstijl interventies op leukocyten 
activatie na de maaltijd. 
Activatie van leukocyten door chylomicron remnants
In hoofdstuk 4 hebben we onderzoek gedaan naar de rol die een bepaald type athero-
geen lipoproteïne, het chylomicron remnant, speelt bij inflammatie. Chylomicronen 
worgen gesynthetiseerd in de darm en transporteren lipiden vanuit ons voedsel naar 
de circulatie, waar triglyceriden worden afgesplitst, waardoor er chylomicron remnants 
overblijven. Deze remnants kunnen de vaatwand binnendringen en daar schuimcelvor-
ming, inflammatie en atherosclerose stimuleren. Dit was het eerste onderzoek naar het 
directe effect van chylomicron remnants op leukocyten activatie in de circulatie. Omdat 
ieder chylomicron remnant één apo B48 eiwit op het oppervlak heeft, is een meting 
van apo B48 een goede afspiegeling van het totale aantal chylomicron remnants. Ons 
onderzoek toont aan dat in de nuchtere situatie een hoog apo B48 geassocieerd is met 
meer leukocyten activatie, zowel bij patiënten met als zonder atherosclerose. Na een 
vetrijke maaltijd was zowel nuchter als postprandiaal apo B48 geassocieerd met post-
prandiale leukocyten activatie. Dit wijst erop dat chylomicron remnants mogelijk niet 
alleen direct in de vaatwand bijdragen aan atherosclerose, zoals nu wordt aangenomen, 
maar ook indirect, door het stimuleren en activeren van leukocyten in de circulatie. 
ViTAMiNE d EN PosTPrANdiALE LEukocyTEN AcTiVATiE
Er is steeds meer bewijs dat vitamine D mogelijk ook postprandiale inflammatie remt. 
Een pilot studie van onze onderzoeksgroep liet zien dat een enkele dosis van 100 000 
IE vitamine D3 postprandiale vaatelasticiteit bij zowel mannen als vrouwen verbeterde, 
terwijl postprandiale leukocyten activatie alleen werd geremd bij vrouwen. In hoofd-
stuk 5 hebben we in een dubbelblinde gerandomiseerde studie geprobeerd deze 
resultaten bij vrouwen te bevestigen. Bij deze studie ondergingen gezonde, premeno-
pauzale vrouwen met overgewicht een vetbelastingstest, voor en week na een enkele 
lage (75 000 IE) of hoge dosis (300 000 IE) vitamine D3. Bij deze studie vonden we geen 
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gunstig effect van vitamine D3 op postprandiale vaatelasticiteit of leukocyten activatie, 
in tegenstelling tot onze eerdere studie. Dit verschil kan met meerdere factoren te ma-
ken hebben. Ten eerste hadden de proefpersonen in de gerandomiseerde studie meer 
inflammatie, mogelijk door hun overgewicht, waardoor mogelijk meer vitamine D nodig 
is voor een gunstig effect. Ten tweede was de vaatelasticiteit bij deze relatief jongere 
vrouwen lager. Ten derde had 42% van de proefpersonen in de gerandomiseerde studie 
ook na suppletie nog een vitamine D tekort, en mogelijk moeten hogere vitamine D 
spiegels bereikt worden voor gunstige effecten. Hoewel vitamine D in dit onderzoek 
geen effect had op leukocyten activatie, was de nuchtere complement C3 spiegel na 
beide doseringen vitamine D significant lager. Dit kan van belang zijn, omdat C3 geas-
socieerd is met het atherosclerose en het metabool syndroom. Mogelijk remt vitamine 
D de productie van C3 door adipocyten, en zorgt dit voor betere gevoeligheid voor 
het hormoon ‘acetylation-stimulating hormone’, wat vetopslag en glucose transport 
bevordert. 
LEukocyTEN AcTiVATiE iN hET VoorsPELLEN VAN hArT- EN VAATziEkTEN
Verschillende inflammatoire markers, waaronder leukocyten aantal, CRP en C3, zijn 
geassocieerd met cardiovasculair risico. In hoofdstuk 6 hebben we onderzocht of het 
meten van leukocyten activatie in de coronaire circulatie kan voorspellen welke patiën-
ten een verhoogd cardiovasculair risico hebben. Na gemiddeld zes jaar follow-up bleek 
coronaire leukocyten activatie (de marker CD11b op monocyten en neutrofiele granu-
locyten, CD66b op neutrofiele granulocyten en intracellulair MPO) niet geassocieerd te 
zijn met de progressie van coronaire hartziekten. Een mogelijke verklaring voor deze 
negatieve uitkomst is dat leukocyten met de integrines CD11b en CD66b makkelijker 
aan het endotheel hechten en deze geactiveerde leukocyten dus gemist worden bij 
bloedafname. Bovendien geven geactiveerde leukocyten MPO af aan endotheelcellen 
en is een meting hiervan een onderschatting van het daadwerkelijke niveau van leuko-
cyten activatie. 
BLoEdcEL GEBoNdEN APoLiPoProTEiNE B EN AThEroscLErosE
In het eerste deel van dit proefschrift hebben we ons gericht op de negatieve kanten 
van inflammatie. Inflammatie is echter ook een fysiologische reactie die essentieel is 
voor overleving. Zo is inflammatie belangrijk bij het bestrijden van infecties en herstel 
van letsel. Er zijn ook aanwijzingen dat inflammatie niet alleen atherogeen is, maar dat 
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bijvoorbeeld monocyten en macrofagen ook een belangrijke rol spelen bij het herstel 
van beschadigd myocardweefsel na een myocardinfarct. 
Een andere manier waarop inflammatie wellicht een positief effect heeft op atheros-
clerose, is door het faciliteren van de binding van atherogene apo-B bevattende lipopro-
teïnen aan erytrocyten in de circulatie. Serum apo B is sterk positief geassocieerd met 
het ontstaan van atherosclerose. Onze onderzoeksgroep heeft een methode ontwikkeld 
om apo B gebonden aan het oppervlak van erytrocyten en leukocyten te meten met een 
flow cytometer. We hebben aangetoond dat de binding van apo B-bevattende lipopro-
teïnen aan erytrocyten (ery-apoB) omgekeerd geassocieerd is met de aanwezigheid 
van atherosclerose, mogelijk door een verminderde interactie tussen deze atherogene 
deeltjes en het endotheel, en door het verwijderen van deze deeltjes uit de circulatie. 
Dit proces is zeer waarschijnlijk afhankelijk van inflammatie, en een belangrijke receptor 
hierbij is de complement receptor 1 (CR1). Deze receptor bindt schadelijke deeltjes aan 
erytrocyten, zodat deze via de lever en milt kunnen worden afgevoerd. 
Erytrocyt-gebonden apolipoproteïne B in relatie tot inflammatie, 
cardiometabole factoren, ABo bloedgroep en toekomstige hart- en vaatziekten
In het tweede deel van dit proefschrift hebben we het fenomeen van bloedcel gebon-
den apo B verder onderzocht. In hoofdstuk 7 hebben we onderzocht welke factoren 
het ery-apoB mogelijk beïnvloeden. Ery-apoB was omgekeerd geassocieerd met CRP, 
complement C3 en de aanwezigheid van het metabool syndroom. Ook vonden we een 
sterke associatie met de ABO bloedgroep: het ery-apoB was gemiddeld bijna 3 keer 
hoger bij proefpersonen met bloedgroep O, die een lager cardiovasculair risico hebben, 
dan bij proefpersonen met bloedgroep A, B of AB. Een andere factor die gerelateerd was 
aan het ery-apoB was het CR1 polymorfisme: ery-apoB was hoger bij diegenen met een 
genetische aanleg voor een hoge expressie van CR1 op erytrocyten. Deze resultaten la-
ten zien dat inflammatie mogelijk ook een gunstige kant heeft, doordat het gebruik van 
het complement systeem door erytrocyten om atherogene lipoproteïnen te vervoeren 
mogelijk beschermt tegen atherosclerose. 
In hoofdstuk 8 beschrijven we de resultaten van het eerste prospectieve onderzoek 
naar de rol van ery-apoB in cardiovasculaire aandoeningen en sterfte. De incidentie van 
cardiovasculaire aandoeningen verschilde significant tussen proefpersonen met laag, 
intermediair of hoog ery-apoB, met een trend voor een hogere incidentie in personen 
met een laag ery-apoB. Degenen met een laag ery-apoB hadden een hoger risico op 
sterfte en op het krijgen van een fatale of niet-fatale cardiovasculaire aandoening. In een 
subgroep analyse was dit verhoogde risico aanwezig in de groep proefpersonen met 
een cardiovasculaire voorgeschiedenis, maar niet bij degenen die niet eerder hart- en 
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vaatziekten hadden gehad. Hieruit concluderen we dat ery-apoB mogelijk een nieuwe 
marker voor cardiovasculair risico is voor secundaire preventie.  
Leukocyt-gebonden apo B en cardiovasculaire ziekte
Niet alleen erytrocyten, maar ook monocyten en neutrofiele granulocyten hebben apo 
B op hun oppervlak. In hoofdstuk 9 hebben we onderzoek gedaan naar de relatie tus-
sen leukocyt-gebonden apo B en hart- en vaatziekten. Zoals we in Hoofdstuk 1 en 4 van 
dit proefschrift beschrijven, kunnen atherogene lipoproteïnen met apo B leukocyten 
activeren en de productie van pro-inflammatoire cytokinen stimuleren. Onze hypothese 
was daarom dat een hoog leuko-apoB geassocieerd zou zijn met meer hart- en vaat-
ziekten. Apo B gebonden aan monocyten (mono-apoB) en neutrofiele granulocyten 
(neutro-apoB) was lager in proefpersonen met een cardiovasculaire voorgeschiedenis, 
en was omgekeerd geassocieerd met de intima media dikte van de arteria carotis, 
een maat voor subklinische atherosclerose. Het mono-apoB en neutro-apoB was, net 
als ery-apoB, omgekeerd geassocieerd met cardiometabole factoren en inflammatie, 
zoals body mass index, tailleomtrek, triglyceriden, CRP en C3. Deze resultaten waren 
tegengesteld aan onze hypothese, en aan de huidige opvattingen over het effect van 
de interactie tussen leukocyten en atherogene lipoproteïnen. Mogelijk beschermt een 
hoog mono- en neutro-apoB tegen atherosclerose door het binden en wegvangen van 
atherogene lipoproteïnen uit de circulatie, waardoor zij minder in aanraking komen met 
het endotheel. Mono- en neutro-apoB was positief geassocieerd met ery-apoB. Deze 
associatie, en het feit dat de associatie met cardiometabole factoren, inflammatie en 
hart- en vaatziekten hetzelfde was als voor het ery-apoB, suggereert dat er mogelijk een 
gezamenlijk bindingsmechanisme is. Een waarschijnlijk mechanisme is via CR1, aange-
zien dit één van de weinige receptoren is die zich op zowel erytrocyten als monocyten 
en neutrofiele granulocyten bevindt.  
complement receptor 1 gen polymorfismen zijn geassocieerd met 
cardiovasculair risico
Verschillende ‘single nucleotide polymorfismen’ (SNPs), ofwel kleine variaties in het 
DNA,  in het CR1 gen zijn gerelateerd aan de expressie van CR1 op erytrocyten. Omdat 
de binding van apo B aan erytrocyten en leukocyten waarschijnlijk via de CR1 receptor 
gaat, en ery-apoB en leuko-apoB is gerelateerd aan cardiovasculaire ziekten, hebben 
we onderzocht of deze CR1 polymorfismen geassocieerd zijn met cardiovasculaire 
ziekten. In hoofdstuk 10 beschrijven we dat verschillende CR1 polymorfismen geas-
socieerd waren met het risico op een fataal of niet-fataal myocardinfarct, en een aantal 
van deze polymorfismen was ook geassocieerd met het risico op vasculaire mortaliteit 
en met totale mortaliteit. Mogelijk komt dit door een verschil in de binding van apo B 
aan erytrocyten, monocyten en/of neutrofiele granulocyten. Verder onderzoek naar dit 
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verband is nodig, omdat we in deze studie niet de binding van apo B aan deze bloedcel-
len hebben gemeten. Ook is er nog weinig bekend over de mate waarin de onderzochte 
polymorfismen het CR1 op erytrocyten beïnvloeden. 
coNcLusiEs
In dit proefschrift hebben we laten zien dat inflammatie zowel nadelige als gunstige 
effecten heeft op hart- en vaatziekten. Glucose en lipiden veroorzaken inflammatie na 
de maaltijd, en deze postprandiale inflammatie is geassocieerd met het ontstaan van 
atherosclerose. Aan de andere kant lijkt enige mate van inflammatie ook te beschermen 
tegen hart- en vaatziekten. Met dit proefschrift hebben we eerdere bevindingen over 
het beschermende effect van de binding van apolipoproteïne B aan erytrocyten op 
atherosclerose uitgebreid. Ook hebben we voor het eerst aangetoond dat de binding 
van apolipoproteïne B aan leukocyten mogelijk ook beschermt tegen atherosclerose. 
Voor dit proces is zeer waarschijnlijk een lage mate van inflammatie nodig, omdat de 
binding van immuuncomplexen en lipiden aan de complement receptor 1 afhankelijk is 
van het complement systeem. 
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the first three years of her life in the small town of Hwidiem in Ghana, in West-Africa, 
where her parents were working as doctors for the non-governmental organization Me-
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25OHD 25-hydroxyvitamin D
ACE-i angiotensin-converting enzyme inhibitor
AGEs advanced glycation end products 
AIx augmentation index
ANOVA analysis of variance 
Apo apolipoprotein
ASA acetylsalicylic acid
ASP acylation-stimulating protein 
au arbitrary units
AUC area under the curve
BMI body mass index
BP blood pressure
C3 complement component 3
CAD coronary artery disease
CAG coronary angiography 
CCA common carotid artery 
CI confidence interval
cIMT carotid intima media thickness
CR1 complement receptor 1
CRP C-reactive protein
CV coefficient of variation 
CVD cardiovascular disease
CVE cardiovascular event
DAG diacylglycerol 
dAUC delta area under the curve
DBP diastolic blood pressure
DM diabetes mellitus
EAS European Atherosclerosis Society 
ECD PE-Texas Red 
ER endoplasmatic reticulum 
ery-apoB erythrocyte-bound apolipoprotein B
ESC European Society of Cardiology
FCH familial combined hyperlipidemia
FFA free fatty acid
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FH familial hypercholesterolemia 
FHTG familial hypertriglyceridemia 
FITC fluorescein isothiocynate 
HDL high-density lipoprotein
HDL-C high-density lipoprotein cholesterol
HR hazard ratio
hs-CRP high-sensitivity C-reactive protein
ICAM-1 intercellular adhesion molecule-1 
IDL intermediate-density lipoprotein
IFN-γ interferon-gamma 
IL-1β interleukin-1 beta
IL-6 interleukin-6
IMT intima media thickness
IQR interquartile range
LCA left coronary artery
LD linkage disequilibrium 
LDL low-density lipoprotein
LDL-C low-density lipoprotein cholesterol
LDL-r low-density lipoprotein receptor 
leuko leukocyte
leuko-apoB leukocyte-bound apolipoprotein B
LF-L lactoferrin-like polypeptide 
LOX-1 lectin-like oxidized LDL receptor 1 
LPL lipoprotein lipase 
LPS lipopolysaccharide
LRP-1 LDL receptor-related protein 1
LSD least significant difference 
MAG monoacylglycerols 
MAPK mitogen-activated protein kinase 
MCP-1 monocyte chemotactic protein-1
MDA malondialdehyde
MetS metabolic syndrome
MFI mean fluorescent intensity 
MI myocardial infarction
MIP-1α macrophage inflammatory protein-1 alpha
MMP-9 matrix metalloproteinase 9
mono monocyte
MPO myeloperoxidase 
MTP microsomal transfer protein 
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MUFA monounsaturated fatty acid
NCEP National Cholesterol Education Program 
neutro neutrophil
NF-κB nuclear factor kappaB
non-HDL-C non-high-density lipoprotein-cholesterol 
OFLT oral fat loading test 
OGTT oral glucose tolerance test
oxLDL oxidized low-density lipoprotein
PE phycoerythrin 
PKC protein kinase C 
PON-1 paraoxonase 1
PTH parathyroid hormone
PUFA polyunsaturated fatty acid
PWV pulse wave velocity
RAG rabbit anti-goat 
RAGE receptor for AGE 
RCA right coronary artery
RER rough endoplasmatic reticulum 
RFLP restriction fragment length polymorphism 
ROS reactive oxygen species
RRR relative risk ratio 
SBP systolic blood pressure
SCID severe combined immunodeficiencie
SD standard deviation
SEM standard error of the mean
SER smooth endoplasmatic reticulum 
SFA saturated fatty acid
s-ICAM-1 soluble intercellular adhesion molecule 1
SNP single nucleotide polymorphism
T2DM type 2 diabetes mellitus
TC total cholesterol
TG triglyceride
TNF-α tumor necrosis factor alpha
TRL triglyceride-rich lipoprotein
VCAM-1 vascular cell adhesion molecule 1
VLDL very low-density lipoprotein
WBC white blood cell count 
WT wild type
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Promotor: Prof. Dr. W.W. de Herder
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Good clinical practice 2013 1
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The symbols used throughout this thesis are Adinkra symbols. These symbols are 
believed to have been created ages ago by Ashanti craftsmen. The Ashanti are an 
ethnical group in the South of Ghana. They speak Twi, a dialect of the Akan language. 
The symbols are used to decorate items such as clothes and furniture. Apart from their 
decorative use, the symbols have philosophical, educational and historical value. I have 
chosen these particular symbols, because in my opinion, they represent life lessons or 
meanings that are applicable to the challenges experienced with (medical) science. On 
the following pages, the meaning of the different symbols will be explained.
De symbolen die in dit proefschrift zijn gebruikt zijn Adinkra symbolen. Men denkt dat de 
symbolen lang geleden gecreëerd zijn door Ashanti ambachtslieden. De Ashanti zijn een 
ethische groep uit het zuiden van Ghana. Ze spreken Twi, een dialect van de Akan taal. De 
symbolen worden gebruikt om voorwerpen zoals kleding en meubels te versieren. Behalve 
hun decoratieve waarde, hebben de symbolen ook filosofische, educatieve en historische 
waarde. Ik heb deze specifieke symbolen gekozen, omdat ze naar mijn mening levenslessen 
of betekenissen weergeven die van toepassing zijn op het doen van (medisch) wetenschap-
pelijk onderzoek, en het doorlopen van een promotietraject. Op de volgende pagina’s zal de 
betekenis van de verschillende symbolen worden uitgelegd. 
Source: Agbo AH. Values of Adinkra Symbols. 1st ed. Kumasi: Ebony designs and publica-
tions; 1999
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Ananse Ntontan Wisdom
‘Ananse Ntontan’ – Spider’s web
The spider Ananse is a well-known character in 
West African folktales. The spider is known for its 
wisdom and creativity. 
De spin Ananse is een bekend figuur in West-
Afrikaanse volksverhalen. Hij staat bekend om zijn 
wijsheid en creativiteit. 
Aya Endurance
‘Aya’ – Fern 
The fern is a hardy plant, able to endure any 
weather conditions and soil types. This symbol 
teaches that the survival of mankind requires the 
will to face all challenges, to be self-reliant and 
resourceful.
De varen is een robuuste plant, die bestand is tegen 
elke weersomstandigheid en ieder type grond. 
Dit symbool toont dat om te kunnen overleven, 
men alle veranderingen het hoofd moet bieden en 
onafhankelijk en vindingrijk moet zijn. 
Dame Dame Intelligence
This symbol represents a board game. It signifies 
the power of the mind to reason and solve 
problems.
Dit symbool stelt een bordspel voor. Het staat 
voor de kracht van de geest om te redeneren en 
problemen op te lossen. 
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Denkyem Adaptability
‘Denkyem’ – Crocodile 
The crocodile is noted for its ability to live in the 
water, while it needs air to breathe. The symbol 
signifies the importance of adaptation to changing 
circumstances, especially those that seem difficult.
De krokodil is in staat om in het water te leven, terwijl 
het lucht nodig heeft om te ademen. Dit symbool staat 
voor het belang van het aanpassen aan veranderende 
omstandigheden, vooral aanpassingen die moeilijk 
lijken. 
Dwennimmen Humility and strength
‘Odwennini’ – Ram, ‘Mmen’ – Horns
This symbol refers to the ram, noted for its strength 
in a fight, but also its submission upon slaughter. It 
signifies the importance of modesty and toughness.
Dit symbool verwijst naar de horens van de ram, 
een dier dat sterk is in een gevecht, maar zich ook 
onderwerpt voor de slacht. Het staat voor het belang 
van bescheidenheid en onverzettelijkheid. 
hwe Mu dua Strive for quality
‘Hwe mu’ – Look in, ‘Dua’ – Stick
This symbol represents a measuring stick, and 
encourages examination of all aspects of human life, 
and to strive for high quality.
Dit symbool stelt een meetlat voor. Het zet aan tot 
grondige inspectie van alle aspecten van het leven, en tot 
het streven naar hoge kwaliteit. 
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Mate Masie Wisdom and consideration
‘Mate’ – I have heard, ‘Sie’ – To keep
This symbol represents the need to take in 
wisdom and knowledge, but also to keep secrets 
and to overthink issues before taking decisions.
Dit symbool staat voor het belang van het vergaren 
van wijsheid en kennis, maar ook van het bewaren 
van geheimen en het overdenken van zaken voordat 
een beslissing wordt genomen. 
Mmere dane Change and dynamics
‘Mmere dane’ – Time changes
This symbol represents change and the dynamics 
of life.
Dit symbool staat voor de verandering en de 
dynamiek van het leven. 
Nea onnim do sue a ohu Knowledge and education
‘Nea onnim do sue a ohu’ – He who does not 
know can know from learning
This symbol represents the value of knowledge 
and education.
Dit symbool staat voor het belang van kennis en van 
onderwijs. 
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Owo Foro Adobe Persistence and diligence
‘Owo’ – Snake, ‘Foro’ – Climb, ‘Dobe’ – Raffia palm
The raffia palm is a thorny tree, which is difficult to 
climb. A snake climbing this tree has accomplished 
an impossible task. This symbol encourages people 
to be persistent and diligent in their efforts in order 
to achieve success.
De raffia palm is een boom met doornen die moeilijk 
te beklimmen is. Een slang die deze boom beklimt 
heeft een onmogelijke taak volbracht. Dit symbool 
moedigt aan om volhardend en ijverig te zijn om 
succesvol te zijn. 
Sankofa Learn from the past
‘Sanko’ – Go back, ‘Fa’ – Take  
This symbol signifies that progress is based on the 
right use of the positive contributions of the past, 
and that one must learn from the past. The symbol 
exists in two forms: that of a heart turned upside 
down, and a bird taking an egg of its back.
Dit symbool geeft weer dat vooruitgang gebaseerd is 
op de positieve bijdrage van het verleden, en dat men 
moet leren van het verleden. Het symbool bestaat in 
twee vormen: die van een omgekeerd hart, en een 
vogel die een ei van zijn rug pakt.  
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Wawa aba Toughness and perseverance
‘Wawa’ – A type of tropical rainforest tree, ‘Aba’ 
– Seed 
The seed of a wawa tree has a very hard outer 
covering, but it is broken by the slowly developing 
seedling from within, which in life defies all 
types of weather and grows into a big tree. This 
signifies the meaning to persist even in the face of 
difficulty.
De zaden van de wawa boom, een type boom 
in het tropisch regenwoud, heeft een harde 
buitenkant, maar wordt van binnenuit gebroken 
door het langzaam ontwikkelende kiemplantje, dat 
gedurende het leven alle weersoorten doorstaat 
en uitgroeit tot een grote boom. Dit symbool staat 
voor het belang van volhouden, ook in moeilijke 
omstandigheden. 
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Een gezegde onder reizigers is “It’s not the destination that matters, but the journey”. Het 
gaat dus niet om de uiteindelijke bestemming, maar om de reis daarnaar toe. Dat geldt 
voor reizen, maar zeker ook voor het doen van promotieonderzoek. Natuurlijk heb ik de 
afgelopen jaren toegewerkt naar Het Boekje dat je nu in handen hebt, maar tijdens mijn 
onderzoekstijd heb ik vooral ook veel geleerd. Het doen van promotieonderzoek leert je 
onder andere als een zelfstandige wetenschapper te denken, onderzoeksvragen gericht 
om te zetten in een experiment of onderzoeksprotocol, om te gaan met tegenslagen 
(als de resultaten van je experiment bijvoorbeeld tegenvallen) en het presenteren van 
je data, zowel op papier als voor een publiek. Mijn ‘reis’ naar dit proefschrift heb ik niet 
alleen gemaakt: ik heb onderweg hulp en steun gehad van veel personen. 
Prof. dr. de herder, beste Wouter, met mij als perifere promovenda hadden we een 
wat ongebruikelijke promotor-promovendus verhouding. We ontmoetten elkaar voor 
het eerst toen het eerste jaar van mijn promotieonderzoek achter de rug was. Desalni-
ettemin heb ik veel gehad aan onze gesprekken over de voortgang van mijn proefschrift 
en je input bij mijn artikelen. 
dr. castro cabezas, beste Manuel, ik heb het enorm getroffen met jou als betrokken 
co-promotor. Bijna wekelijks nam je uitgebreid de tijd om alle lopende projecten samen 
door te nemen, en een manuscript dat ik je toestuurde voor correcties had ik altijd bin-
nen twee dagen weer terug. Het gebeurde zelfs een keer dat ik een manuscript ’s avonds 
naar je mailde, blij om er even van af te zijn, om het de volgende ochtend nagekeken 
op mijn bureau terug te vinden. Samen op congres was altijd een feest: niet alleen naar 
praatjes luisteren, maar ook genieten van bezienswaardigheden, goed eten en uiteraard 
goede wijn of cognac. Na mijn allereerste slagroomproef heette je me welkom in het 
“selecte gezelschap van postprandiale weirdo’s”. Ik ben trots om net als jij een postpran-
diale weirdo te mogen zijn!
Gert-Jan, zonder jouw hulp was het helemaal niets geworden op het lab. Je stond altijd 
voor me klaar voor mijn kleine en grote vragen. Daarnaast was je altijd kritisch op mijn 
experimenten en de resultaten daarvan. Ik heb niet alleen inhoudelijk veel aan je gehad, 
maar het was met jou om de hoek ook altijd gezellig in het lab. 
Noëlle, lieve Noëlle, jij hebt je eindeloos ingezet voor mij en mijn onderzoek, daarvoor 
ben ik je enorm dankbaar. We maakten samen lange dagen voor de slagroomproeven, 
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maar liefst achtenveertig ochtenden ben jij voor dag en dauw naar het Franciscus Gas-
thuis gekomen om al rond 7 uur te kunnen opstarten voor weer zo’n proef. Je bent een 
kanjer.
Boudewijn, ontzettend bedankt voor je hulp gedurende mijn hele promotietijd. De 
eerste weken heb je me wegwijs gemaakt in het ziekenhuis en op het lab. Het was 
ontzettend handig om met jouw tips en trics aan de slag te kunnen. Ook nadat je voor 
je opleiding was vertrokken naar Dordrecht was je altijd bereikbaar en bereid om me te 
helpen met de artikelen die ik schreef, je aanvullingen en suggesties hielpen me altijd 
verder. Dankzij jou, en natuurlijk ook dankzij Arash en sarah, stapte ik in een lopende 
onderzoekstrein die mede dankzij jullie inzet flink op stoom was. 
Erwin, bij jou kon ik altijd terecht voor al mijn statistische en methodologische vragen. 
Ontzettend bedankt voor al je hulp en geduld.
Ik wil ook de klinisch chemici en artsen van het lab bedanken voor al hun hulp. In het 
begin van mijn onderzoekstijd waren dat hans en Tjin, later hebben Ellen, Lenneke en 
fokke het stokje overgenomen. Bedankt voor jullie tijd en input tijdens de vele vascu-
laire research besprekingen, bij mijn artikelen en voor al mijn vragen op het lab. John, 
bedankt voor je hulp bij het meedenken over de planning van de slagroomproeven, 
je hebt altijd je best gedaan om mijn onderzoek qua bezetting op de flow cytometer 
zo goed mogelijk te faciliteren. hamid, rené B, Jochem en rita, bedankt voor jullie 
hulp met pipetteren bij de slagroomproeven. Ook de andere flowspecialisten, Martijn, 
yvonne en Monique, bedankt voor jullie geduld en jullie gezelligheid tijdens de lange 
dagen op het lab. Ook alle andere analisten en medewerkers van het KCHL wil ik bedan-
ken voor jullie gastvrijheid en bereidheid tot hulp als ik bijvoorbeeld weer op zoek was 
naar een serumbuis van mijn slagroomproeven. Mijn dank gaat ook uit naar henk, die 
eindeloze hoeveelheden LPS voor mijn incubatie experimenten heeft vervaardigd. 
Als arts-onderzoeker in een perifeer ziekenhuis is het soms een beetje zoeken naar je 
plek. Gelukkig heb ik veel steun gehad van mijn collega arts-onderzoekers stefanie 
en yasmine, die net als ik in hetzelfde schuitje zaten. Daarnaast heb ik veel gezellige 
borrels en skiweekenden mogen meemaken met de groep arts-assistenten interne. 
Tijdens mijn onderzoek heb ik veel hulp gehad van stagiaires uit binnen- en buitenland. 
selvetta, Lana en Ashnaa, bedankt voor jullie hulp en gezelligheid! fernando y José, 
muchas gracias por su ayuda y sociabilidad. 
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Benvinda en simone, bedankt voor het steeds weer geblindeerd klaarzetten van de 
vitamine D drank voor mijn slagroomproeven. Zonder jullie hulp had ik mijn proeven 
niet kunnen afronden. 
Uiteraard bedank ik ook alle proefpersonen die hebben meegedaan aan mijn verschil-
lende studies en zich hebben onderworpen aan alle bloedafnames en sommigen zelfs 
het drinken van een grote beker ongeklopte slagroom op lege maag! Zonder jullie was 
dit proefschrift niet tot stand gekomen. 
Dames van de bibliotheek, carmen en katja, bedankt voor de eindeloze hoeveelheid 
artikelen die jullie altijd binnen no-time voor me hebben opgevraagd. Vaak kreeg ik bin-
nen een paar uur van jullie de artikelen die ik nodig had om mijn onderzoek te kunnen 
voortzetten. 
Alle dames (en heer) van het Diabetes en Vasculair Centrum: Ayse, denise, don, 
Evelien, ineke, Jacqueline, Jeanette, Jolanda, Mavis, Monique, Noëlle, Paulien, en 
Petra, vanaf dag één voelde ik me ontzettend welkom bij jullie op de poli. De gezellige 
koffiepauzes waren altijd een welkome afleiding van de uren achter de computer, en de 
uitjes met het team waren altijd geslaagd. De kers op de taart was het verrassingsetentje 
dat jullie voor mijn afscheid hadden georganiseerd. Ik zal jullie nooit vergeten! Ook de 
doktersassistenten bij balie 18 en Els wil ik bedanken voor alle ondersteuning bij mijn 
onderzoek. 
Ook de maatschap interne specialismen, en in het bijzonder Arie rietveld, ben ik 
grote dank verschuldigd voor de steun tijdens mijn promotietijd. Ontzettend fijn ook dat 
ik aansluitend aan mijn onderzoek mijn opleiding tot internist bij jullie mocht beginnen. 
De raad van Bestuur van het Franciscus Gasthuis, en in het bijzonder karen kruijthof, 
wil ik bedanken dat ze mij de gelegenheid hebben gegeven om promotieonderzoek te 
doen in hun mooie ziekenhuis. 
Welkome afleiding van het onderzoek en het werk vond en vind ik bij de yuppengroep, 
Lisanne, sanne, Martijn, karsten, Mirelle en Tim, altijd in voor een drankje in de Locus, 
uitgebreid eten en Sinterkersternieuw. Toke, genieten van je heerlijke kookkunsten 
onder het genot van een goed glas wijn doet me altijd goed. kirsten, met jou de stad 
onveilig maken, of het nou Rotterdam of Eindhoven is, is altijd gezellig. Ook de hele 
club uit dordrecht, en Peter en rené, jullie zijn altijd present bij feestjes bij ons thuis 
of elders. 
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En dan mijn lieve familie. Papa en mama, jullie hebben mij van jongs af aan altijd 
de kans gegeven om mij te ontwikkelen zoals ik dat zelf wilde, en me tegelijkertijd 
gemotiveerd om mijn dromen na te streven. Ik had me geen lievere en fijnere ouders 
kunnen wensen, jullie zijn altijd mijn voorbeelden geweest. Mijn broer en zussen, Erik, 
Janneke en dorien, en natuurlijk renzo, die ik ook beschouw als mijn broer, wat is 
het altijd heerlijk thuiskomen als jullie er zijn. Bedankt voor alle steun en gezelligheid 
de afgelopen jaren. Lieve opa, Walther Jan, je bent altijd geïnteresseerd en bij jou kan 
ik altijd terecht met mijn verhalen over mijn onderzoek en opleiding. Ik ben gezegend 
met zo’n lieve opa. Mijn schoonfamilie, John, Esther, Marsha, Jeroen, oma Agnes en 
ome Antoon, bij jullie voel ik me helemaal thuis en ik wil ook jullie bedanken voor jullie 
gezelligheid en steun de afgelopen jaren. 
Lieve Nikolaj, het allermooiste dat de reis naar mijn promotie me heeft opgeleverd 
ben jij. Ik leerde jou halverwege mijn promotie kennen tijdens de afterparty van het 
personeelsfeest. Sindsdien delen we lief en leed, en ben jij mijn klankbord geweest voor 
alles wat goed, maar soms ook minder goed ging tijdens het onderzoek. Je motiveerde 
me om toch nog even die paar uurtjes in het weekend aan mijn artikelen te werken, en 
deelde mijn vreugde als een artikel na zo vaak proberen eindelijk geaccepteerd werd 
voor publicatie. Ik denk nog altijd met veel plezier terug aan onze reis door Florida, waar 
we samen, na een congres in Orlando, met de auto doorheen zijn gereisd. Lief, ik hou 
meer van je dan ik op papier kan uitdrukken! Wat ben ik dankbaar dat ik jou tegen het 
lijf ben gedanst. 


